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Venous leg ulceration is a recurring condition causing pain, reduced mobility, 
and depression.  Randomised controlled trials evaluating treatments for venous 
leg ulcers provide evidence to inform clinical decision-making.  However, for 
findings to be useful, outcomes need to be clinically meaningful, consistently 
reported across trials, and fully reported.  Research has identified that the 
outcomes important to all stakeholders are not always reported.  Research has 
also identified that there are a large number of different outcomes being 
reported, impacting synthesis of results, and clinical decision-making.  A core 
outcome set is an agreed standardised set of outcomes which should be, as a 
minimum, measured and reported in all trials which evaluate treatment 
effectiveness for a given indication.   
Aim 
To develop a core outcome set for research evaluations of interventions used 
for venous leg ulceration.   
Methods 
 
1) A scoping review identified the outcome domains and outcomes that 
have been reported in randomised controlled trials and qualitative 
research. 
2) eDelphi consensus study on the outcome domains. 
3) eDelphi consensus study on the outcomes. 
Results 
 
1) The scoping review identified 807 different outcomes that have been 
reported in the venous leg ulcer randomised controlled trials included in 
the review.  Fifteen outcomes were identified from qualitative studies.   
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2) Ten outcome domains were rated as core by participants in the 
consensus study. 
3) The consensus study on the outcomes refined the outcome domains to 
produce a core outcome domain set comprising of 5 outcome domains.  




A core outcome domain set and a set of 11 candidate outcomes have been 
developed.  The development of a core outcome set has the potential to reduce 
research waste, improve the utility of trials, reduce outcome reporting bias, 
facilitate treatment comparisons across different sources of evidence and 
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Chapter 1 Background 
1.1 Introduction 
This chapter presents an overview of the PhD and the foundations to the 
development of a core outcome set.  It will begin with an overview of venous 
leg ulceration, describing the pathophysiology of a venous leg ulcer, its effect 
on a persons’ quality of life and its financial implications for individuals and 
healthcare organisations.  Randomised controlled trials (RCTs) evaluating 
treatments for venous leg ulceration provide evidence to inform clinical decision 
making.  However, for findings to be useful, outcomes need to be clinically 
meaningful, consistently reported across trials, and fully reported.  Research 
has identified that the outcomes are not always fully reported and there are a 
large number of different outcomes reported across RCTs, impacting upon 
synthesis of results, and clinical decision making.  This chapter then gives an 
explanation to what a core outcome set is, and how it can help.  A discussion 
on core outcome set conceptual frameworks and guidance initiatives then 
follows.  Finally a rationale for the development of a core outcome set for 
venous leg ulceration is provided.       
This PhD is part of a project called the CoreVen (Core outcome set for Venous 
leg ulceration) project which aims to develop a core set of outcome 
measurements for use in research evaluations of interventions used for venous 
leg ulceration.   
1.2 PhD Overview 
This PhD examines the need for a core outcome set and critically examines 
three stages of the research process.  The three stages of the research 
process included: 
1. Scoping review of the outcome domains and outcomes 
reported in venous leg ulcer RCTs and qualitative research. 
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2. Consensus study on the outcome domains identified during 
the scoping review. 
3. Consensus study on the outcomes identified during the 
scoping review. 
1.3 Venous Leg Ulceration 
A venous leg ulcer is a chronic open wound occurring below the knee which 
lasts longer than six weeks or occurs in a person with a history of venous leg 
ulceration (Norman et al., 2016).  It is a chronic and reoccurring condition 
(NICE, 2015).  People can have an ulcer for 10 years or more with some ulcers 
never healing (Cullum et al., 2016; Miller et al., 2017).  For those that do heal 
26-69% experience recurrence within 12 months after healing (Monk and 
Sarkany, 1982; Moffatt and Dorman, 1995; Vowden et al., 1997).   
Venous leg ulceration is caused by venous insufficiency (reduced return of 
venous blood) which is, in turn, caused by damage to the valves in the lower 
legs or blockages in the leg veins.  The function of the venous system of the 
legs is to carry deoxygenated blood from the capillaries in the tissue back to the 
heart before being re-oxygenated in the lungs and filtrated in the kidneys 
(Moffatt et al., 2007).  The combination of the calf muscles and functional 
valves forms the ‘calf-muscle pump’, whereby deformation of the calves, 
through exercise, movement or massage, leads to changes in the pressure in 
the veins within the calves causing the propulsion of the blood towards the 
heart from the capillary bed.  Damage to the valves of the calves allows the 
blood to flow in either direction which results in reduced efficiency of the blood 
returned to the heart (Doughty and Holbrook, 2007).  Reduced efficiency of the 
blood returned to the heart increases the pressure of the blood in the legs; a 
condition known as chronic venous hypertension, causing swelling of the leg 
veins, oedema and leakage of circulatory fluid into the surrounding tissue from 
the capillaries in the lower legs (Smith et al., 1988).  The thin walls of the 
capillaries means when the pressure increases above normal limits (5-15 
mmHg) the capillary walls stretch increasing the size of the pores in the walls 
allowing larger molecules, such as red blood cells and leukocytes, to leak out 
into the surrounding tissue (Burnand et al., 1981; Moffatt et al., 2007).   
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When leakage into the surrounding tissue occurs it causes irritation and fragility 
of the epidermis resulting in ulceration (Doughty and Holbrook, 2007).  The full 
thickness of the skin can be affected from the epidermis to the subcutaneous 
tissue (Lazarus et al., 2013).  The resulting skin lesion is known as a venous 
leg ulcer.   
There are a number of hypotheses that seek to explain the precise mechanism 
for ulceration that directs the care of venous leg ulcers and their prevention.   
Many theories on venous leg ulceration have been suggested however the 
chronicity of venous leg ulceration remains poorly understood.  All hypotheses 
appear to agree that venous hypertension is a critical condition which leads, if 
unchecked, to venous leg ulceration (Morison and Moffat, 1997; Ghauri and 
Nyamekye, 2010).   
The ‘fibrin cuff’ theory was first described by Burnand et al. (1976) who stated 
that venous hypertension and deficient fibrinolysis was related to pericapillary 
fibrin (fibrin cuff).  The theory recognised that nutritional transfer across the 
capillary wall is inhibited by fibrin cuffs (Burnand et al., 1976), and forms a 
barrier to the movement of blood to the epidermal cells (Browse et al., 1977).  
The theory also suggests that the transfer of oxygen across the capillary wall is 
impeded (Stacey et al., 2000).  Falanga et al. (1987) highlight that whilst in vivo 
studies have not provided evidence to support the impediment of oxygen; in 
vitro studies have shown that oxygen cannot transfer across the fibrin layer.   
The ‘trap’ hypothesis suggests that venous leg ulceration is caused by 
macromolecules leaking into the dermis caused by hypertension which ‘traps’ 
growth factors and other factors required for healing such as fibroblasts and 
keratinocytes, hindering their ability to assist healing and maintain skin integrity 
(Falanga et al., 1987).    
Treatment is directed towards seeking to reduce venous hypertension, through 
crude mechanical means, for example the application of devices, bandages 
and pumps, or physiological measures such as the removal of incompetent 
segments of the vein.  
Compression therapy (bandages or hosiery) to treat the underlying venous 
hypertension is considered as the cornerstone of therapy for patients with 
venous leg ulceration (Dealey, 2012; O’Meara et al., 2012).  Adjunct treatment 
options include, for example topical agents, debridement, vasoactive drugs, 
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ultrasound, negative pressure therapy and physical therapies.  There are many 
variants of these treatments and relative effectiveness needs to be established 
in order to provide optimum information to inform evidence based practice.  
However the evidence base supporting some of the adjunct treatments is 
lacking due to the lack of rigorous RCTs.  For example Gethin et al. (2015a) 
concluded in their Cochrane review that there is limited evidence to support 
that debridement of a venous leg ulcer will lead to a clinically significant impact 
on healing.  Cullum and Liu’s (2017) Cochrane systematic review found limited 
evidence to determine whether ultrasound improves healing.  There is also a 
lack of rigorous RCT evidence to support the use of negative pressure wound 
therapy (Dumville et al., 2015).  The evidence was limited in many Cochrane 
reviews because the rigour of the RCTs was not adequate; for example Gethin 
et al. (2015a) found that the included RCTs in their Cochrane review on 
debridement had a small number of participants, incomplete outcome data and 
lack of information on the outcomes leading to a high risk of reporting bias.  
Seven (7/11) RCTs included in Cullum and Liu’s (2017) Cochrane review on 
therapeutic ultrasound had high risk of bias, and three (3/11) had an unclear 
risk of bias.  There was a lack of rigorous RCTs for inclusion in Dumville et al’s 
(2015) Cochrane review on negative pressure therapy.   
The diagnosis of a venous leg ulcer is determined by healthcare professionals, 
such as a nurse or GP, through visual inspection of the leg and the surrounding 
skin around the ulcer.  Diagnosis relies upon a combination of visual inspection, 
a patient’s medical history, clinical tests, signs and symptoms.  A patient’s 
history is important in determining a venous leg ulcer; risk factors suggestive of 
venous disease include increasing age, being female, lipodermatosclerosis, 
family history, previous ulceration, high BMI, venous thromboembolism, 
physical inactivity, increasing number of pregnancies and severe trauma to the 
leg (Lim et al., 2018).  Other signs that the ulcer is caused by venous disease 
includes pain and oedematous skin surrounding the ulcer, dilated veins, venous 
skin changes and it is warm to touch (Lim et al., 2018).  Symptoms such as 
corona phlebectatica (ankle flare), varicose veins, atrophie blanche, 
hyperpigmentation and eczematous skin near the ankle and/or lower leg are 
also indicators of venous disease (Mills and Armstrong, 2018).   
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A hand-held Doppler ultrasound probe can assist in the assessment of venous 
reflux (Moffatt and Franks, 2004).  A hand-held Doppler ultrasound probe can 
assist in distinguishing venous leg ulceration from other causes of leg ulcers 
such as arterial disease.   Distinguishing between causes of ulceration is 
important in determining the safe use of compression therapy.  It helps prevent 
misdiagnosis by assisting the identification of arterial disease for referral to a 
specialist and assesses the appropriateness of compression bandaging (Liao 
and Cheater, 2000).  However it is one element of assessment and should not 
be used in isolation (Vowden and Vowden, 2009).  Relying on the reading of a 
hand-held Doppler ultrasound probe alone can be dangerous because it can 
lead to misdiagnosis, causing incorrect management which affects healing 
rates and in rare occasions loss of a limb (Moffatt et al., 2007).  The hand-held 
Doppler ultrasound probe is used alongside a sphygmanometer to calculate the 
ankle brachial pressure index (ABPI).  The ABPI is calculated by measuring the 
brachial and ankle arterial pressures and then dividing the individual ankle 
pressures by the highest of the brachial pressures to give a ratio (Adderley, 
2013).  
 
The ABPI is calculated using the formula:     
 
Ankle systolic pressure         
                                            = ankle brachial pressure index 
Brachial systolic pressure 
 
An ABPI below 0.5 indicates severe arterial impairment and an ABPI of 
between 0.5 and 0.8 denotes moderate to severe peripheral arterial disease 
(Vowden and Vowden, 2001; NICE, 2015).  An ABPI of 0.81- 1.0 indicates mild 
peripheral arterial disease (Staines, 2018).  A reading above 1.0 indicates no 
peripheral arterial disease (Staines, 2018).  An ABPI above 1.2 indicates 
possible calcification and therefore the application of high compression is 
contraindicated (NICE, 2017). 
A hand-held Doppler ultrasound probe test may not be suitable for people with 
rheumatoid arthritis, diabetes mellitus, atherosclerotic disease and systemic 




Venous leg ulcers are one type of ulcer on the lower leg, other types include 
arterial leg ulcers and mixed aetiology ulcers.  Venous disease and a significant 
level of arterial disease are present in patients with mixed aetiology ulcers.  
Venous leg ulcers are the single most common lower limb ulceration type 
(Harding et al., 2015), accounting for 70% of ulcers of the lower limb (Abbade 
et al., 2005).  
There has been a shortage of good-quality prevalence studies on venous leg 
ulceration (Graham et al., 2003).  Following a systematic review of prevalence 
studies on lower limb ulceration, Graham et al. (2003) concluded that better-
quality prevalence studies are needed.  The systematic review included 21 
prevalence studies.  Graham et al. (2003) found that few of the studies used 
rigorous methods, did not provide a clear definition of ulceration and did not 
validate ulceration with diagnostic tests and clinical assessment.  Graham et al. 
(2003) point out that not all prevalence studies may have been included in their 
review, and studies that were published in another language other than English 
were not included.   
In more recent years leg ulcer prevalence has been investigated along with its 
impact upon financial burden.  It has been estimated that the prevalence of 
venous leg ulceration affects 1% of the population in the Western World but it 
could be as high as 3% in people over the age of 65 (Gohel and Poskitt, 2009).  
The prevalence of current (defined as persisting for four weeks or more) 
venous leg ulcers has been estimated at 0.29 per 1000 population in the United 
Kingdom (95% confidence interval 0.25-0.33 per 1000) (Hall et al., 2014).  Hall 
et al’s (2014) cross-sectional point prevalence survey was completed by care 
providers in Leeds, including Leeds NHS community and primary care services 
(1 community trust, 1 primary care trust, 113 general practices), NHS mental 
health services (1 trust), NHS acute services (1 trust), independent hospitals 
(n = 3), prisons (n = 2), nursing homes (n = 46), and hospices (n = 2).  Hall et 
al’s (2014) data collection took place over two weeks in 2011. 
Guest et al. (2017) analysed data from The Health Improvement Network 
(THIN) which showed that the annual figures for venous leg ulceration in 
2012/2013 in the UK was 277,749 out of a total 731,000 leg ulcers.  However of 
the 731,000 leg ulcers 24,442 were mixed aetiology and 419,956 were not 
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specified.  In Leeds, UK venous leg ulceration is the most common wound type 
in men with a point prevalence of 0.25 per 1000 (95% CI 0.20 to 0.30 per 1000) 
(Cullum et al., 2016).  Cullum et al’s (2016) research included complex wounds 
described as being wounds that heal by secondary intention and include lower-
limb ulcers, pressure ulcers, and surgical wounds that healed by secondary 
intention.  
It has been difficult to estimate the prevalence of venous leg ulcers accurately 
because studies do not always differentiate between the types of the ulcers, for 
example whether the ulcer was venous, arterial or mixed aetiology (Vowden 
and Vowden, 2009; Cullum et al., 2016).  Firth et al. (2010) also highlight doubt 
over the rigour of prevalence studies in terms of diagnostic inclusion criteria, 
and Firth et al also state that self-report by patients in prevalence studies is 
open to recall and nonresponse bias.  
1.5 Impact of Venous Leg Ulceration  
Venous leg ulceration can have a significant impact on a person, causing 
distress due to pain, malodour, susceptibility to infection and lack of mobility 
(Nelzen et al., 1994; Briggs and Flemming, 2007; Franks et al., 2016).  The 
moist atmosphere of a venous leg ulcer creates an ideal medium for bacterial 
growth, and it has been suggested that bacterial burden can prolong healing 
which impacts quality of life and may have financial implications for patients 
and healthcare organisations (Miller et al., 2017).  Infection is associated with 
pain, swelling and odour (O'Meara et al., 2014).  A person’s quality of life is 
affected through the reduction in social activity, limits on their capacity to work, 
inability to carry out self-care and maintain personal hygiene (Herber et al., 
2007).   
A number of studies have sought to explore the experiences of people living 
with venous leg ulcers, some of which were captured in systematic reviews by   
Persoon et al. (2004) and Herber et al. (2007).  Persoon et al. (2004) and 
Herber et al. (2007) investigated a total of 49 studies including both quantitative 
and qualitative methods.  The main findings of the studies included pain which 
restricted physical activity which in turn reduced social interaction.  Pain also 
caused sleep deprivation and an increased need to administer analgesia.  
Ulceration was also associated with malodour, pruritus, limited capacity to work 
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and perform leisure activities, and swelling in addition to psychosocial impacts 
such as depression and helplessness (Herber et al., 2007).   
Briggs and Flemming (2007) performed a meta-synthesis on 12 qualitative 
studies examining patients’ experiences associated with venous leg ulceration.   
One hundred and seventy-two experiences arose which were synthesised into 
five categories; one: physical effects of ulceration including pain, odour, itch, 
leakage and infection, two: describing the leg ulcer journey which included 
experiences such as accepting the chronic nature and cycle of hope and 
hopelessness, three: patient-professional relationship both positive and 
negative, four: the cost of a leg ulcer which exemplifies the physical, social and 
financial limitations including; reduced mobility and social isolation, and five: 
psychological impact such as feelings of embarrassment.   
The consistent reporting of the findings identified by the systematic reviews 
(Persoon et al., 2004; Herber et al., 2007) and synthesis of qualitative studies 
(Briggs and Flemming, 2007) means that it can be inferred that venous leg 
ulceration causes pain, limits mobility, impacts social interaction and causes 
psychosocial impacts such as depression, helplessness and low self-esteem. 
1.6 Financial Burden  
Venous leg ulcers are associated with significant direct and indirect costs which 
are increasing annually, it has been estimated that the cost of open venous leg 
ulcers to the NHS is at least £168m-£198 million per year (Posnett and Franks, 
2007).  More recently a retrospective cohort analysis of the records of 2000 
patients on The Health Improvement Network (THIN) Database showed that 
venous leg ulceration cost the NHS an annual sum of approximately £941.13 
million (including ambulance and A and E attendances) between 2012 and 
2013 (Guest et al., 2017).  Of which, community nurse visits cost £131.27 
million, practice nurse visits cost £60.31 million, GP visits cost £44.82 million, 
specialist nurse visits cost £0.27 million, Allied health care cost £2.86 million, 
hospital outpatient appointments cost £56.92 million, hospital admissions and 
day cases cost £ 102.33 million, diagnostic tests cost £28.90 million, wound 
care products cost £168.08 million, non-wound devices cost £23.94 million and 
drug prescriptions cost £319.48 million (Guest et al., 2017 p. 327). 
9 
 
There is a considerable financial impact to patients and carers with prescription 
costs (dressings, bandages and medication), increased laundry expense due to 
leakage from the ulcer and loss of work days (Charles, 1995; Rabe and 
Pannier, 2010). 
1.7 Evidence-based Practice 
As discussed in the previous sections, venous leg ulceration is a problem for 
individuals and for society therefore effective management is required.  Good 
quality evidence is needed on the effectiveness of interventions for the 
treatment of venous leg ulceration to guide practice.  Evidence-based practice, 
also termed evidence-based medicine, evidence based-nursing or evidence-
based decision making has been explained by Sackett et al. (1996) as being 
“about integrating individual clinical expertise and the best external evidence” 
(p. 71).  It is also about integrating patient’s preferences and predicaments 
(Sackett et al., 1996).  It is concerned with the use of the best source of 
evidence to answer a research question with clinical expertise to assist 
decision making.   
Healthcare professionals have a responsibility to ensure that patients receive 
high quality care through evidence-based practice.  This in turn can improve an 
individual’s quality of life and it means NHS resources are used more efficiently 
and effectively.  Healthcare professionals often have to make decisions (with 
the patient wherever possible) about a patient’s care.  Sub-optimal care will 
have a negative effect on a patient’s quality of life as well as increasing the cost 
of managing venous leg ulcers for the NHS (NHS RightCare, 2017). 
The Nursing and Midwifery Council code (NMC, 2018) contains professional 
standards of practice that must be upheld by registered nurses and midwives.  
Under the standard ‘Practise effectively’ the code states that practice should be 
in line with the best available evidence by using evidence-based information.  It 
also states under the standard ‘Preserve safety’ that the current evidence, 
knowledge and developments should be taken into account so that mistakes 
and their effects are reduced.   
The NHS’s Five Year Forward View includes its’ ‘Triple Aim’ which is: ‘better 
experiences for people, better outcomes and better use of resources’ (NHS, 
2016).  There are 10 aspirational commitments to help achieve the ‘Triple Aim’, 
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one being; “We will lead and drive research to evidence the impact of what we 
do” which encompasses a key message that research should be used to 
improve care (NHS, 2016, p.126).   However this can only happen if the 
available evidence is of high quality, coherent, relevant, clinically meaningful 
and consistently reported. 
The generation of high quality evidence is reflected in the development of trial 
networks such as Trial Forge (2018) which aims to improve trial efficiency in 
systematic reviews using an evidence based approach to designing, running, 
analysing and reporting trials.  In addition, organisations have also sought to 
improve the reporting of trials through initiatives such as the Equator Network 
(2018) and CONSORT (Consolidated Standards of Reporting Trials, 2018).  
Further, the decisions that trialist’s make on what to report is also being 
improved through the development of core outcome sets which standardise the 
outcomes reported in RCTs.  
1.8 The Current Problem 
It is vital that the outcomes reported in trials are important to decision makers 
including patients, their nurses, doctors and family.  However, the outcomes 
reported in RCTs are not always what are regarded as important to patients 
(Chalmers and Glasziou, 2009).  Patients hold unique knowledge about venous 
leg ulceration through living with and experiencing the effects it can have 
therefore it is essential that the outcomes reported in trials are outcomes that 
are important to patients as well as other stakeholders.  Research that reports 
on the outcomes that are of the greatest importance to patients will assist 
patients and their clinicians to communicate more effectively and efficiently 
enabling better informed choices about their care (Franks et al., 2016). 
A qualitative study by Cullum et al. (2016) which identified the most important 
outcomes for complex wounds, including venous leg ulcers, from the 
perspectives of patients, carers, and healthcare professionals, found that 
healing of the wound was the primary treatment goal yet patients were also 
greatly troubled by the social consequences of having a complex wound.  It is 
essential that the outcomes measured and reported in trials are outcomes that 
are needed by all decision makers.  Research cannot help patients and 
healthcare professionals if it is not usable, meaningful or comparable.  A lack of 
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consideration over the choice of outcomes has led to waste in the production 
and reporting in trials which could be avoidable with the use of a core outcome 
set (Chalmers and Glasziou, 2009; Williamson et al., 2017; van ‘t Hooft et al., 
2018).  An intervention may be tested for its impact on healing whilst other 
outcomes important to patients and carers such as pain, harms and costs are 
not reported on.  It is a waste of research to not report on outcomes that are 
core to important stakeholders, such as patients, rather than just the trialist. 
There are many types of study designs such as cohort, cross-sectional, case-
control, RCT, case study, and observational studies.  The selection of the most 
suitable study design depends upon the research question.  For example 
qualitative research has been praised for its ability to reveal additional insights 
when a person is given the freedom to talk (Mason, 2002; Briggs and 
Flemming, 2007).  However, non-experimental approaches to testing whether 
something works have been criticised for giving false positive conclusions on 
efficacy (Sackett et al., 1996).  Venous leg ulcer RCTs provide evidence to 
inform decision making in healthcare.  RCTs are a rigorous way of establishing 
the clinical effectiveness, and the efficacy and safety of an intervention 
(Pocock, 1983; Jadad and Enkin, 2007).  RCT’s randomly allocate all 
participants to two or more treatment options, often participants are randomly 
allocated to either a control group and to an experimental group.  The effects of 
the intervention are observed by assessing the outcomes of both the 
experimental group(s) and the control group(s) (Torgerson and Torgerson, 
2008).   
The large number of outcomes that are reported in venous leg ulcer RCTs  
pose challenges in comparing the outcomes and limits the ability for meta-
analysis and impedes systematic reviews (Gethin et al., 2015b).  High quality 
systematic reviews and meta-analyses are vital tools in summarising the 
evidence.  They help keep clinicians up to date with the evidence, aid decision 
making, provide evidence for policy makers, assist clinical guideline developers 
and summarise the evidence for patients and carers (Liberati et al., 2009).  
Systematic reviews collate and synthesise studies using tools to minimise bias 




Systematic reviews can sometimes include a meta-analysis.  A meta-analysis 
combines the results of two or more studies to produce a statistical estimate 
(Deeks et al., 2011).  The results of the studies are pooled together to produce 
a single overall effect size (Petticrew and Roberts, 2006).  Effect size is the 
magnitude of difference between the intervention groups (Sullivan and Feinn, 
2012).  A meta-analysis has the potential to increase power and precision, and 
may help resolve controversies that arise from conflicting claims (Deeks et al., 
2011).  When trial outcomes are not similar or at least comparable it means a 
meta-analysis cannot be performed (Eysenck, 1994).  The use of a core 
outcome set can improve the reliability of systematic reviews and meta-
analyses because it increases the amount of usable information (Kirkham et al., 
2013). 
The reported outcomes need to be easily interpreted, evaluated and compared.  
However literature reviews suggest that the outcomes measured in venous leg 
ulcer trials vary considerably (Dwan et al., 2008; Gottrup et al., 2010; Gethin et 
al., 2015b; Liu et al., 2017).  A vast and varied number of outcomes create 
challenges in comparing and contrasting the outcomes.  It potentially means 
that a partial view of important findings is presented, affecting synthesis of the 
results and clinical decision making.  Liu et al. (2017) analysed outcomes pre-
specified in Cochrane Wounds systematic reviews and found a large number 
(n=126) of different outcome domains (such as wound healing) were specified.  
Liu et al (2017) state that the large number reflects the variation of reported 
outcomes in trials.  
In addition to the variation in outcomes, there are also issues with the definition 
of the outcomes.  Gottrup et al. (2010) produced a recommendation document 
to improve the quality of evidence in wound management.  The 
recommendations are based on position documents, systematic reviews and 
an analysis of comparative studies.   As part of the recommendation document 
Gottrup et al (2010) performed a literature review on studies published between 
2003-2009 whose objectives included the examination of chronic wounds and 
ulcer endpoints, and endpoint definitions.  Gottrup et al (2010) define an 
endpoint as being “the objective of an evaluation or study” (p. 249).  They found 
that 45% of 176 articles did not predefine their endpoints or their definition was 
not sufficient; for example of the 53 articles whose endpoint included wound 
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closure, 36% did not define what was meant by wound closure.  In a systematic 
review by Gethin et al. (2015b) a lack of wound healing definitions was also 
found with 61% (62/102) of RCTs on venous leg ulceration not providing a 
definition.  The systematic review assessed the heterogeneity of wound 
outcome measures in RCTs of treatment for venous leg ulceration published 
between 1998 and 2013. 
There are also issues with the reporting of measurement instruments used to 
measure the outcomes.  Seventy percent (123/176) of studies defined the 
measurement instrument that was used but 76% (134/176) of the instruments 
did not meet the reproducibility criteria and 30% (53/176) were not robust.  
Gottrup et al. (2010) defined robustness as the adequacy of information on the 
measurement method used in order for another to replicate the data collection 
and defined reproducibility as (p.262):  
the inclusion of a verifiable source of data, e.g. photos, to secure 
the possibility of validation from an external source by 
reproducing the study, or the involvement of an external 
validation source as part of the study design  
 
Similarly, Gethin et al. (2015b) found problems with the reporting of 
measurement methods.  Gethin et al. (2015b) found that only 5% (5/102) of the 
studies made a reference to the reliability or validity of the measurement 
methods. 
Different types of bias can arise when trials do not adequately report outcomes.  
Outcome reporting bias is the selective reporting of data for an outcome, the 
selective reporting of subsets of the data and the selective reporting of the 
analyses using the same data, for example when a researcher changes from 
an intended comparison of the final values to the difference between baseline 
to the final value (Higgins et al., 2011).  Outcome reporting bias can result in 
the reader having an overly optimistic estimate of an interventions effect which 
wrongly influences decision making (Clarke, 2007).  Post-hoc decisions to 
report on other outcomes not specified in the protocol due to the results of the 
trial results in a biased data environment.   
Reporting bias is the reporting of statistically significant findings of a trial 
opposed to reporting both significant and non-significant findings (Higgins et al., 
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2011).  Publication bias is the reporting or non-reporting of the results of a trial 
dependent upon its results (Song et al., 2010).  
Data dredging is a slang term for when analysis is done post hoc which is not 
relevant to a pre-stated hypothesis (Porta, 2016).  It has also been called 
“cherry picking” whereby a biased selection of favourable results are reported 
or a subset of data is analysed (Porta, 2016).  Multiple analyses whereby 
comparisons of groups for more than one outcome can lead to a false positive 
(Lord et al., 2004).  The standardisation of outcomes reported in venous leg 
ulceration research will potentially reduce data dredging.   
Gethin et al’s (2015b) systematic review showed that 39% (40/102) of RCTs 
did not report any endpoints in the methods section.  Forty percent (41/102) of 
RCTs did not state whether the outcome was primary or secondary.  Hodgson 
et al. (2014) performed a methodological overview of chronic wound trials 
published between 2004 and 2011 which investigated the influence of industry 
funding on methodological quality.  Hodgson et al. (2014) found that only 59% 
(98/167) of trials defined their primary outcome.  Failure of RCTs to report 
outcomes in full is likely to result in only a subset of data being available for 
synthesis.  A methodological study (Outcome Reporting Bias In Trials - ORBIT) 
found that only 55% (157/283) of the eligible trials in a cohort of Cochrane 
reviews, published in three issues of the Cochrane library between 2006 and 
2007, included full data for primary outcomes (Kirkham et al., 2010).  The 
CONSORT guidelines state that the primary and secondary outcomes should 
be pre-specified (Moher et al., 2010).  The pre-specified primary outcome is 
thought of as being the most important to stakeholders and it is normally used 
to base the sample size calculation upon (Moher et al., 2010).  In a systematic 
review by Dwan et al. (2008) it was found that 40-62% of wound care studies 
had a primary outcome that was either changed, omitted or introduced in the 
studies publication compared to the protocol. 
1.9 Core Outcome Sets 
A core outcome set is an agreed standardised set of outcomes which should 
be, as a minimum, measured and reported in all RCTs or other forms of 
research which evaluate treatment effectiveness for a given indication 
(COMET, 2019).  It includes what to measure and how to measure.  An 
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outcome is a precisely defined method of assessing the effectiveness (benefit) 
or adverse effects (risk) of a healthcare intervention (Williamson et al., 2017). 
The core outcome set is a minimum list therefore trialists can add additional 
outcomes relevant to their trial if they wish.  An agreed standardised set of 
outcomes is a set of outcomes that have been agreed by stakeholders to be 
core and should be reported in all RCTs or other forms of research which 
evaluate treatment effectiveness.    
A core outcome set for use in research evaluations of interventions used for 
venous leg ulceration has the potential to:  
• include the outcomes that really matter to all stakeholders 
• reduce research waste 
• increase the utility of RCTs which in turn assists decision making 
• reduce publication and outcome reporting bias 
• facilitate treatment comparisons across different sources of evidence 
• expedite the production of systematic reviews, meta-analyses and 
evidence-based clinical guidelines 
Many areas of healthcare across varying populations and condition types have 
developed core outcome sets.  Examples of other core outcome set developers 
include HOME (Harmonizing Outcome Measures for Eczema) (Schmitt et al., 
2011), OMERACT (Outcome Measures in Rheumatology) (Boers et al., 2014), 
BARIACT (Coulman et al., 2016) which is a project developing a core outcome 
set for bariatric and metabolic surgery, and Millar et al. (2017) who developed a 
core outcome set for optimising prescribing in older adults in care homes.  The 
reasons for core outcome set development in these areas are similar to the 
problems faced in venous leg ulceration research.  For example HOME 
(Schmitt et al., 2011) aimed to achieve a better standardisation of outcomes in 
eczema rather than the wide variation that existed before the core outcome set 
and Millar et al (2017) found that heterogeneity of outcomes hindered 
comparisons of interventions aimed to optimise prescribing.  OMERACT (Boers 
et al., 2014) found that rheumatologists used trial outcomes very differently 
resulting in varied conclusions about treatment efficiency.  Similarly, BARIACT 
(Coulman et al., 2016) also found heterogeneity of reported outcomes causing 
challenges to cross-study comparisons and meta-analysis.   
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There is currently no core outcome set for use in research that evaluates 
interventions used for venous leg ulceration therefore this PhD set out to 
develop a core outcome set for use in research evaluations of interventions 
used for venous leg ulceration. 
1.10 Guideline Initiatives and Conceptual Frameworks 
COMET (Core Outcome Measures in Effectiveness Trials, 2019) is an initiative 
which brings together researchers interested in the development and 
standardisation of core outcomes.  The initiative’s website contains many 
protocols and published papers on core outcome sets. 
The COMET initiative provides guidance and resources on the development of 
a core outcome set.  The COMET database is home to completed and ongoing 
projects.  Further details on the CoreVen project can be found on the COMET 
database: http://www.comet-initiative.org/studies/details/680. 
Methodological frameworks have been developed by experienced core 
outcome set developers to help guide the process of core outcome set 
development, such as the frameworks by OMERACT (Boers et al., 2014) and 
HOME (Schmitt et al., 2015).   
OMERACT established over 20 years ago, is an initiative of international health 
professionals developing outcome measures in rheumatology.  Boers et al. 
(2014) developed the OMERACT filter 2.0, shown in Figures 1 and 2, which is 
a conceptual framework that guides the development of core outcome 
measurement sets for rheumatology but it can also be used for other areas of 
healthcare.     
The first OMERACT filter was designed in 1998 (Boers et al., 1998) and it was 
then updated to the OMERACT filter 2.0 in 2014.  The first filter was developed 
through a consensus process, involving various health research experts and 
patients.  It was grounded in a framework by Fries et al. (1982), and later 
adapted by Kirwan (1992).  Then in 2014 Idzerda et al, who are part of the 
OMERACT team, performed a scoping review to establish if there were any 
other available conceptual frameworks or models.  Idzerda et al. (2014) 
concluded that there was a lack of frameworks on measurement in trials of 
efficacy and effectiveness, and those that were identified lacked sufficient 
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documentation to their development process thus prompting the development 
of the OMERACT filter 2.0 in 2014. 
The OMERACT filter 2.0 was used to help guide the development of the core 
outcome set for venous leg ulceration and to ensure comprehensiveness of the 
core outcome set.   
The first part of the filter shown in Figure 1 aims to ensure comprehensiveness 
of the core outcome set by specifying key areas.  It specifies the core concepts 
of the health condition, these being; “Impact of Health Conditions” and 
“Pathophysiological Manifestations”.  ‘Impact of health conditions’ includes 
aspects that directly ‘impact’ service users and other stakeholders. It contains 
three ‘core areas’; Death, Life Impact and Resource Use.  The core concept 
and core area ‘Pathophysiological manifestations’ contains important markers 
of the disease, for example organ function (e.g. lung function). 
The second part of the filter (Figure 2) shows the process for the core outcome 
set development (the process for deciding what to measure).  OMERACT 
provide a stepwise process to aid the development of a core outcome domain 
set.  The first step involves investigation into which (if any) contextual factors 
need to be measured and whether there are specific adverse events that need 
to be included.  The ‘what’ to measure should be determined by performing a 
literature review on the domains and instruments.  Simultaneously, 
stakeholders are consulted on what they think should be measured.   
The list of ‘what’ to measure, which has been matched to their specific 
domains, is then put through a consensus process involving stakeholders 
resulting in a core domain set (Boers et al., 2014).  
The framework highlights that the choice of the ‘domains’ is influenced by 
context, therefore meaning the domains are dependent upon the health 
condition.   
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Figure 1 OMERACT filter 2.0 core concepts of the health condition  
(Boers et al., 2014, p. 748)  
 
Figure 2 OMERACT filter 2.0 stepwise process to the development of a core 
domain set  






HOME have published a ‘roadmap’ which guides the development of core sets 
of outcome measurements (Schmitt et al., 2015).  The first part of the 
‘roadmap’ gives guidance on the development of a core outcome set and the 
second part guides the development of outcome measurements.   HOME 
shares their experience of developing a core outcome set and the methods 
they used which is useful for other core outcome set developers whilst 
increasing the transparency of their methods.  The experiences that HOME 
encountered were drawn upon during the development of the core outcome set 
for venous leg ulceration.  The roadmap provided a robust approach to 
agreeing what is ‘core’.  
The first part of the roadmap contains two steps; the first step outlines the 
scope and applicability of a core outcome set, including: 
• Population (i.e. healthcare area, venous leg ulcers) 
• Setting (e.g. clinical trial) 
• Geographical scope  
• Stakeholders (e.g. patients, researchers, healthcare professionals) 
Step two recommends that the development of the core outcome set is done 
using a consensus study, ideally the Delphi technique or the Nominal Group 
Technique (NGT).  Consensus methods are discussed in chapter 2.   
OMERACT and HOME also provide guidance on the development of a core set 
of measurement instruments which is discussed in chapter 6, section 6.9.3. 
The COMET initiative, the OMERACT filter 2.0, and the HOME ‘roadmap’ were 
chosen to help guide the development of a core outcome set.  They are 
workable models, produced by established core outcome set developers. 
1.11 Core Outcome Set for Venous Leg Ulceration 
The outcomes in the core outcome set need to be applicable, and therefore 
core, to every venous leg ulcer trial.  Figure 3 displays a pictorial representation 
of what is meant by ‘core’.  An example of an important but not core outcome 
might be sub-bandage pressure, it is an important outcome for a trial that is 
focusing on compression but it is not applicable in trial evaluating other types of 
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interventions such as dressings.  The trials on the interventions displayed in 
Figure 3 are examples and there are many more interventions that trials 
investigate.   




1.12 Scope of the Core Outcome Set 
 
Kirkham et al. (2017) recommend defining the scope of the core outcome set 
which includes outlining the research setting to which the core outcome set is 
to be applied, the health condition, the population and the intervention(s) 
covered by the core outcome set.   
The core outcome set will be aimed for use in research evaluations of venous 
leg ulceration interventions, for example randomised controlled trials, audits, 
clinical guidelines, systematic reviews and meta-analyses.  
The core outcome set will pertain to all patients regardless of sex, age, duration 
of disease and the severity of the ulceration. 
Outcomes relevant 












‘Core’ outcomes are 
relevant to ALL 
randomised controlled 
trials, regardless of 
intervention type  
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Although venous leg ulceration can be treated by various interventions 
(discussed in section 1.3), the intention of the core outcome set is to relate to 
all research evaluations of venous leg ulcer interventions, regardless of the 
type of intervention.   
1.13 Definitions 
This section provides the definitions used in this PhD.  The definitions are 
summarised in Table 1.  Chapter 4, section 4.2, discusses the rationale behind 
the definitions. 
Table 1 Definition of the terms used 
Outcome domain This relates to what is being measured. Outcome 
domains are broad, descriptive categories under 
which several, more specific, outcomes might be 
grouped.  An example of an outcome domain is 
‘healing’.  Outcome domains have also been 
referred to as ‘domains’ by some core outcome set 
developers (Boers et al., 2014). 
Outcome This also relates to what is being measured. An 
outcome should be a precisely defined method of 
assessing the effectiveness (benefit) or adverse 
effects (risk) of a healthcare intervention (Williamson 
et al., 2017).  Where the outcome domain is defined 
as ‘healing’ (as in the example above), examples of 
related outcomes could include: time to healing; the 
number of ulcers completely healed at 3 months, or; 
the change in ulcer surface area relative to baseline 
at 3 months.  
Candidate outcome 
domain 
The candidate outcome domains were the outcome 
domains that were subjected to the consensus 
process.   
Candidate outcome A candidate outcome is an outcome which could 
potentially be included in the core outcome set.   
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Core outcome set  An agreed standardised set of outcomes which 
should be, as a minimum, measured and reported in 
all RCTs or other forms of research which evaluate 
treatment effectiveness for a given indication 
(COMET, 2019).  It includes what outcome domains 
and outcomes should be measured and how the 






An agreed set of measurement instruments to 
measure the core outcome domains and outcomes.  




Venous leg ulceration continues to be a significant problem, impacting upon 
people worldwide, affecting their quality of life and causing financial burden to 
patients and healthcare organisations.  One of the key clinical challenges is 
therefore to identify effective methods for treating venous leg ulcers, reducing 
their impact on people, providing effective care, and make the best use of 
resources.  RCTs, systematic reviews and meta-analyses are fundamental in 
establishing the clinical effectiveness, and the efficacy and safety of 
interventions to treat venous leg ulceration.  However RCTs do not always 
report outcomes that matter to patients, nurses and doctors.  The heterogeneity 
of reported outcomes across RCTs causes problems in the comparing and 
contrasting of the outcomes, impeding different sources of evidence synthesis 
thus obstructing decision making.   
The development of a core outcome set has the potential to help overcome the 
problems identified in the reporting of outcomes in venous leg ulceration 




Consensus methods are a useful way of gaining agreement from stakeholders 
on what the most important outcomes are and should be reported in research 
evaluations of interventions used for venous leg ulceration. 
The next chapter will explain what is meant by consensus, it will discuss the 







Chapter 2 Consensus Methods 
2.1 Introduction 
This chapter begins by explaining what consensus is, it will then discuss the 
different methods for arriving at consensus (individual, group, informal and 
formal).  It will explore the four main consensus methods being the Delphi 
method, Nominal Group Technique, consensus development conference and 
the RAND/UCLA Appropriateness method before comparing the methods and 
examining their methodological issues.  Finally it will discuss the rationale 
behind selecting the Delphi method as the main consensus method used in this 
PhD. 
Consensus is concerned with the level of agreement that respondents have 
with an issue, cue, item or statement under investigation, which is commonly 
rated on a numerical or categorical scale (Jones and Hunter, 1995).  
Consensus methods are used to define levels of agreement amongst 
individuals on a controversial issue (Fink et al., 1984).  The objective of 
consensus is to reach a final statement or set of statements.  The level of 
consensus is contingent upon the sample size, the aim of the research and 
resources available (Hasson et al., 2000).  The methods used, including how 
consensus was defined and its rationale, need to be clearly reported for a study 
to demonstrate rigour.  The optimum level of consensus would be 100% 
however many researchers have not been able to achieve unanimity.  A 
universally agreed level (other than 100%) of consensus does not exist 
(Hasson et al., 2000).  A variety of ways to define consensus have been 
suggested but the majority do not justify their reasons (Williamson et al., 2017).     
Judgements made by one person (the ’best person’ model) have a number of 
issues: how is the ‘best person’ identified?, it is not possible for one person to 
have access to all the relevant evidence, and they may have limited credibility 
restricting the credibility of the results (Murphy et al., 1998), therefore a group 
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decision by means of consensus is advantageous.  The ‘group’ decision 
enables a wider range of experience and expertise to be voiced, whilst 
encouraging group members to consider a range of options they might not 
have considered if making a decision individually (Murphy et al., 1998).  A 
group view may also carry more weight than an individuals’ view and 
idiosyncrasies are filtered out, however sometimes wrongly (Murphy et al., 
1998).  
Informal methods of consensus, such as face-to-face discussions are often 
used but they are at risk of dominance by individuals with powerful and 
intimidating personalities (Jaeschke et al., 2008).  The presence of individuals 
with authority, for example a manager, may threaten the integrity of elicited 
views.  Face-to-face discussions can lead to a person defending their stand 
point without consideration to other options and opinions, or a person can be 
persuasively influenced by the opinions of more dominant individuals in the 
group (Dalkey and Helmer, 1963; Sinha et al., 2011).  Thus demonstrating that 
the way in which consensus methods are conducted is important. 
Formal consensus methods can provide structure to the consensus process, 
allowing for the synthesising of judgements when there is uncertainty (Black et 
al., 1999).  They are a way of establishing shared agreement on a topic where 
there is a lack of agreement (Moules et al., 2017).  Formal methods can define 
the levels of agreement on contentious topics (Fink et al., 1984).   
Formal consensus methods have been used by many researchers to develop 
core outcome sets (Taylor et al., 2008 (OMERACT team) ; Schmitt et al., 2011 
(HOME team) ; Sinha et al., 2012; Gargon et al., 2014; Coulman et al., 2016; 
Gorst et al., 2016a; Gorst et al., 2016b; MacLennan et al., 2017; Millar et al., 
2017; Orbai et al., 2017; Davis et al., 2018).   
There are four main formal consensus method approaches that have been 
used in healthcare over the last 69 years.  The Delphi method was introduced 
in the 1950s, then the nominal group technique in the 1970s, then the 
consensus development conference in 1977, followed by the RAND/UCLA 
Appropriateness Method (RAM) in the 1980s. 
The four main formal consensus methods will now be presented and each 
method will be critically considered whilst comparing and contrasting their 
methodological features.  Comparisons of the four formal consensus methods 
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including the Delphi method, Nominal Group Technique, consensus 
development conference and RAND/UCLA Appropriateness Method are 
presented in Table 3, section 2.6. 
2.2 Delphi Method 
 
In an exploratory study on ‘How good are expert predictions in areas germane 
to policy’ by Kaplan et al (1950) it was found that the statistical combination of 
individual responses is stronger than face-to-face group responses which may 
be affected by specific effects of collective effort.  Statistical combination is for 
example the combination of ratings in a survey to produce an overall result i.e. 
the overall rating score for an item on a survey.  A measure of central tendency 
is needed to analyse the levels of agreement.  Following Kaplan et al’s (1950) 
findings, the Delphi method was developed, also termed the Delphi technique 
or Delphi study, which was originally named Project Delphi during 1950-1960’s.  
The then named ‘Project Delphi’ was first used at the RAND (Research ANd 
Development) corporation as part of a military defence project.  The RAND 
corporation is a non-profit research organisation that develops solutions to 
challenges that arise in public policy with an aim to make communities safer 
and more secure (RAND Corporation, 2018).   
Due to security reasons the first publication on RAND Corporation’s Delphi 
method was first published thirteen years later by Dalkey and Helmer (1963).  
The aim of ‘Project Delphi’ was to estimate the number of A-bombs to reduce 
munitions output by a prescribed amount (Dalkey and Helmer, 1963).  The 
object of the Delphi method was “to obtain the most reliable consensus of 
opinion of a group of experts…by a series of intensive questionnaires 
interspersed with controlled opinion feedback” (Dalkey and Helmer, 1963 p. 
458).   
The method was made up of five questionnaires which were completed in 
private and submitted at weekly intervals. The first and third questionnaires 
were followed by interviews.      
The rationale behind the series of questionnaires lies in Dalkey and Helmer’s 
(1963) belief that the repeated individual questioning and the design of the 
questions elicits reasoning behind respondents’ answers to the primary 
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question.  Respondents also consider the factors involved when they think 
about the question/topic (Dalkey and Helmer, 1963).   
The interviews that followed the first questionnaire asked participants to 
estimate the number of bombs required to reduce munitions output with 10% 
and 90% confidence of success, and they were asked what type of data is most 
useful in helping him or her to work out the estimate.  The interview that 
followed the third questionnaire clarified any uncertainties.  No further details 
were given on the interviews, such as how the interviews were performed and 
structured, therefore it is difficult to fully assess the rigour of the study. 
The method was found to elicit responses that are more conducive to 
independent opinion compared to face-to-face discussions and helped guide 
participants to the consider another’s opinion (Dalkey and Helmer, 1963).  In 
the context of developing of a core outcome set, a participant may alter his or 
her opinion once he or she has seen the opinions of other stakeholder groups 
(e.g. patients) without the risk of dominance by individuals with powerful 
personalities or with positional power.  Dalkey and Helmer (1963) stated that 
direct confrontation provokes a response of defending ones stance, a 
predisposition to be influenced by dominant others and a tendency to close 
one’s mind to novel ideas. 
Dalkey and Helmer (1963) pointed out a number of limitations to their 
‘experimental procedure’ and state that further experimentation is required 
because the design was in the preliminary stages.  The limitations included the 
potential for respondents to have discussed their responses with each other 
(some respondents worked alongside each other), and Dalkey and Helmer 
(1963) state that the information supplied by the “experts” may have caused 
some “leading” by the researchers however they do not explain this further.   
Following the development of the Delphi method by Dalkey and Helmer (1963), 
Dalkey (1967) summarised the Delphi method into three characteristics: 
anonymity, controlled feedback and statistical group response whereby the 
respondents ratings are aggregated to produce an overall result (e.g. overall 
rating score).  Dalkey (1967) stated that anonymity reduces the effect of a 
dominant individual by provoking individual responses in private without the risk 
of another person influencing them.  Conversely, anonymity may lead to a lack 
of accountability (Lelkes et al., 2012), thus suggesting responses in an 
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anonymous survey may not elicit ‘true’ responses because participants are not 
accountable for their answers. 
Controlled feedback, whereby the results of each questionnaire is fed back to 
the respondents, reduces “noise” allowing respondents to focus on the issue at 
hand (Strauss and Zeigler, 1975).  Dalkey (1967) highlighted that the method 
was still in the experimental stages.  Since then there has been a broadening of 
the Delphi method which has been used across a variety of disciplines 
including nursing, health services and medical research (Chin et al., 1990; 
Beers et al., 1991; Mobily et al., 1993; Smith and Murphy, 1994; Palmer and 
Batchelor, 2006).   
An overview of the method is displayed below (Jones and Hunter, 1995): 
Round one: Relevant (based on knowledge or experience) individuals 
are invited to provide their opinions, and the research team express their 
opinions.  The opinions are collated in preparation for a survey.  
Appropriate ‘experts’ to take part in subsequent survey rounds are 
selected. 
Round two: Participants rate their agreement with the survey 
statements. 
Round three: Summarised ratings of participant’s agreement with the 
survey statements are shown to participants.  Participants are asked to 
re-rate their agreement with the same statements with an opportunity to 
change their score in light of the group’s responses.  If an acceptable 
level of consensus is achieved the survey round process may cease, if 
not, the third round is repeated. 
 
In more recent years, the Delphi process has been modified (thus called the 
‘modified Delphi’) by researchers dependent upon their research question, for 
example the use of the Delphi method in the development of a core outcome 
set may start by asking participants open questions to generate a list of 
outcomes instead of the list being produced by the research team (Sinha et al., 
2012).  Alternatively researchers have performed a literature/systematic review 
to identify outcomes for the list of outcomes to be presented to participants in 
round one of the Delphi study (Al Wattar et al., 2017).  Others have opted for a 
combination of a literature/systematic review and interviews with participants to 
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generate a list of outcomes for the consensus process (Millar et al., 2017).  The 
number of rounds have also been modified.  The number of rounds is an 
important factor to consider because reliability increases as the number of 
rounds increase, however too many rounds can result in participant fatigue 
(Hasson et al., 2000).  Reliability is the extent to which similar ratings are 
produced under constant conditions on every occasion (Hasson et al., 2000).  
Traditionally the Delphi method used five rounds (Dalkey and Helmer, 1963), 
but two to three rounds with an optional face-to-face meeting or consensus 
meeting have been used in the modified Delphi (COMET, 2019). 
The different types of Delphi methods that have evolved since Dalkey and 
Helmer’s (1963) ‘classical Delphi’ are summarised in Table 2 (Dalkey and 
Helmer, 1963; Beretta, 1995; Keeney et al., 2011; Donohoe et al., 2012; Al 
Wattar et al., 2017).  
Table 2 Type of Delphi methods and their characteristics  
Classical Delphi Open first round which generates ideas, and elicits 
opinions 
 
Five postal rounds  
 
Optional interviews  
Modified Delphi First postal round is replaced with face-to-face 
interviews or focus groups 
And/or a literature/systematic review is conducted  
 
May use fewer than three rounds 
 
The surveys are sent out via post or email  
 
Optional face to face meeting or consensus meeting 
e-Delphi (electronic 
Delphi) 
Similar to the modified Delphi but the survey uses an 
online platform to collect data, and communicate 
Real Time Delphi Similar to the classical Delphi but consensus is gained 
anonymously by an electronic app in real time instead 
of by post   




The Delphi method, namely the modified Delphi, is a multistage method used to 
gain consensus among experts.  The benefits of the Delphi method include; an 
opportunity to include a diverse population in terms of experience and/or 
expertise, a greater number of people can participate compared to methods 
that only use face-to-face meetings, costs are low and logistics are more 
feasible (Linstone and Turoff, 1975).  An electronic Delphi (eDelphi) also 
enables the views of many and geographically dispersed to be included at a 
relatively cheap cost because it can be accessed remotely (Jones and Hunter, 
1995).  This is an important factor because reliability increases as the number 
of respondents increase (Keeney et al., 2011).  Respondent ‘side tracking’ is 
avoided due to the controlled feedback between rounds (McKenna, 1994).  It 
allows for a convergence of opinion and it allows for views of all participants to 
be equally heard (Murphy et al., 1998).  It is believed that it encourages honest 
opinions free from dominance of peers (Williams and Webb, 1994).  Hirsch et 
al. (2016) suggest that an online Delphi allows participants to score each item 
without the influence of dominant individuals so reducing the possibility that 
participants provide sociably desirable scores or scores that are agreeable with 
senior members.  There is a greater likelihood that anonymity will be 
maintained compared to methods that only use face-to-face discussions 
(McKenna, 1994). 
One of the main characteristics of the Delphi method is anonymity, however 
Sackman (1975) criticised the method stating that anonymity can lead to a lack 
of accountability and produce quick responses without thought.  
The lack of face-to-face interaction has been criticised for the lack of positive 
effects that visual interactions can have, such as the interactions between 
participants and body language which can identify reasons for any 
disagreements that may arise (Sackman, 1975; Murphy et al., 1998).  The 
modified Delphi does however offer an optional face-to-face meeting for 
participants to discuss the results, or an optional consensus meeting to finalise 
the results (Schneider et al., 2016; Tomkins-Lane et al., 2016).   
Sackman (1975) also criticised the validity and reliability of the Delphi method 
stating that the questionnaire items are ambiguous and not clearly defined.  
However Sackman (1975) critiqued the studies rather than the Delphi method.  
Sackman (1975) focused on the studies poor survey design, the methods used 
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to select ‘experts’, their analysis methods and how authors tested reliability and 
validity thus suggesting the flaws in the Delphi were to do with poor study 
design as opposed to the use of the Delphi method.  For example Sackman 
(1975) criticised a study by Gordon and Helmer (1964) for not including more 
than medians, quartiles and descriptive scatter-plots in their analysis, and a 
study by Nanus et al. (1973) for only providing frequency distributions and 
some percentages for quantitative results.   
The reliability and validity of the Delphi method was tested by Tomasik (2010) 
who analysed the responses of 55 physicians who took part in a two-round 
Delphi study to develop guidelines for the management of hypertension.  
Tomasik (2010) found the Delphi method to have good reliability and 
satisfactory validity.  Internal correlation coefficient, or Cronbach’s alpha, was 
the method used to assess reliability.  Cronbach’s alpha assesses internal 
consistency (Bland and Altman, 1997).  Internal consistency is the extent to 
which items on a scale measure the same thing (Vogt, 1999).  The results for 
reliability of the first round in Tomasik’s (2010) study was high with a 
Cronbach’s alpha of 0.944, and round two was 0.850.  Tomasik (2010) 
provides a detailed description of the methods used to assess three types of 
validity including; construct, content and criterion validity.  Tomasik found 
construct validity was good, content validity was satisfactory but criterion 
validity was only fulfilled in part.  Construct validity is the extent to which the 
scores of a measurement instrument are consistent with hypotheses (if the 
content validity is adequate) (COSMIN, 2018).  Content validity is concerned 
with the extent to which the content of a measurement instrument is an 
adequate reflection of the construct it is measuring (COSMIN, 2018).  Criterion 
validity is the degree to which the scores of a measurement instrument reflect 
the ‘gold standard’ (COSMIN, 2018).  It is the correlation of a measure with 
another which is accepted as a valid criterion measure (referred to as the ‘gold 
standard’) (Bowling, 2009).  When no ‘gold standard’ exists concurrent and 
predictive validity are used.  Concurrent validity is the independent 
corroboration that the measurement instrument measures what it intends to 
measure and predictive validity is the ability of the instrument to predict 
changes of variables in the future (Bowling, 2009).  However, because a variety 
of participants from a range of backgrounds and countries can take part in an 
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eDelphi confounding variables can rarely be controlled.  Confounding variables 
can rarely be controlled therefore opinion is not static which limits the 
assessment of methodological rigour (Hasson and Keeney, 2011).  Various 
writers have declared that the method provides evidence of content and face 
validity (Goodman, 1987; Morgan et al., 2007; Huang et al., 2008).  Face 
validity is a subjective assessment on whether the instrument appears to 
measure what it intends to measure (Bowling, 2005).   
The Delphi method has been used by many core outcome set developers 
(Taylor et al., 2008 (OMERACT team) ; Schmitt et al., 2011 (HOME team) ; 
Sinha et al., 2012; Gargon et al., 2014; Coulman et al., 2016; Gorst et al., 
2016a; Gorst et al., 2016b; MacLennan et al., 2017; Millar et al., 2017; Davis et 
al., 2018). 
2.3 Nominal Group Technique 
The Nominal Group Technique, originally called the Program Planning Model 
(PPM) was developed by Delbacq and Van de Ven (1971).  Unlike the Delphi 
method, the Nominal Group Technique’s main method involves a structured 
face-to-face meeting which attempts to gain qualitative information in an orderly 
manner (Van de Ven and Delbecq, 1972).  Delbacq and Van de Ven (1971) 
developed the structured group process to structure committee decision 
making such as the development of a service program for elderly people in a 
small community where there is no existing service.  The development of the 
service program required assistance from a number of social agencies and 
health service institutions.  They aimed to design a method which had an 
explicit process, and structured participation within each phase to cater for the 
internal exchange across internal and external organisational units.  Delbacq 
and Van de Ven (1971) proposed the group process model for identifying 
strategic problems and for developing programs to solve the problems.  The 
technique was developed using social-psychological studies of decision-
conferences and from studies on program planning in a Community Action 
Agency.   
Since Delbacq and Van de Ven (1971) the model, now termed Nominal Group 
Technique, has been modified but the main aims of the method continue.  The 
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main aim of the technique is to structure interactions of participants within 
groups.  Participants record their ideas privately to begin with then the ideas 
are listed in turn by a group facilitator.  Each item is discussed by the group.  
Delbacq and Van de Ven (1971) state that the specific voting procedure used 
depends upon the specificity of the information that is required from the group, 
therefore if only general, preliminary information is required then listing of 
priorities is adequate.  Whereas, if the researcher wants to know the magnitude 
of the difference between priorities then the ratings of the priorities is required. 
Participants are then asked to vote (by number) on the items in private.  Further 
rounds of discussion and voting may follow.  The votes are aggregated 
statistically to produce a group judgement (Murphy et al., 1998).  Classically, 
the Nominal Group Technique involves groups of five to eight participants (Van 
de Ven and Delbecq, 1972).   
The classical nominal group technique is summarised below (Van de Ven and 
Delbecq, 1972): 
1. Introduction to the meeting including an explanation to the purpose of 
the research 
2. Silent generation of ideas on critical barriers in writing by individual 
participants  
3. Round-robin listing of each participant’s ideas on a flip chart until all 
the participants have exhausted their individual lists 
4. Discussion of ideas on the flip-chart to clarify, elaborate, defend or 
dispute the ideas 
5. Break 
6. Ranking priorities and problem elements: private ranking of the ideas 
to produce a top 10, tallied, list for each participant 
7. Voting of the top 10  
8. Discussion on the vote 
9. Re-ranking and rating priorities in private 
10. Conclusion of the meeting 
Delbacq and Van de Ven (1971) state that the use of nominal groups and the 
specific group processes increased creativity amongst participants.  Delbacq 
and Van de Ven’s reasoning behind participants’ initial generation of ideas 
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individually lay in their belief that when groups are allowed to interact they “fall 
into a rut” because they concentrate on a single dimension.   
The advantages of the Nominal Group Technique include structured interaction 
of a group which enables all group members to voice their opinions.  The 
structured interaction makes it more difficult for individual’s with more dominant 
personalities to inhibit others from speaking (Murphy et al., 1998).  The 
technique brings a small group of people together to make a relatively quick 
decision on a subject.   
The disadvantages of the Nominal Group Technique include the dominance of 
group members when the items are discussed prior to the vote which could 
drive the results, and time limits meaning the amount of time to discuss each 
item may be limited (Nair et al., 2011).  Additionally, bringing people together 
for a face-to-face meeting can be costly (Nair et al., 2011).  It makes the 
involvement of internationally dispersed individuals challenging and potentially 
costly.  Concerns over small group sizes facilitated by the technique raises 
questions over whether there are enough “experts” involved to be 
representative of the subject area which in turn raises questions over its 
reliability (Raine et al., 2005; Black, 2006).   
A series of four systematic reviews were performed by Gargon et al. (2014), 
Gorst et al. (2016a), Gorst et al. (2016b) and Davis et al. (2018) whose 
objectives were to report on the methodological techniques used to develop a 
core outcome set and examine the quality of core outcome sets. The 
systematic reviews suggest that the Nominal Group Technique has not been 
used often by core outcome set developers.  Davis et al. (2018) collated all 
three systematic reviews (Gargon et al., 2014; Gorst et al., 2016a; Gorst et al., 
2016b) and included 18 studies carried out since Gorst et al’s systematic 
review in 2016.  Davis et al. (2018) found that the Nominal Group Technique 
has been used by less than 1% (n=1/259) of core outcome set developers and 
the technique was used as part of a mixed method design by only four studies 
(4/259).  Further details on the systematic reviews can be found in section 
2.6.1.  If the Nominal Group Technique has not been used and tested in core 
outcome set development it is difficult to establish the validity and reliability of 
the technique for use in core outcome set development.   
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The technique has been used in different fields including health and education, 
for example Bajracharya (2006) used the technique to clarify the perceived 
barriers to accessing screening for colorectal cancer, and Chasens and 
Olshansky (2008) developed a list of issues that people with type 2 diabetes 
have with sleeplessness. 
2.4 Consensus Development Conference 
The National Institutes of Health (NIH) in the United States introduced the 
consensus development conference in 1977.  A selected group are invited to 
an open meeting where evidence on the topic is presented by “experts” who 
are not part of the decision-making group.  The participants are then left in 
private to discuss, in an informal format, the topic in light of the “experts” 
presentation.  The chairperson of the group then encourages the participants to 
reach consensus.  If no consensus is met then minority or alternative views are 
considered (Murphy et al., 1998).  The consensus development conference has 
been used by the National Heart, Lung, and Blood Institute, NIH Center for 
Drugs and Biologics of the Food and Drug Administration and the NIH Office of 
Medical Applications of Research who convened a consensus development 
conference on Platelet Transfusion Therapy in 1986 to resolve issues 
associated with the increase in platelet transfusion such as the transmission of 
diseases.   The panel at the consensus development conference aimed to 
agree on the following questions: 
1. What are the appropriate indications for platelet transfusion?  
2. What products are available, and what are their relative merits?  
3. What are the risks associated with platelet transfusion?  
4. What are the most important directions for future research? 
The consensus development conference brings a group of people together to 
make a relatively quick decision on a subject.  A disadvantage of the method is 
that it facilitates an interaction that is not structured and there is a lack of a 
formal feedback system (Nair et al., 2011).  Similarly to informal methods the 
interactions at a consensus development conference are at risk of dominance 
by individuals with powerful and/or intimidating personalities and the presence 
of individuals with authority threatening the integrity of elicited views.   
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The consensus development conference has been used by 5% (13/259) of 
core outcome set developers whose studies were included in Davis et al’s 
(2018) systematic review. 
2.5 RAND/UCLA Appropriateness Method  
The RAND Corporation collaborated with clinicians at the University of 
California, Los Angeles (UCLA) in the 1980s to develop the RAND/UCLA 
Appropriateness Method.  The method was developed in response to a lack of 
evidence at a sufficient level, or the ‘gold standard’ (Fitch et al., 2001).  The aim 
of the method was to combine scientific evidence and the assessment of 
indicators by panellists on the appropriateness of carrying out surgical 
procedures with consideration to a patient’s symptoms, medical history and 
diagnostic test results (Fitch et al., 2001).   
The RAND/UCLA Appropriateness Method was developed to determine the 
appropriateness (the relative weight) of the benefits and harms of surgical or 
medical procedures. The method is used to collate the opinions of experts and 
it has been applied to different health conditions and procedures (Fitch et al., 
2001).  An overview of the method is given below: 
1. A detailed literature review is performed to collate the scientific evidence 
on a topic.  A list of indications and definitions are produced concurrently.   
2. A panel of experts are then sent the literature review along with the list of 
indications and definitions.  The panel are asked to rate the benefit-to-
harm ratio of the procedure on a scale of 1 to 9 (1 being expected harms 
greatly outweigh the expected benefits and 9 being the expected benefits 
greatly outweigh the expected harms).  A “modified Delphi” process takes 
place over two rounds.  In round one the panellists rate the procedures 
individually at home then in round two the panellist meet for 1 to 2 days 
with a moderator present.  The distribution of all the panellists’ first round 
ratings are given to each panellist along with their own ratings.  The 
results are discussed in the meeting, especially the areas of 
disagreement.  Round two of voting takes place.  The aim of two rounds 
is to decipher whether discrepant ratings are due to real clinical 
disagreement, due to fatigue or due to misunderstanding. 
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3. A face-to-face meeting is facilitated over 1-2 days to allow the expert 
panel to discuss the results of the above.  Any areas of disagreement are 
discussed, if necessary, resulting in an adjustment to the indications and 
definitions.  Each indication is then rated by the panel in private. 
4. Each indication is then classified as “appropriate”, “uncertain” or 
“inappropriate” depending on the panellists’ median score and the level 
of disagreement among the panel members.  Procedures with median 
scores of between 1 and 3 are classified as inappropriate, scores 
between 4 and 6 are classified as uncertain, and scores between 7 and 9 
are classified as appropriate.  However, all procedures rated “with 
disagreement” (irrespective of the median) are classified as uncertain.  
“Disagreement” means there is either a lack of consensus, judgements 
are spread over the 1 to 9 scale or there is polarisation of the group.  The 
levels of agreement (i.e. with agreement or indeterminate agreement) are 
sometimes reported alongside the results. 
Although the method was originally designed for use in determining the 
appropriateness of procedures in healthcare such as surgical or medical 
procedures, it has been used widely in different areas of healthcare (Buetow 
and Coster, 2000; To et al., 2010; Saust et al., 2017).  Buetow and Coster 
(2000) used the method to produce angina and heart failure criteria for quality 
assessment in general practice, To et al. (2010) produced performance 
indicators of primary care for asthma, and Saust et al. (2017) produced quality 
indicators for the diagnosis and antibiotic treatment of acute respiratory tract 
infections in general practice. 
Shekelle et al. (1998) support the method and present evidence for the 
predictive validity of the method for performing carotid endarterectomy.  The 
method uses elements of the Delphi method and Nominal Group Technique 
such as private rating of items and face-to-face meeting of participants which 
allows areas of disagreement to be refined, increasing the likelihood that 
agreement is achieved.  Tan et al. (2007) criticised the method for being too 
complex and time consuming.     
Panellists are asked to rate predetermined statements.  Although panellists are 
encouraged to suggest, and in turn rate amendments, they are not asked to 




The method has had limited use in the development of a core outcome set 
(Howell et al., 2013).  Some researchers have opted to use a different method 
for the consensus process and the RAND/UCLA disagreement index to 
determine agreement (Prowse et al., 2013). 
2.6 Comparison of the Consensus Methods 
Table 3 displays the characteristic comparisons between the four different 
consensus methods (Black et al., 1999; Schneider et al., 2016; COMET, 2017).  
Aggregation of the methods in the table refers to the methods used to combine 
participants’ views.  It is a measure of central tendency which is needed to 
analyse the levels of agreement.  Implicit means consensus is implied and not 
expressed directly, whereas explicit means consensus is clear and detailed, 
leaving nothing implied. 
The modified Delphi and the RAND/UCLA Appropriateness Method seem 
essentially the same except that the face to face contact is optional in the 
modified Delphi method.  The RAND/UCLA Appropriateness Method uses an 
initial literature/systematic review whereas the classic Delphi does not, however 













































Yes  Yes No Yes 
Feedback of 
group scores 
Yes  Yes No Yes 
Face-to-face 
contact 
Optional Yes Yes Yes 
Structured 
interaction 
Yes  Yes No Yes 
Aggregation 
method 
Explicit Explicit Implicit Explicit 
 
2.6.1 Use of Consensus Methods in Core Outcome Set 
Development  
A series of four systematic reviews were performed by Gargon et al. (2014), 
Gorst et al. (2016a), Gorst et al. (2016b) and Davis et al. (2018) whose 
objectives were to report on the methodological techniques used to develop a 
core outcome set and examine the quality of core outcome sets.  The reviews 
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searched a variety of databases including MEDLINE via OVID, EMASE, 
SCOPUS, and the Cochrane Methodology Register without language 
restrictions.  The COMET database was also searched in reviews by Gorst et 
al. (2016a), Gorst et al. (2016b) and Davis et al. (2018).  All four reviews used 
the PRISMA checklist which is guides the reporting of systematic reviews 
(PRISMA, 2015).  A multifaceted search strategy was applied and a 
comprehensive selection process was performed.  Davis et al’s. (2018) 
systematic review incudes all the studies from the three preceding reviews by 
Gargon et al. (2014) Gorst et al. (2016a) and Gorst et al. (2016b).  Table 4 
displays the combined studies reviewed by the four systematic reviews (Davis 
et al., 2018, p.8). The studies included in the systematic reviews were 
published between 1981 and December 2016.  The table displays the number 
and percentage of each method used by core outcome set developers 
assessed by the systematic reviews. 
Table 4 Methods used to develop core outcome sets 
Main methods N (%) 
Mixed methods 116 (45) 
Delphi + another method(s) 48 (19) 
Semi-structured group discussion + another method(s) 42 (16) 
Literature/systematic review + another method(s) 14 (5) 
Consensus development conference + another method(s) 7 (3) 
Nominal group technique + another method(s)  4 (2) 
Semi-structured group discussion only 59 (23) 
Unstructured group discussion only 18 (7) 
Literature/systematic review only 19 (7) 
Consensus development conference only 13 (5) 
Delphi only  10 (4) 
Survey only 3 (1) 
Nominal Group Technique 1 (<1) 
No methods described 20 (8) 




The most used single method for developing a core outcome set appears to be 
the semi-structured group discussion approach, such as workshops, meetings, 
and round the table discussions (Gargon et al., 2014). 
The second most used method to develop a core outcome set is the Delphi 
method as part of a mixed method approach.  A higher proportion of core 
outcome set developers have used mixed methods (45%, n= 116/259) of which 
the Delphi was the most used technique combined with another method (48%, 
n=19/45).   
2.7 Methodological Issues 
2.7.1 Validity 
 
There has been debate over the validity of consensus methods because it is 
difficult to assess (Jones and Hunter, 1995; Murphy et al., 1998; Tan et al., 
2007; Hasson and Keeney, 2011).  Validity is the term used to describe 
whether a research method measures what it intends to measure (Vogt, 1999).   
Validity assessment includes different types of validity such as content validity, 
face validity and criterion validity.  Content validity is concerned with the degree 
of agreement between the instrument and its relevance (Polit and Beck, 2006).  
Face validity is a subjective assessment on whether the instrument appears to 
measure what it intends to measure (Bowling, 2005).  Criterion validity refers to 
how reliably a variable can be measured (Bowling, 2005) and how able the 
instrument is to make accurate predictions (Vogt, 1999).   
In the context of consensus it is difficult to determine whether a  ‘good’ 
judgement is made at the time it is made, however the use of a rigorous 
method can increase the likelihood that a ‘good’ judgement is derived (Murphy 
et al., 1998).   
Comparison with the ‘gold standard’, concurrent validity and internal logic are 
ways of assessing validity (Murphy et al., 1998).  Comparison with the ‘gold 
standard’ involves testing the method against questions that have a correct 
answer, however because there is no conclusive evidence (no ‘correct’ answer) 
when it comes to judgements on peoples’ opinions the answers cannot be 
compared against ‘correct’ answers.  Consensus on a topic does not mean the 
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“correct” answer has been derived.  There is a risk that collective ignorance is 
established through consensus rather than wisdom (Jones and Hunter, 1995).   
Concurrent validity is the extent of how well the method correlates with another 
method which is believed to be valid (Vogt, 1999).  Internal logic is a concurrent 
approach which looks at the internal logical order of a group’s results which 
determines the consistency of decisions made by respondents (Murphy et al., 
1998).   
Consensus methods are liable to paradoxes that can potentially undermine 
validity, for example the notion of alliance formation whereby a respondent will 
vote for another respondents ‘favourite’ if they return the favour (Murphy et al., 
1998).  Alliance formation might take shape in the context of the consensus 
process when a participant rates an item favourably because a co-participant 
will return the favour later on, possibly on another survey which has meaning 
for them.  However, the risk of alliance formation is reduced in such methods 
as the Delphi method and the RAND/UCLA Appropriateness Method which 
maintain privacy between participants thus reducing interaction with each other 




Consensus methods have been criticised for their lack of reliability (Jones and 
Hunter, 1995; Murphy et al., 1998; Hasson and Keeney, 2011).  Reliability is 
concerned with the ability and stability of the method to produce the same 
results with different groups (Hasson et al., 2000; Raine et al., 2005; Keeney et 
al., 2011).  Reliability is the consistency that the instrument repeatedly 
measures the same thing with identical or nearly identical results every time 
(Vogt, 1999).  Sensitivity is the instruments ability to respond to change over 
time (Bowling, 2005).   
Inter-rater reliability is the degree to which results obtained by two or more 
raters agree for the same population (Bowling, 2009).  Intra-rater reliability is 
concerned with variation within a rater, often as a result of multiple exposures 
or ratings (Streiner and Norman, 2008). 
Uhl (1975) tested the reliability of the Delphi method using the test-retest 
method.  Uhl (1975) gave 26 faculty members a Delphi questionnaire to 
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complete.  The questionnaire sought their perceptions on the degree of 
importance given by an institution to different goals and their opinion on what 
they think the degree of importance should be placed on the goals.  An 
identical questionnaire was completed by the same faculty members’ a year on.  
It was found that the faculty members’ ratings in the final round (a year on) 
were similar to the first round suggesting that the Delphi method was reliable in 
Uhl’s (1975) study.  Duffield (1993) found that 93% (156/168) of competencies 
were agreed upon by two panels using the Delphi methods, thus indicating a 
high level of similarity when the Delphi method was used.  Duffield (1993) 
compared two panels’ agreement on competencies expected on first-line nurse 
managers.  However Duffield (1993) points out that further research is needed 
to determine whether the results were due to a lack of disagreement on the 
subject or if they did in fact reflect the reliability of the Delphi method. 
Reliability of group judgement can be increased with more group members 
(Richardson, 1972; Black et al., 1999), however this can lead to costly logistics 
especially when participants are being invited to take part in a series of face-to-
face discussions.   
The reliability of results can be affected by the judgments made by “experts”.  A 
number of influences can play a role in the extent to a person’s expertise in an 
area, such as level of experience, exposure to the area of interest and 
qualifications (Hasson and Keeney, 2011).  International differences may also 
affect the agreements between participants.  A systematic review by Hutchings 
and Raine (2006) assessed factors affecting judgements produced by formal 
consensus development methods.  Hutchings and Raine (2006) found that 
there were international differences in the overall and chance-corrected 
agreement on healthcare interventions between different countries 
(Switzerland, US, UK, Israel, Netherlands).  Hutchings and Raine (2006) 
suggested that the difference may have been due to differences in healthcare 
resources between the countries, for example the UK’s health resources are 
funded by the National Health Service whereas healthcare resources in 
Switzerland are regulated by the Swiss Federal Law on Health Insurance, each 
healthcare resource may have different policies and procedures.  Raine et al. 
(2005) point out that because it is challenging to determine the validity and 
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reliability of judgements at the time they are made then it is essential that the 




The definition and use of ‘experts’ has been debated over the years.  Sackman 
(1975) questioned the use of ‘experts’ stating it is a manipulated group 
suggestion instead of real consensus, and stated that non-experts (a person 
without professional or lived experience of the subject in question) and experts 
have been found to give undistinguishable responses.  Many argue that the 
participants should be experts because they have a deep understanding of the 
issue (Lomas, 1991; Jones and Hunter, 1995; Williamson et al., 2017).  
However, Skvoretz (1988) suggested that people with a higher status 
(supposedly more expertise) attempt to dominate the group thus influencing 
another’s judgement on a topic.  It is suggested that it is better to have a 
heterogeneous group on a consensus panel rather than a homogenous group 
(Jackson, 1992).  A multidisciplinary panel reflects the different specialities 
involved in the field of interest (Fitch et al., 2001).  However diverse opinions 
can lead to disagreement which can inhibit consensus (Nair et al., 2011).  
Nursing literature which has applied the Delphi method was examined by 
Beech (2001) who performed a literature review to understand the diversity of a 
Delphi panel.  Beech (2001) concluded that the definition of an ‘expert’ and 
sample selection varied across the 146 included studies dated between 1995 
and 2001.  
McKenna (1994) stated that the panel should be composed of ‘informed 
individuals’ and Fink et al. (1984) suggest that a panel should be representative 
of their profession, they should have the ability to implement the findings, or the 
panel should be chosen because they will not be challenged as experts in their 
subject area.  Whereas, Williams and Webb (1994) provide explicit criteria of 
whom would constitute as an expert for inclusion on a Delphi panel including; a 
proven track record of practice, experience of greater than two years, able to 
demonstrate continuing professional education and makes an active 
contribution to current educational needs of others.  Weinstein (1993) argued 
that there are two types of expert; one that has gained expertise through the 
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function of what they know and one that has gained expertise through what 
they do.  The COMET initiative (COMET, 2017) states that ‘experts’ are those 
with personal experience such as patients and carers, and healthcare 
professionals that have expertise in the area and experience of treating and 
caring for people with the health condition.   
The selection of participants is important because the results can be affected 
by the variation of stakeholders on a panel (Jones and Hunter, 1995).  Given 
that the aim of a consensus method is to make judgements that will be 
implemented into research it is important that the participants are 
representative of the target audience affected by the implementation of the core 
outcome set. 
The composition of the group is essential to ensure that the consensus reached 
is representative of all relevant stakeholders.  The credibility of a consensus 
study can be enhanced when the full range of respondents reflect the vital 
stakeholders affected by the topic that the consensus is concerning and the 
methods to select and recruit the respondents should be explicit (Black et al., 
1999).  Researchers need to demonstrate that bias was assessed in the 
selection and recruitment of respondents by providing clear methods (Black et 
al., 1999).    
There can be a risk of selection bias when the participants that are willing to 
take part are not be representative of their targeted stakeholder group 
(Bowling, 2009).  Also, researchers that select participants based on their 
expected judgements will affect the overall results which are not likely to 
represent a variety of stakeholders.   
 
2.7.4 Patient and Carer Involvement 
 
Although it has been advocated in consensus studies that patients should be 
part of the stakeholder group (Fink et al., 1984; Jones and Hunter, 1995; Black 
et al., 1999), there is little evidence that patients have been involved in 
consensus studies.  In a systematic review by Gargon et al. (2014) it was found 
that only 16% of 198 (n= 31) studies included patients, carers, patient support 
group representatives or service users in the development of core outcome 
sets.  Gargon et al’s (2014) review included studies that developed a core 
46 
 
outcome set between 1981 and 2013, since then the involvement of patients 
and carers appears to be gradually improving.  In a systematic review by Davis 
et al. (2018) it was found that 80% of 15 (n=12) studies involved patients, 
carers and service users in core outcome set development.  However the 
attrition rates for patient representatives in some studies has been high (Al 
Wattar et al., 2017).  In a study by Al Wattar et al. (2017) which developed a 
core outcome set for epilepsy in pregnancy, 24 patient representatives 
completed round one but none completed rounds two and three, two patient 
representatives did however attend a final consultation meeting.  The reasons 
for the high attrition are not discussed in the paper. The most popular method 
which involved patients and carers has been the Delphi method mixed with 
another method (n=48/259, 45%), for example a systematic review and a 
modified Delphi which includes a consultation meeting (Davis et al., 2018).  
It has been found that patients identify outcomes that have not been suggested 
by others (Arnold et al., 2008; Sanderson et al., 2010; Cullum et al., 2016).  A 
qualitative study performed by Arnold et al. (2008) explored how fibromyalgia 
affects the lives of 48 women living with fibromyalgia.  Arnold et al. (2008) 
highlight that the domains identified by the women are not always assessed in 
RCTs on fibromyalgia.  Sanderson et al. (2010) developed a core set for 
pharmacologic treatments and found that the outcomes identified by patients 
are not included in the commonly used professional core sets for 
pharmacologic treatments.  It is therefore recommended that patients, carers 
and healthcare professionals participate in core outcome set development 
(Williamson et al., 2017).   
The James Lind Alliance have brought patients, carers and clinicians together 
to identify and prioritise uncertainties which affect clinical practice and 
treatment effects on urinary incontinence (Buckley et al., 2010; Snape et al., 
2014; Madden and Morley, 2016).  The James Lind Alliance identified that 
there was a disparity between the priorities of clinicians and researchers, and 
those of patients and carers.  Priority Setting Partnerships were established by 
the James Lind Alliance which includes at least one patient organisation and 
one clinical organisation.  Priority Setting Partnerships are made up clinicians, 
patients and carers working together to identify and prioritise evidence 
uncertainties which can be resolved by conducting research (James Lind 
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Alliance, 2019).  Each partnership identified their own method for eliciting 
questions and uncertainties relating to the management and treatment of 
incontinence (Buckley et al., 2007; Buckley et al., 2010).  The James Lind 
Alliance acknowledges that the task of involving patients and clinicians together 
as a partnership is ambitious and challenging (Madden and Morley, 2016).  The 
unstructured approach of the partnerships determining their own methods of 
initial information gathering, prioritisation, and selection of participants meant 
that the partnerships found it difficult to structure meaningful discussions with 
patients, carers and healthcare professionals (Madden and Morley, 2016).  
Similarly Rolls and Elliott (2008) also found the inclusion of patient-relative 
representatives to be difficult in a consensus study which developed clinical 
practice guidelines for intensive care.  
Attempts have been made to improve the guidelines on patient involvement 
(Staniszewska et al., 2011; INVOLVE, 2018).  For example INVOLVE (2018), 
established in 1996, supports public involvement in social care, public health 
and NHS research.  INVOLVE (2018) has produced guidelines to help 
researchers involve the public in research.   
 
2.7.5 Analysing and Defining Consensus 
 
The objective of consensus is to reach a final statement or set of statements, in 
this case a set of outcomes that most participants agree are core.  It is an 
integral part of a Delphi study (Diamond et al., 2014).  It is also concerned with 
within group agreement; the extent to which respondents agree with each other 
(Jones and Hunter, 1995; Murphy et al., 1998).    
In the absence of all participants agreeing 100% on all elements within a 
consensus process, the researchers usually define, on the outset, the extent of 
agreement considered as consensus having been reached.  A variety of ways 
to define consensus have been suggested but the majority do not justify their 
reasons (Williamson et al., 2017). 
When analysing the levels of agreement participants have with an issue, cue, 
item or statement a measure of central tendency is required.  To measure 
consensus both the central tendency (what people are clustering around) and 
dispersion (the extent to which participants’ opinions are spread out away from 
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the central tendency) are needed.  Because group views are seldom normally 
distributed the median should be used and not the mean (Black, 2006).  The 
median is more robust to the effect of outliers (Murphy et al., 1998).   
Within group agreement is analysed using the measure of dispersion.  Black 
(2006) states that the interquartile range is an appropriate measure of 
dispersion.  However, other methods have been used such as the mean 
absolute deviation from the median (MAD-M) and the RAND disagreement 
index (Fitch et al., 2001; Phillips et al., 2014).  The MAD-M is the average 
distance of a participant’s rating from the group’s median rating, it is preferred 
compared to the standard deviation because it does not give extra weight to 
extreme observations and it measures variation about the medians (Hutchings 
et al., 2005).  The MAD-M analyses the extent of disagreement for each cue, 
item or statement.  It is the average distance (for example on a 9 point Likert 
scale) of the respondents’ ratings from the group’s median rating (Hutchings et 
al., 2005).  Whilst Hutchings et al. (2005) argue that the MAD-M is the best 
method, Murphy et al. (1998) argue that the interquartile range is more robust.  
Fitch et al. (2001) point out that the MAD-M is rarely used other than as a guide 
on what to focus on during a panel meeting.  Following the development of the 
RAND/UCLA Appropriateness Method which only allows a maximum of 9 
people on a panel, Fitch et al (2001) developed the RAND disagreement index, 
which allows for larger group panels.  The RAND disagreement index is a 
measure of dispersion using the interpercentile range and the interpercentile 
range adjusted for symmetry using the formula: IPRAS = IPRr + (AI * CFA).  
IPRAS stands for (Fitch et al., 2001, p.60): 
Interpercentile Range Adjusted for Symmetry required for 
disagreement; IPRr is the Interpercentile Range required for 
disagreement when perfect symmetry exists; AI is the Asymmetry 
Index; and CFA is the Correction Factor for Asymmetry   
Fitch et al. (2001) state that when ratings are symmetric then the interpercentile 
range needed to label an indication as disagreement is smaller than when they 
are asymmetric.  
Core outcome set developers have determined participants’ agreement on an 
outcome for inclusion in the core outcome set by using the percentage of 
participants scoring each outcome, for example Loughlin and Moore (1979) 
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advocated a consensus level of at least 51% agreement amongst participants, 
whereas Rosenthal (2012) recommends a consensus level of at least 70%, 
while Green et al. (1999) suggests 80%.  Alternatively, Schmitt et al. (2011) 
used a consensus level of 60% and Bennett et al. (2012) used 75%.   
The use of a consensus level of at least 70% has been used by many core 
outcome set developers to define consensus (Potter et al., 2015; Coulman et 
al., 2016; Egan et al., 2017; Millar et al., 2017).  Meaning that at least 70% of 
respondents agree that the outcome should be IN/OUT of the core outcome set 
for a consensus to be ‘reached’.   
Thresholds for inclusion in a core outcome set have been specified by some 
researchers for example Wylde et al. (2015) implemented a threshold of at 
least 70% or more of participants scoring an outcome 7 to 9 (indicating the 
outcome to be critically important) and 15% or less scoring an outcome 1 to 3 
(having limited importance) by both clinician and patient groups or at least 90% 
or more scoring an outcome 7 to 9 from any single panel for it to be included in 
the core outcome set.  The 70/15% (70% or more participants score the 
outcome 7 to 9, and 15% or less score it 1 to 3) consensus definition suggests 
that the majority believe that the item should be in the core outcome set and 
only a small minority think it is of little or no importance (Williamson et al., 
2017).   
Defining consensus criteria is an important part of developing a core outcome 
set because a too accommodating criteria can result in too many outcomes 
therefore creating a long list of outcomes whereas a too stringent criteria risks 
excluding fundamental outcomes that may have otherwise been included 
(Williamson et al., 2017).   
2.8 Why the eDelphi Method was Chosen 
The methodology and practice of developing a core outcome set is under 
developed compared to clinical trial methodology (Gargon et al., 2014; Gorst et 
al., 2016a; Gorst et al., 2016b; Davis et al., 2018; Kottner et al., 2018) but the 
field continues to improve guidance by addressing essential methodological 
questions and uncertainties (Williamson et al., 2017; Kottner et al., 2018; 
COMET, 2019).   
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To maximise content validity the eDelphi method was used to develop the core 
outcome set.  The eDelphi method was favoured over the other types of 
consensus methods for the following reasons:  
• Remote participants who are geographically dispersed can take part 
• Relatively low costs 
• Anonymity and confidentiality maintained 
• Dominance of strong personalities and/or those with authority do not 
influence other’s opinions 
 
The eDelphi method enables the views of many to be equally heard and it 
allows people who are geographically dispersed to take part at a relatively low 
cost with feasible logistics which is crucial because reliability increases as the 
number of respondents increase (Keeney et al., 2011).  The surveys can also 
be completed remotely, thus allowing and hard to reach stakeholders to take 
part and international involvement.  In contrast, the Nominal Group Technique 
and RAND/UCLA Appropriateness Method only facilitates smaller groups and it 
can be costly to bring international participants together.  
The Delphi method elicits responses that are more conducive to independent 
opinion but allows participants to see other peoples’ opinions without the 
dominance of strong personalities and/or those with authority.  The successive 
rounds of repeated questioning keeps participants focused and helps elicit 
reasoning behind participants’ responses.  The performance of two or more 
rating rounds, such as those used in the Delphi and the Nominal Group 
Technique, increases the likelihood that there will be a convergence of opinion 
(Murphy et al., 1998).  They can consider other peoples’ opinions without 
dominance of individuals, therefore if a participant chooses to change their 
opinion or retain their original answer it is not caused by their desire to be seen 
as agreeing with domineering individuals or someone that is senior (Sinha et 
al., 2011).  Skvoretz (1988) suggested that those with a higher status attempt 
to dominate the group thus influencing others judgement on a topic. The non-
face-to-face successive survey approach employed by the eDelphi method 
reduces conformity compared to techniques that involve only face-to-face 
discussions, such as the Nominal Group Technique, the consensus 
development conference and the RAND/UCLA Appropriateness method.  The 
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method allows for anonymous responses thus encouraging ‘true’ opinions 
because participants do not have to present their opinions in front of others and 
they are free from the dominance of peers.   
Participants do not need to interact directly during the survey rounds therefore 
maintaining anonymity is more straightforward.   
The eDelphi method which is recommended by COMET (2017) has been used 
by other core outcome set developers (Taylor et al., 2008 (OMERACT team) ; 
Schmitt et al., 2011 (HOME team) ; Sinha et al., 2012; Gargon et al., 2014; 
Coulman et al., 2016; Gorst et al., 2016a; Gorst et al., 2016b; MacLennan et 
al., 2017; Millar et al., 2017; Davis et al., 2018). 
Various aspects required consideration before the eDelphi consensus study 
was undertaken, such as the choice of stakeholders on the panel, the survey 
items, the number of rounds, whether a face-to-face discussion took place and 
the definition of consensus.  The considerations are discussed further in 
chapter 4. 
2.9 Summary 
Consensus methods were chosen to establish common agreement on what 
outcome domains and outcomes are core for research evaluations of 
interventions used for venous leg ulceration. 
Informal methods are not appropriate because they are at risk of fundamental 
flaws such as participants being influenced by dominant individuals with 
powerful, intimidating personalities or individuals with authority.  They lack a 
structured approach to the consensus process, whereas formal methods 
provide a structure whilst encouraging participants to consider a range of 
options and they allow for the synthesising of opinions.   
The eDelphi method was used to establish consensus on the outcome domains 
and outcomes identified during the scoping review.  The method enables the 
views of many to be equally heard and it allows people who are geographically 
dispersed to take part at a relatively low cost with feasible logistics.  The 
inclusion of a diverse population is important so that the consensus on the 
outcome domains and outcomes is representative of all stakeholders.   
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The next chapter describes and discusses how the scoping review identified 
the outcome domains and outcomes for the consensus process which is 














Chapter 3 Scoping Review (Stage 1) 
3.1 Introduction 
A scoping review was performed to identify what outcome domains and 
outcomes have been reported in RCTs and qualitative research. 
This chapter begins with an overview of the different types of reviews.  A 
rationale to why a scoping review was chosen as the method for identifying 
outcome domains and outcomes reported in RCTs and qualitative research is 
then provided.   
The chapter goes on to describe and discuss the methods used in the scoping 
review which generated a list of candidate outcome domains and outcomes for 
the consensus process.  The results of the scoping review are then reported.  
Finally, the process of grouping the outcomes into outcome domains and 
condensing the list of outcomes is explained. 
3.2 Why a Scoping Review was Performed 
The aim of the scoping review was to identify what outcome domains and 
outcomes have been reported in venous leg ulceration research.  There were a 
number of approaches that could have been used and the following section 
discusses these approaches.   
Some core outcome set developers start with a blank page and generate a list 
of outcomes by asking open questions (Sinha et al., 2012), others have 
performed a literature review to identify outcomes for the list of outcomes (Al 
Wattar et al., 2017). 
There are different types of literature reviews, such as scoping reviews, 
systematic reviews, critical reviews and rapid reviews, which address different 
types of questions, and feature different methods including data extraction and 
synthesis, and quality assessment.  Systematic, critical and rapid reviews use 
focused research questions, whereas scoping reviews use broad research 
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questions.  The aim of a scoping review is to assess the volume and/or 
characteristics of the available literature in a particular field, identifying any 
gaps therefore a broad research question is used to generate breadth of 
coverage.  Whereas a systematic review seeks to collate all the evidence using 
pre-specified eligibility criteria to address a specific research question, and they 
can produce an overall effect or finding, for example treatment effect (Higgins 
and Green, 2011).  A scoping review can be performed prior to a systematic 
review to explore the extent of the literature without describing the findings in 
detail (Armstrong et al., 2011), identify the potential costs of a systematic 
review (Arksey and O’Malley, 2005), and assist in defining a more precise 
research question and inclusion criteria (Joanna Briggs Institute, 2015).  A 
critical review generates conclusions concerning the research question and a 
rapid review finds the quality of the literature and direction of effect.  The 
inclusion and exclusion criteria for systematic reviews and rapid reviews is 
defined prior to the search whereas the inclusion and exclusion criteria in 
scoping reviews is defined a priori and post hoc.  It is recommended that the 
criteria is refined post hoc once the researcher becomes familiar with the 
literature (Levac et al., 2010). 
Summarised information on the types of literature reviews are presented in 
Table 5 (Carnwell and Daly, 2001; Petticrew and Roberts, 2006; Grant and 





Table 5 Differences between types of reviews  
 Scoping review Systematic review Critical review Rapid review 
Research question Broad research question(s) Focused research question Research question can be 
focused depending on the 
topic 
Focused research question 
Inclusion/exclusion 
criteria 
Inclusion/exclusion developed a 
priori and post hoc 
Inclusion/exclusion defined 
prior to the search 
Inclusion/exclusion 
developed a priori and post 
hoc 
Inclusion/exclusion defined 
a priori  
Search strategy Determined by time and scope 
constraints 
Exhaustive and 
comprehensive search  
Identifies the most significant 
literature in the field 
Time restraints determine 
completeness of search  
Quality 
assessment 
Quality of study not a priority.  
Option to include critical 
appraisal 
Critical appraisal required  No formal quality 
assessment.  Evaluation can 
be according to contribution 
Critical appraisal required 
Data synthesis Usually tabular with narrative 
commentary 
Narrative with tabular 
accompaniment 
Normally narrative, perhaps 
conceptual or chronological 
Narrative and tabular   
Conclusions Identifies extent and range of 
research in a the field of interest 
and identifies gaps in the 
literature 
Generates estimates of 
effect.  Meta-analysis or 
meta-synthesis may also be 
done 
Generates conclusions 
concerning the research 
question 
Finds the quantity of the 






A scoping review was chosen as the method to identify the outcome domains 
and outcomes for the consensus process because it enables concepts in a field 
of interest to be ‘mapped’ out and outlines the breadth and nature of the 
evidence (Arksey and O’Malley, 2005).  It allows for a more rapid underpinning 
of the key concepts (Mays et al., 2001).  A scoping review can also assess the 
types of existing studies and find where they are located in advance of a 
systematic review (Petticrew and Roberts, 2006), finding any gaps in the 
literature and locating any previous systematic reviews on the topic. 
Scoping reviews are becoming increasingly popular (Daudt et al., 2013; Tricco 
et al., 2016).  In spite of this there remains an uncertainty over the definition 
and terminology of a scoping review (Colquhoun et al., 2014).  There are 
different names applied to this type of review including; scoping review, scoping 
study, scoping exercise, systematic scoping review, scoping project, scoping 
report and evidence mapping.   For the purpose of this PhD it is referred to as a 
scoping review.   
In a web-based survey involving various stakeholders and a consultation phase 
to explore others’ experience and perspectives on scoping reviews O’Brien et 
al. (2016) conclude that participants’ consider scoping reviews to be  
systematic and transparent.  However the researchers highlight that the small 
sample size of 54 participants as a limitation to their study. 
Weaknesses of a scoping review include the potential for bias due to limitations 
in the rigour and duration of a review (Grant and Booth, 2009), and 
interpretation of the subject due to reviewers’ research interests (Anderson et 
al., 2008).  Scoping reviews have been criticised for focusing on breadth 
instead of depth (Tricco et al., 2016), however this was not a concern because 
breadth of evidence was useful for identifying as many outcomes that have 
been reported in venous leg ulcer research as possible. 
Because the aim of the scoping review was to identify as many outcomes that 
have been reported as possible the quality assessment of the RCTs and 
qualitative studies was not required.  Critical appraisal is optional for scoping 
reviews, whereas it is mandatory for systematic reviews which assess the 
validity of the findings of studies for example the assessment of the risk of bias 




The aim of the scoping review was to identify what outcome domains and 
outcomes have been reported in RCTs evaluating treatments for people with 
venous leg ulceration.  The scoping review also aimed to identify what 
outcomes have been identified by patients and carers in qualitative research.  
Both quantitative and qualitative research was searched to gain a broader 
insight into what outcome domains and outcomes have been reported.  The 
definitions used in this PhD can be found in section 1.12.   
3.4 Method 
The overall methods used in this PhD are displayed in the flow chart below 
(Figure 4).  The box highlighted in red is the stage that this chapter explains; 
the scoping review.   





Scoping reviews have been criticised for their lack of methodological guidance 
(O’Brien et al., 2016), therefore Levac et al’s. (2010) adapted version of Arksey 
and O’Malley’s (2005) framework for conducting a scoping review was utilised 
which provided a methodological structured approach to performing the review.   
Levac et al’s (2010)  adapted version of Arksey and O’Malley’s (2005) 
methodological framework contains six-steps: 
• Step one: Identification of the research question 
• Step twoː Identification of relevant studies 
• Step threeː Study selection 
• Step fourː Charting the data 
• Step fiveː Collating, summarising and reporting 
• Step sixː Consultation 
Levac et al. (2010) updated and clarified areas of Arksey and O’Malley’s (2005) 
framework. The adaptions made by Levac et al. (2010) are supported by Daudt 
et al. (2013) who concurrently evaluated Arksey and O’Malley’s (2005) 
framework by performing a scoping review using the framework.   
Levac et al. (2010) clarified step one of the framework on ‘identification of the 
research question’ by explaining that the question should be clearly explained, 
including its concept, population and health outcomes.  The research question 
guides the search strategy, it can be broad but requires the inclusion of the 
study population, in this case people with venous leg ulcers.  Using a broad 
question reduces the likelihood of appropriate articles being missed, however 
this can lead to an unmanageable number of articles (Arksey and O’Malley, 
2005).  If a large number of references are retrieved Arksey and O’Malley 
(2005) suggest that the parameters are changed once a sense of the volume 
and scope has been found.  Additionally, Levac et al. (2010) suggest that the 
concept and health outcomes are specified in the research question.   
Arksey and O’Malley (2005) state that the inclusion and exclusion criteria can 
be applied post hoc as the researcher becomes increasingly familiar with the 
literature.  Levac et al. (2010) state that if limiting the scope of the search is 
unavoidable then justifications to why need to be provided and any limitations 
to the review should be acknowledged.  Levac et al. (2010) state that the scope 
of the review should be guided by the research question and its purpose 
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therefore the team should have sufficient content and methodological expertise.  
When limiting the identification of the studies in step two is unavoidable, Levac 
et al. (2010) suggest that acknowledgment of any limitations and justifications 
is needed.  Searching of the literature, refining the search strategy and 
reviewing the articles should be an iterative process.  An iterative process is a 
process of repeated rounds or cycles to generate a final decision or result.  
Reviewers should meet at the beginning, during and in the final stages to 
discuss any challenges to the study selection and refine the search strategy if 
needed.  Two reviewers should independently check the articles for inclusion, if 
any disagreements occur then a third reviewer will need to decide the final 
inclusion.  The reviewing team should develop a charting form and decide 
which variables to extract.  The data charting form should be continually 
updated.  For the first five to ten included articles two reviewers should 
independently extract the data and compare the data charting forms to check 
for consistency.  Qualitative content analysis is recommended for the charting 
of data. 
The collating, summarising and reporting stage should be divided into three 
steps; analysis, reporting the results and finding meaning.  Descriptive 
numerical summary analysis and qualitative thematic analysis should be used.  
The reported results should be related to the research question and meaning 
relating to the overall review purpose should be sought.   
The consultation stage provides stakeholders with the opportunity to suggest 
additional insights.  It allows for knowledge transfer and exchange by allowing 
additional sources of information and opinions to be offered by the 
stakeholders.  The type of stakeholders involved in the consultation stage 
should be defined.  How data will be collected, analysed, reported and 
integrated should be decided upon.  Knowledge transfer and exchange with 
stakeholders should be facilitated. 
The following sections describe the steps taken during the scoping review 
which were guided by Levac et al’s. (2010) adapted version of Arksey and 
O’Malley’s (2005) framework.  The steps are broken into quantitative and 
qualitative research to show how the two types of research were searched, 




3.4.1 Identification of the Research Question 
 
The scoping review addressed the following questions: 
Quantitative research search: 
What outcomes have been reported in RCTs evaluating treatments for venous 
leg ulceration?  
 
Qualitative research search: 
What outcomes have been described in qualitative research on venous leg 
ulceration? 
 
3.4.2 Identification of Relevant Studies 
 
Because a large number of RCTs evaluating treatments for venous leg ulcers 
are included in the Cochrane Database of Systematic Reviews (CDSR) it was 
decided that RCTs within Cochrane reviews should produce an adequate 
number of articles.  Cochrane reviews aim to collate all the evidence that suits 
the pre-specified eligibility criteria by regularly downloading from a variety of 
databases with sensitive search strategies (Higgins and Green, 2011), they 
search grey literature and hand searching is performed to optimise the collation 
of all the appropriate evidence.  Unpublished studies are also assessed for 
inclusion in the Cochrane Review (Higgins and Green, 2011).  Jadad et al. 
(1998) found Cochrane reviews to be more frequently updated and have 
greater methodological rigour compared to systematic reviews in paper-based 
journals.  Jaded et al (1998) compared 36 Cochrane reviews with 39 
systematic reviews and meta-analyses published in paper-based journals.   
Members of the research team and steering group were asked to identify 
additional relevant papers not identified through database searching.  The 
members of the steering group have expertise in different aspects of leg 
ulceration and wound care research, including experience of consensus studies 
and core outcome set development.  Their role in the research was to also 
support the development of the methods, verification of the interpreted results 





The Cochrane Database of Systematic Reviews (CDSR) was searched using 
the term ‘venous leg ulcer*’.   
 
Qualitative research: 
The qualitative search strategy was updated post hoc because the first search 
generated a vast number (n=3259) of irrelevant articles therefore meaning the 
search strategy was too broad.  The search strategy was then refined to 
include more specific concepts such as the different names given to venous leg 
ulcers and the types of qualitative literature e.g. interviews.  The search 
strategy for the qualitative search can be found in appendix 1.  The dates of the 
databases that were searched are as follows: Ovid MEDLINE 1946-2018, 
Scopus 1823- 2018, Ovid EMBASE 1980- 2018 and CINAHL 1960- 2018.   
No date restrictions were applied to the searches but they were limited to 
English language publications due to lack of resources for translation services.   
Articles not relevant to the review questions were excluded at this stage.  
Potentially relevant articles were retrieved as full reports and checked against 
the selection criteria detailed in the next section. 
 
3.4.3 Study Selection   
 
RCTs recruiting people with open venous leg ulcers that assess the 
effectiveness of venous leg ulcer treatment were included.  RCTs assessing 
interventions focusing on the primary or secondary prevention of venous leg 
ulcers were excluded. 
Qualitative studies recruiting people with venous leg ulcers or their carers that 
include exploration of venous leg ulcer outcomes were included.   
Date restrictions were not applied to the searches but they were limited to 
English language publications. 
Levac et al. (2010) recommend that once the researcher is familiar with the 
literature then the inclusion/exclusion criteria is refined post hoc.  The 
inclusion/exclusion criteria however did not need refining.  When the RCTs 
were not available through the link on the Cochrane review reference section 
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the RCTs were searched using the University of Leeds’ library database, 
Google scholar, and journal websites.  
 
3.4.4 Charting the Data 
 
The template shown in Table 6 was developed to chart the data extracted from 
RCTs.  Data extracted from the RCTs was done before data was extracted 
from the qualitative studies.  The template shown in Table 7 was developed to 
chart the data extracted from qualitative research.  Tables 8 and 9 show 
examples of the extracted data from an RCT and a qualitative study using the 
templates. 
Levac et al (2010) recommend that the charting of the data is an iterative 
process whereby the determination of which variables to collect is continually 
updated.  Levac et al. (2010) also recommend that the charting form should be 
developed as a collective team which the team continually update.  The data 
charting forms were developed with the research team, and continually updated 
to ensure that the correct variables were collected.  The extracted data were 
inputted into Excel and then transferred to Microsoft Word. 
In line with Levac et al’s (2010) suggestion that two independent researchers 
should extract data from the first five to ten articles, data from the first 7 RCTs 
was independently extracted by two members of the research team (SH and 
SO’M), and then compared to check for consistency.  An extract of the 
collected qualitative data was also checked by two members of the research 










Table 6 Template for charting the data extracted from RCTs 




Author(s), year of publication 
Details: Description of each outcome, verbatim as presented by the 
authors 
 Reviewer interpretation (if different from the article’s verbatim 
outcome) of the outcome was done to ensure it is 
understandable and demonstrates what it is that the article 
intended in the context of the whole article.  Classification of 
the outcome into its outcome domain 
 Method e.g. semi-structured interview  
 Comments including relevant information on type of leg ulcer 




Author(s), year of publication, title of Cochrane review 
RCT details: RCT identifier (author(s), year of publication) 
 Description of each outcome, verbatim as presented by the 
trial authors 
 Reviewer interpretation (if different from the RCT’s verbatim 
outcome) of the outcome was done to ensure it is 
understandable and demonstrates what it is that the RCT 
intended to measure in the context of the whole trial.  
Classification of the outcome into its outcome domain 
 Whether the outcome was defined as primary or secondary by 
the RCT, or not clear  
 Follow up period for each outcome 
 Measurement instrument used to evaluate each outcome 
 Unit of analysis measured e.g. ulcer or limb or person 
 Comments including relevant information on the type of leg 
ulcer 
 

























Wear time (number of days). 
Difference in the number of 






Instrument not specified 
[patients randomised]. 
Mixed aetiology (venous= 
36/44).  Assessment 





in ulcer area” 
Decrease in ulcer area (mm2 
and percentage).  (Relative 







Mixed aetiology (venous= 
36/44).  Assessed on 
enrolment, on days 14 and 









Number and percentage of 
patients that achieved 7-day 
wear time. 
Percentage difference 
between groups for the 





Yes or no question Mixed aetiology (venous= 
36/44).  Assessment 














6 point scale (0=none, 1= 
mild, 2= moderate, 
3=severe, 4=excruciating, 
5= unable to respond) 
Mixed aetiology Mixed 
aetiology (venous= 36/44).  





"Level of pain on 
removal of 
dressing" 






6 point scale (0=none, 1= 
mild, 2= moderate, 
3=severe, 4=excruciating, 
5= unable to respond) 
Mixed aetiology (venous= 
36/44).  Assessment 
periods not clear. 
 
Study ID       
(year) 
Outcomes (verbatim) Outcomes (reviewer 
interpretation) 







“sleeping problem….itching of the wound” Sleep deprivation 
Itching 
Interview Venous leg ulcers only.  
141 patients.  
Heinen et 
al 2007 
“sleeping problem….wound leakage” Sleep deprivation 
Leakage 




“compression therapy….difficulties in putting-on 
and taking off elastic stockings” 
Ease of applying stockings 
Ease of removing stockings 












“compression therapy….warm and itching” Itching (related to 
compression) 
Interview Venous leg ulcers only.  
141 patients. 






3.4.5 Collating, Summarising and Reporting 
 
Arksey and O’Malley (2005) and Levac et al. (2010) state that a descriptive 
numerical summary and a thematic analysis should be used when collating and 
summarising the data.  Arksey and O’Malley (2005) provide guidance on the 
numerical summary but stated it lacked adequate guidance on thematic 
analysis.  Levac et al (2010) acknowledge this omission but do not provide 
further guidance other than stating that the analytical stage may require 
qualitative content analytical techniques.  Levac et al. (2010 p. 6-7) go on to 
refer to a paper by Ehrich et al. (2002) and wrote “In our experience, this 
analytical stage resembled qualitative data analytical techniques, and 
researchers may consider using qualitative content analytical techniques [10]”, 
10 being a reference for Ehrich et al’ s. (2002) paper but on investigation the 
paper does not appear to provide usable guidance on qualitative content 
analysis. 
With Levac et al’s (2010) recommendation to use qualitative content analysis in 
mind, it was decided that the framework approach would be adopted, therefore 
elements of Ritchie and Spencer’s (1994) qualitative data analysis framework 
was used.  Although Ritchie and Spencer’s (1994) framework is initially for 
material collected through qualitative methods, for example interviews, it was 
used for guiding the identification of connections between data extracted from 
the RCTs and qualitative research.  The framework contains five key stages: 
1. Familiarisation 
2. Identifying a thematic framework   
3. Indexing 
4. Charting 
5. Mapping and interpretation 
The key stages that were useful for the scoping review were ‘identifying a 
thematic framework, ‘charting’, and ‘mapping and interpretation’.  The 
researcher identifies key concepts and themes during the ‘identifying a 
thematic framework’ stage producing a thematic framework.  The researcher 
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needs logical and intuitive thinking whilst making decisions on the meaning of 
the data and if there are any connections between data.  When the extracted 
data was identified during the scoping review the meaning of many outcomes 
had to be interpreted in the context of the papers because they were not 
consistently described and reported.  The extracted outcomes from each paper 
were recorded verbatim and an interpretation in the context of the whole paper 
was included which was checked by every member of the research team to 
ensure the interpreted outcome reflected the outcome reported in the paper.  
Themes were constantly identified as data were extracted and charted. 
Extracted data were rearranged during the ‘charting’ stage to build a picture as 
a whole and to identify the outcome domains.  The outcome domains 
recommended by OMERACT (2014), see Figure 1 (p. 18), were used to guide 
the grouping of the outcomes under each outcome domain.  Because the filter 
was applied to a different healthcare area compared to OMERACT’s original 
use in rheumatology it meant some outcome domains were not included in the 
filter or they were worded differently compared to those outlined in the filter.  
For example ‘healing’ was identified as an outcome domain in venous leg 
ulceration research during the scoping review but it is not part of OMERACT’s 
filer 2.0.   
During the ‘mapping and interpretation’ stage the extracted data as a whole 
was sifted and charted according to the outcome domains.  Ritchie and 
Spencer (1994) suggest the charts include headings and subheadings obtained 
from the thematic framework.  Headings were included above each section to 
identify each outcome domain and the specific outcomes within it. 
The list was continually sifted and rearranged to produce a workable document 
that could then be condensed into a more manageable list of outcome domains 




A session was held within the European Wound Management Association 
(EWMA) conference in May 2017.  Patient organisation representatives, 
various healthcare professionals and researchers that attended the session 
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were consulted in the planning phase of the consensus methods (discussed in 
chapter 4).   
 
Participants had the opportunity to provide qualitative comments and suggest 
additional outcomes during the consensus process in stages two and three of 
the research (discussed in chapters 4 and 5).  Consultation with the 
participants built upon the outcomes extracted from the scoping review and 
offered greater meaning and context expertise. 
3.5  Results 
3.5.1 Scoping Review Results 
 
The search of the Cochrane Database of Systematic Reviews identified 48 
Cochrane reviews, of which 25 Cochrane reviews were relevant for inclusion.  
The search identified 23 Cochrane reviews that were not relevant for inclusion 
because they were either protocols, or they were not venous leg ulceration 
related.  The 25 Cochrane reviews contained 535 RCTs.   
The search for qualitative studies identified 667 studies and two studies were 
suggested for inclusion by members of the research team and steering group.  
After duplicated RCTs and qualitative studies were removed and records were 
screened, 308 records remained.  Fifty non-venous leg ulcer related articles 
were then removed which resulted in 258 records for inclusion, of which 230 
were RCTs and 28 were qualitative studies. 



































Records identified Cochrane 
reviews 
(n = 48) 
Cochrane reviews included 
(n = 25) 
Identified RCTs (including full text reports, 
conference abstracts, unpublished reports) 
 (n = 535) 
Qualitative records 
identified through database 
searching  
(n = 667) 
Additional qualitative 
records identified through 
other sources 
(n = 2) 
Records after duplicates removed  
(n = 1195) 
Records screened  
(n = 1195) 
Records excluded  
(n = 887) 
Full-text articles assessed for 
eligibility  
(n = 308) 




(n = 50) 
Studies included in the 
scoping review  
RCTs n= 230 
Qualitative studies n= 28 
 
Records before duplicates removed  





The initial extraction of the outcomes yielded 1180 potential outcomes pre-
deduplication.  The first table in appendix 2 displays the outcomes that 
appeared more than once.  It displays how many times they appeared across 
the RCTs.  In addition to the outcomes in the table there were 460 outcomes 
that appeared once across the RCTs and 108 outcomes relating to adverse 
events, for example “digestive upset”.  The outcomes that appeared once are 
not included in the appendix due to limits on the maximum length of the thesis. 
Following deduplication 807 outcomes remained from 230 RCTs and 15 
outcomes remained from 28 qualitative studies. The list in appendix 2 displays 
the outcomes extracted from qualitative studies.  The references for the 
included RCTs and qualitative studies can be found in appendix 3. 
Twenty-four percent (54/230) of the RCTs included in the scoping review stated 
an outcome or outcomes at the start of the paper but failed to report them in the 
results.  Four percent (9/230) of the RCTs introduced an outcome in the 
discussion when it had not been stated in any other part of the paper.  Further 
discussed in chapter 6. 
Forty-five percent (63/140) of RCTs did not provide a definition of healing.  
Nineteen percent (44/230) of the RCTs failed to provide any information on the 
instruments used to measure outcomes.  Seventy-four percent (83/112) of the 
RCTs that measured an outcome relating to quality of life, signs and symptoms 
(e.g. pain, discomfort and heavy leg sensation) used trial specific scales. 
 
3.5.2 Grouping the Outcomes into Outcome Domains 
 
The core areas of OMERACT’s filter 2.0 displayed in Figure 1, chapter 1 (Boers 
et al., 2014) was used to help guide the grouping of the outcomes into outcome 
domains.  The core areas of the filter 2.0 include; death, life impacts resource 
use and pathophysiological manifestations.  To begin with, the outcomes 
extracted during the scoping review were grouped under the filter 2.0’s four 
core areas.  Once the outcomes were listed under the core areas with the 
addition of two outcome domains; healing and performance of the intervention, 
they were organised into outcome domains.   The outcomes relating to 
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symptoms which were grouped under ‘pathophysiological manifestations’ were 
reorganised into three outcome domains; ‘patient reported symptoms’, ‘clinician 
reported symptoms’ and ‘carer reported symptoms’.  The outcomes within the 
core area ‘pathophysiological manifestations’ were broken down into ‘clinical 
signs’ and ‘clinical measurement’.  Resource use outcomes were separated 
into outcomes relating to supplies and outcomes relating to clinician time.  The 
outcomes relating to healing were grouped together and the outcomes relating 
to performance of the intervention were also grouped together.  The outcomes 
were classified into their outcome domains as they were charted (see Table 6), 
for example the outcome ‘time to complete healing’ was classified under the 
outcome domain ‘healing’.  The 11 outcome domains are: 
1. Healing 
2. Patient reported symptoms 
3. Clinician reported symptoms 
4. Carer reported symptoms 
5. Life impacts 
6. Clinical signs 
7. Clinical measurement 
8. Performance of the intervention 
9. Resource use: supplies 
10. Resource use: clinician time 
11. Adverse events 
Although symptoms are things that are felt/perceived by the patient, the two 
outcome domains; ‘clinician reported symptoms’ and ‘carer reported symptoms’ 
were included.  There are times when a clinician and/or carer will be required to 
report on a person’s symptoms, for example a person may not be able to 
articulate or express whether s/he has pain and to what extent, therefore a 
clinician or carer may need to report on the person’s pain. 
The scoping review also identified that RCTs report on outcomes, such as pain, 
measured by clinicians and carers. 
Outcome domains contain many different outcomes.  This is highlighted by the 
outcome domain ‘healing’ which contained 111 different outcomes.  The other 
outcome domains also contained a large number of outcomes.  The outcome 
domain symptoms (including patient, clinician and carer reported symptoms) 
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contained 109 outcomes, life impacts contained 30 outcomes, clinical signs 
contained 88 outcomes, clinical measurement contained 184 outcomes, 
performance of the intervention contained 58 outcomes, resource use 
contained 52 outcomes and adverse events contained 190 outcomes.   
The 111 outcomes on healing are presented in Table 10.  All of the extracted 
outcomes that appeared more than once are presented in appendix 2. 
 
Table 10 Outcomes within the outcome domain ‘healing’ identified during the 
scoping review 
1. Number of patients that completely healed 
2. Number of ulcers that completely healed  
3. Number of healed ulcers in the case of multiple ulcers  
Number of ulcers completely healed at… 
4. 6 months 
5. 12 months 
6. Percentage of completely healed ulcers 
Percentage of patients with healed legs 
7. At 12 weeks 
8. At 24 weeks 
9. Per month 
10. Percentage of patients completely healed 
Percentage of healed ulcers….  
11. Per fortnight 
12. Per month 
13. Time to healing (not specified) 
14. Number of weeks to complete healing 
15. Cumulative healing times 
16. Number of days to healing 
Number of patients that achieved healing within each quintile:  
17. “≤25 days” 
18. “>25 days & ≤46 days” 
19. “>46 days & ≤82 days” 
20. “>82 days & ≤127 days” 
21. “>127 days & ≤263 days” 
22. Percentage of ulcers healed per week 
23. Number of ulcer healed per week 
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24. Percentage healed at each visit 
25. Number of limbs with complete healing 
26. Percentage of limbs with complete healing 
27. Relative risk of ulcer closure at any time point 
Relative risk of healing at… 
28. 12 weeks 
29. 6 months 
30. Residual area remaining 
31. Percentage of the remaining area at the end 
32. Proportion of healed ulcer within 90 days 
33. Number of ulcers healed within 90 days 
34. Proportion of healing within 180 days 
35. Number of ulcers healed within 180 days 
36. Number of ulcer free days 
37. Number of weeks patients were free from ulcers 
38. Number of ulcers that remained healed 
39. Number of patients with an improvement in wound score/rating 
40. Percentage reduction in ulcer area 
41. Percentage reduction in ulcer area over time 
42. Percentage reduction in ulcer area per week 
43. Percentage decrease in ulcer size 
Percentage reduction in ulcer size… 
44. Per week 
45. Per day 
Percentage change in ulcer area….. 
46. Per week 
47. Over time 
48. Reduction in ulcer diameter 
49. Rate of healing cm2 per day  
50. Healing rate mm2 per day 
51. Rate of healing over time 
52. Closure rate (cm3) per day 
Change in ulcer area……  




Change in ulcer area… 
55. mm2 per day   
56. cm2 per day 
Reduction in ulcer area… 
57. cm2 
58. mm2 
59. Reduction in ulcer area (cm2) per week 
60. Decrease in ulcer area per fortnight 
61. Rate of healing per week cm2 
62. Rate of healing per week cm 
63. Rate of healing per week cm2 
64. Rate of healing per week mm 
65. Change in ulcer size per week 
66. Change in surface area  
67. mm2 
68. Reduction in ulcer area per week cm2 
69. Reduction in ulcer area per day  
70. Relative change in total surface area 
71. Relative rate of ulcer closure 
72. Reduction in volume cm3 
73. Percentage reduction of ulcer volume per week 




77. Change in length cm2 
78. Change in width cm2 
79. Change in ulcer volume 
80. Change in ulcer depth (cm) 
Percentage of surface area healed 
81. per week 
82. Percentage of healing per week 
At least 75% ulcer closure…. 
83. mm2 
84. Number of days till at least 75% reduction in ulcer area 
85. Percentage of patients with 50% reduction in ulcer area 
86. Number of days till at least 50% reduction in ulcer area 
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87. Incidence of at least 50% reduction in ulcer area 
88. Reduction in daily ulcer radius (mm) 




92. Reduction in length of the ulcer  
93. Reduction in width (cm) of the ulcer 
94. Relative reduction in ulcer volume 
95. Healing as a proportion of the baseline ulcer circumference 
96. Number of patients showing a reduction in ulcer area relative to baseline 
97. Reduction in the Gilman method result 
98. Change in Gilman index score 
99.            Change in the healing index (mm) 
100. Increase in the healing index 
101. Percentage of healed ulcer area per fortnight  
102. Percentage of ulcers that decreased by 40% or more 
103. Number of days- percentage healed (i.e. 30% healed at day 70) 
104. Percentage of patients that failed to heal/ remained unhealed 
105. Number of patients whose ulcers were still open at 24 weeks 
106. Number of days to at least 50% epithelialisation 
107. Percentage of epithelializing tissue 
108. Percentage of ulcers with an increase in epithelising tissue 
109. Percentage change in epithelializing tissue 
110. Percentage of ulcer surface covered with re-epithelialisation 
111. Change in condition score: epithelialisation 
 
3.5.3 Condensing the List of Outcomes 
 
How to present the outcome data appropriately was considered because 
retaining each outcome would lead to an unmanageable list of potential 
outcomes for the consensus processes to follow.  The 822 outcomes were 




Table 11 demonstrates how some of the outcomes within the healing outcome 
domain were condensed.  The outcomes in column 1 are the outcomes 
extracted during the scoping review.  The same outcomes were then 
rearranged into groups in column 2.  The unit of randomisation was used for 
some of the healing outcomes, and other outcomes were grouped into 
binary/categorical, continuous or time to event.  The condensing process also 
enabled the detection of any duplicated outcomes which were then removed 
from the list.  The outcomes in column 3 contain the condensed outcomes for 
the consensus process.   
The condensed list of outcomes was then reviewed and agreed by members of 
the steering group.   
Although the list went through the condensing process, 120 outcomes still 
remained.  Due to the vast number of extracted outcomes it made it difficult to 
reduce the list any further without making judgements on what should be 
removed which could have introduced researcher bias because a subjective 












Column 1: Extracted outcomes from RCTs 
and qualitative research.  Grouped under 
each outcome domain. 
Column 2: Grouping process Column 3: Candidate outcomes to be 
included in the eDelphi (dependent upon 
whether the outcome domain was rated as 





 Unit of randomisation: patient  
1. Number of patients that completely 
healed 
1.Number of patients that completely healed Number of patients that completely 
healed 
2. Number of ulcers that completely 
healed  
7. Percentage of patients completely healed Percentage of patients completely healed 
 Unit of randomisation: leg  
3. Number of healed ulcers in the case of 
multiple ulcers  
6. Percentage of patients with healed legs at a specified 
time point e.g. 
At 12 weeks 
At 24 weeks 
Per month 
Percentage of limbs with complete 
healing 




18. Percentage of limbs with complete healing 
17. Number of limbs with complete healing 
Number of limbs with complete healing 
 Unit of randomisation: ulcer  
5. Percentage of completely healed ulcers 2. Number of ulcers that completely healed within the 
trial 
4. Number of ulcers completely healed at specified trial 





Number of ulcers that completely healed 
 
Column 1: Extracted outcomes from RCTs 
and qualitative research.  Grouped under 
each outcome domain. 
Column 2: Grouping process Column 3: Candidate outcomes to be 
included in the eDelphi (dependent upon 
whether the outcome domain was rated as 




Table 11 Example: condensing the list of outcomes within the outcome domain ‘healing’
6. Percentage of patients with healed legs 
At 12 weeks 
At 24 weeks 
Per month 
15. Number of ulcers healed per week 
13. Number of patients that achieved healing within 
each quintile:  
“≤25 days” 
“>25 days & ≤46 days” 
“>46 days & ≤82 days” 
“>82 days & ≤127 days” 
“>127 days & ≤263 days” 
24. Number of ulcers healed within 90 days 
26. Number of ulcers healed within 180 days 
3. Number of healed ulcers in the case of multiple 
ulcers 
Number of ulcers healed per week 








The scoping review highlights the vast number and variety of outcomes that 
have been reported in RCTs on interventions to treat venous leg ulceration.  
The results of the review reinforce the need for the standardisation of outcomes 
in the form of a core outcome set for use in research evaluations of 
interventions used for venous leg ulceration 
The scoping review provided the foundation to the development of a core 
outcome set by generating a comprehensive list of candidate outcome domains 
and outcomes for the consensus process.  The consensus process is 


















Chapter 4 Consensus Process for Identifying Core Outcome 
Domains (Stage 2) 
4.1 Introduction 
The purpose of the stage two consensus process was to identify which of the 
candidate outcome domains extracted during the scoping review are core to 
stakeholders for research evaluations of interventions for venous leg ulcers. 
The chapter will begin by exploring the ways in which terms are defined by core 
outcome set developers and guideline initiatives before presenting the 
definitions in this PhD.  It will then go on to explain the methods used to gain 
consensus on the outcome domains.  Finally, the results of the consensus 
process will be presented. 
4.2 Definitions 
There is no consensus on the definitions to use in the development of core 
outcome sets (Boers et al., 2014; Prinsen et al., 2014).  It appears that 
researchers are using different terminologies for the same concept.  Table 12 
presents the different ways in which people define core outcome sets, outcome 
domains, and outcomes.  The table demonstrates how terms vary among core 
outcome set developers and guideline initiatives.  The table contains verbatim 
quotes from a small sample of core outcome set developers and core outcome 
set guideline initiatives displaying their definitions and/or examples of outcome 







Table 12 How terms have been defined and used by other core outcome set developers and guideline initiatives 
 Definition and/or example    
Author Outcome domain/domain  Outcome  Outcome measurement Set name  
Alkhaffaf et 
al. (2017) 
“Outcome domain….A collection of 
‘outcomes’ which share common 
features, e.g. the outcome domain 
‘respiratory complications’ would 
include outcomes such as ‘pleural 
effusion’, ‘hospital-acquired 
pneumonia’ and ‘atelectasis’” (p.3) 
“A unique endpoint which 
attempts to describe health-
related changes that occur 
secondary to a therapeutic 
intervention, e.g. hospital-
acquired pneumonia” (p.3) 
 
“A method or tool used to measure 
an ‘outcome’ or an ‘outcome 
domain’” (p.3) 
Core Outcome Set: 
“An agreed minimum set of 
outcomes that should be 
measured and reported in all 
trials in a specific condition” 
OMERACT 
Boers et al. 
(2014) 
“(Sub)Domain…Component of Core 
Area: a concept to be measured, a 
further specification of an aspect of 
health, categorized with a Core Area” 
(p.749).  Example: quality of life, loss 
of ability to work, societal (resource 
use), individual (resource use), 
biomarkers and organ function. 
“Core Areas are broad concepts 
consisting of a number of more 
“Any identified result in a 
(Sub)Domain arising from 
exposure to a causal factor or a 
health intervention…Generic 
word that has been used with 
different definitions; has often 
been used interchangeably with 
“Outcome Measure” and 
“Endpoint” (p.749) 
“A measurement instrument 
chosen to assess Outcome.  The 
result of measurement (recently 
termed ‘specific metric’ [33]) can 
be expressed as change, as end 
results, as cumulative results, or 
as “time to event” in a 
(Sub)Domain.” (p.749)  
Example: “in pain measurement, 
the instrument could be a visual 
Core Domain Set: 
“…minimum set of Domains 
and Subdomains necessary to 
adequately cover all Core 
Areas, that is, adequately 
measure all relevant concepts 
of a specific health condition 
within a specified setting.  
Describes what to measure.  





specific concepts called Domains.” 
(p.749).  Includes: Death, life impact, 
resource use/economical impact, 
pathophysiological manifestations. 
analog scale, and outcome could 
be an improvement on that scale” 
(p.749) 
33 (Zarin et al., 2011) 
initiative uses the term “Core 
Outcome Set” for this concept, 
OMERACT has decided not to 
adopt this term, as there is no 
consensus on its technical 










“outcome domains, constructs which 
can be used to classify broad aspects 
of the effects of interventions, e.g. 
functional status.” (p.11) 
“Outcomes from multiple 
domains may be important to 
measure in trials, and several 
outcomes within a domain may 
be relevant or important. Initially 
researchers create outcome 
domains for each outcome to be 
grouped into” (p.11) 
“Different outcomes may be 
measured by a single question, a 
questionnaire, a performance 
based test, a physical 
examination, a laboratory 
measurement, an imaging 
technique, and so forth.  A variety 
of either definitions, measurement 
instruments or devices is often 




“A “Core Outcome Set” is an 
agreed minimum set of 
outcomes or outcome 
measures. It is a 
recommendation of ‘what’ 
should be measured and 
reported in all trials in a 
specific area. Researchers 
also need to consider ‘how’ 
these outcomes should be 
measured, and work is 
ongoing to develop “Core 
Outcome Measurement 
Instrument Sets”, which will 





instruments or tools to use to 
measure the outcomes in a 





Not specified “An outcome refers to what is 
being measured. It is also 
referred to as a construct or 
domain. In the context of a 
clinical trial it refers to what is 
being measured on trial 
participants to examine the 
effect of exposure to a health 
intervention.” 
“An outcome measurement 
instrument refers to how the 
outcome is being measured. It is a 
tool to measure a quality or 
quantity of the outcome. The tool 
can be a single question, a 
questionnaire, a score obtained 
through physical examination, a 
laboratory measurement, a score 
obtained through observation of an 
image, etcetera.” 
Core Outcome Set 
“A COS is a consensus-based 
agreed minimum set of 
outcomes that should be 
measured and reported in all 
clinical trials of a specific 
disease or trial population; it is 
a recommendation of what 
should be measured and 
reported in all clinical trials.” 
Egan et al. 
(2017) 
Domain 
Example: “Measures of pregnancy 
preparation” (p.1193) 
Example:  
“Healthcare professional review 
prior to conception” 
“Thyroid function at first 
antenatal visit” 
 Core Outcome Set 
“It represents a minimum that 
should be collected and 
reported, but does not restrict 





“BP at first antenatal visit 
First trimester HbA1c” 
(p.1193) 




Not specified Not specified Not specified Core Outcome Set  
“A COS describes what 
should be measured in a 
particular research or practice 
setting, with subsequent work 
needed to determine how 
each outcome should be 
defined or measured” (p.3) 
Millar et al. 
(2017) 
Example: “1. Medication 
appropriateness (potentially 
inappropriate prescribing)” (p.9) 
“7. Admissions to hospital (and 
associated costs)” (p.9) 
“• Number of prescribed 
medicines” (p.9) (under the 
“outcome domain” Medication 
appropriateness) 
“• Accident and emergency 
(A&E) visits to hospital (and 
associated costs)” (p.9) (under 
the “outcome domain” 
“‘how’ outcomes could be 
measured (i.e. the identification of 
different measurement instruments 
used to measure the same 
outcome)” (p.9) 
Core Outcome Set 
“A COS is a list of outcomes 
which should be measured 
and reported, as a minimum, 
in all effectiveness trials 
pertaining to a specific health 
area, thereby facilitating 





Admissions to hospital (and 
associated costs)” 




See column 2 “An outcome refers to what is 
being measured, also referred 
to as a concept, construct, or 
(sub)domain. In the context of a 
clinical trial it refers to any 
identified result in an outcome 
arising from exposure to a 
causal factor or a health 
intervention (the OMERACT 
definition refers to ‘(sub)domain’ 
whereas the HOME definition 
refers to ‘outcome domain’).” 
(p.4) 
“An outcome measurement 
instrument refers to how the 
outcome is being measured (the 
tool used to assess the outcome). 
An outcome measurement 
instrument can be a single 
question, a questionnaire, a 
performance-based test, a 
physical examination, a laboratory 
measurement, an imaging 
technique, and so forth (the HOME 
definition refers to ‘outcome 
measure’).” (p.4) 
Core Outcome Set 
“A COS is an agreed 
minimum set of outcomes that 
should be measured and 
reported in all clinical trials of 
a specific disease or trial 
population. A COS includes all 
relevant outcomes of a 
specific health condition within 
a specified setting (the 
OMERACT definition refers to 
‘core domain set’ whereas the 
HOME definition refers to 





“Core sets of outcome domains 
(concepts to be measured) constitute 
an agreed minimum set of outcome 
domains to be measured.  Outcome 
Not defined “Core sets of outcome 
measurement instruments 
constitute an agreed set of 
measurement instruments to 
Core outcome set  
“consensus-derived minimum 
sets of outcomes to be 







domains are aspects of disease, such 
as health-related quality of life, 
symptoms, clinical signs, productivity 
loss, or disability.  Outcome domains 
relate to “what” should be measured” 
(p.25) 
assess the core outcome domains.  
Outcome measurements relate to 
“how” to measure an outcome 
domain (measurement method, 
items, and quantification of 
response).” 
Example: “Psoriasis Area Severity 
Index (EASI) or the objective 
Scoring Atopic Dermatitis index for 
atopic eczema.” (p.25)   
situation” (Schmitt et al., 2015, 
p.1) 
“It was specified that 
outcomes included in the core 
set for eczema trials “should 
be assessed routinely in every 
clinical trial, but not 
necessarily as a primary 
outcome’’ and that those 
outcomes included into the 
core set for clinical 
recordkeeping ‘‘should be 
assessed routinely at every 
patient visit in routine 












Many core outcome set developers and guideline initiatives use the key 
concept ‘core outcome set’ (Sinha et al., 2012; Harman et al., 2013; Prinsen et 
al., 2014; Eleftheriadou et al., 2015; Hopkins et al., 2015; Potter et al., 2015; 
COMET, 2016; Kirkham et al., 2016; Alkhaffaf et al., 2017; Egan et al., 2017; 
Millar et al., 2017; Schaap et al., 2017; COSMIN, 2018; Sahnan et al., 2018; 
Van den Bussche et al., 2018).  However, OMERACT (Boers et al., 2014) use 
the term “Core Domain Set” and state that they decided not to adopt the term 
“Core Outcome Set”.   Whereas Turk et al. (2003, IMMPACT) use the term 
‘core outcome domains’ in their study which developed core outcome domains 
for chronic pain in clinical trials.  HOME (Schmitt et al., 2015) refer to core 
outcome sets stating that there are two levels that need to be differentiated; 
core sets of outcome domains and core sets of outcome measurement 
instruments.  The definition of a core outcome set makes a distinction between 
‘what to measure’ and ‘how to measure’.  HOME (Schmitt et al., 2015) define a 
core set of outcome domains as a “minimum set of outcome domains that 
should be assessed” (p. 27).  HOME also use the term ‘domain’ which they 
define as “The concept to measure…Example: clinical signs of atopic eczema” 
(p.27).  Thus suggesting that the terms ‘outcome domain’ and ‘domain’ hold the 
same meaning.   
Although there have been slight variations in the definitions (i.e. core domain 
set; core outcome domain set) between research studies, they all produce an 
agreed standardised set of outcomes which should be, as a minimum, 
measured and reported in all health related trials or other forms of research 
which evaluate treatment effectiveness for a given indication (COMET, 2016). 
The different terminologies used by core outcome set developers and guideline 
initiatives posed challenges in the development of the definitions used in this 
PhD.  As recommended by COMET (2019) who suggest that researchers 
should clearly define their terms; terms are defined in Table 1 (section 1.13) 
and in the following paragraphs.   Many discussions took place amongst the 





defined.  It was important to establish definitions that are not only relevant to 
core outcome set terminology but also to venous leg ulceration research. 
A core outcome set in this PhD is defined as: 
An agreed standardised set of outcomes which should be, as a 
minimum, measured and reported in all RCTs or other forms of 
research which evaluate treatment effectiveness for a given 
indication (COMET, 2019).  It includes what outcome domains and 
outcomes should be measured and how the outcome domains and 
outcomes should be measured. 
An outcome domain has been defined by others as a collection of outcomes 
with common features (Alkhaffaf et al., 2017), and as a “Component of Core 
Area: a concept to be measured, a further specification of an aspect of health, 
categorized within a Core Area” (Boers et al., 2017, p. 29).  The core areas 
being; Death, Life Impact, Resource Use/Economical Impact and 
Pathophysiological Manifestations (Boers et al., 2017).  Schmitt et al. (2019) 
state that “An example of an outcome domain is Quality of Life, which would 
contain any outcome or measure that assessed quality of life, irrespective of 
the actual instrument used” (p. 5).  The question of how broad or narrow an 
outcome domain should be remains problematic (Kottner et al., 2018).  
An ‘outcome domain’ in this PhD is defined as:  
This relates to what is being measured. Outcome domains are 
broad, descriptive categories under which several, more specific, 
outcomes might be grouped.  An example of an outcome domain is 
‘healing’. 
The definition of an outcome domain was chosen because it reflects the groups 
of outcomes reported in venous leg ulceration RCTs which were identified 
during the scoping review.  An outcome domain can contain many different 
outcomes (an example of this can be found in section 3.5.2). 
The term ‘outcome’ has been defined as “Any identified result in a domain or 
Sub-domain arising from exposure to a causal factor or a health intervention” 
(Boers et al., 2017, p. 34), and as “a measurement or observation used to 





(risk) or effectiveness (benefits)” by Williamson et al. (2017, p. 1).  Prinsen et 
al. (2014) state that an outcome refers to ‘what is being measured’ and state 
that it can be referred to a concept, construct, or (sub) domain.  However 
COSMIN (2018) states that a measurement instrument tool can also be a 
single question, thus suggesting a single outcome written as a single question, 
for example; Number of ulcers that completely healed in a trial period, is an 
outcome as well as an outcome measurement instrument.  The outcome would, 
however, require a definition of what is meant by ‘healed’ and an 
accompanying measurement instrument (e.g. planimetry). 
A single outcome domain may contain many defined outcomes because 
different methods of aggregation, time-points and measures are used (Mayo-
Wilson et al., 2017).  The method of aggregation for a given outcome is the 
procedure for estimating the treatment effect such as whether the outcome is 
regarded as categorical, continuous or a time-to-event variable.  Time-point 
refers to the length of follow-up, and measures refer to the instrument used to 
measure an outcome domain, including the name of the instrument or 
questionnaire (e.g. Eczema Area and Severity Index) and the total score or 
subscale scores to be analysed (Mayo-Wilson et al., 2017).  Mayo-Wilson et al. 
(2017) argue that core outcome sets may not have the intended impact if the 
outcomes are not completely defined, for example researchers need to 
completely define ‘healed’ in their trial.  After analysing ClinicalTrials.gov data, 
Zarin et al. (2011. p. 858) recommend that four levels of specification are 
presented in the reporting of outcome measures, these being: 
Level 1: Outcome domain (e.g. anxiety) 
Level 2: Specific measurement (e.g. Hamilton Anxiety Rating Scale) 
Level 3: Specific metric to characterize each participant’s results (e.g. 
change from baseline at specified time) 
Level 4: Method of aggregating data within each group (e.g. a 
categorical measure such as proportion of participants with a decrease 







An ‘outcome’ in this PhD is defined as:  
This also relates to what is being measured. An outcome should be 
a precisely defined method of assessing the effectiveness (benefit) 
or adverse effects (risk) of a healthcare intervention (Williamson et 
al., 2017).  Where the outcome domain is defined as ‘healing’, 
examples of related outcomes could include: time to healing; the 
number of ulcers completely healed at 3 months, or; the change in 
ulcer surface area relative to baseline at 3 months. 
4.3 Engaging with Potential Stakeholders 
An open session was held at the EWMA conference in Amsterdam on the 4th 
May 2017.  Information on the content of the session was made available in the 
programme handbook.   
Fifty-two people attended the session, a show of hands indicated that the 
audience members included; patient organisation representatives, vascular 
surgeons, physicians, dermatologists, podiatrists, nurses, sociologists, and 
researchers.   
The session aimed to inform delegates about the results of the scoping review 
and share information on the proposed consensus methods.  An overview of 
core outcome sets, the research and its progress was presented to the 
audience.  Presentation of the results of the scoping review, and the proposed 
consensus methodology was then delivered.  The audience members were 
then invited to ask questions. 
Questions and discussion points were raised by members of the audience.  
The questions and discussion points were taken away from the session and 
discussed with the research team.  Responses to the questions and discussion 
points were published in a report in the EWMA journal (Hallas et al., 2017).  
The responses to the questions and discussion points are presented below: 
It was discussed that the participants to be invited to take part in the consensus 
would include patients, carers, healthcare professionals, policy makers, 





The Delphi method, using an online survey tool (Bristol Online Survey), would 
be used to gain consensus on the outcome domains.  The use of a 9 point 
Likert rating scale (1 being not important, and 9 being extremely important) was 
discussed and no concerns with its use arose (discussed further in section 
4.4.7.1).  Discussions took place over the number of rounds that the consensus 
process would use (i.e. two or three), the majority of the audience were in 
favour of using two-rounds.   
An audience member raised a concern that an online format has 
methodological limitations and may limit the ability to reach the patient group.  
Due to funding restraints, it was decided that paper copies of the survey would 
not be sent out (discussed further in 6.5.10).   
It was suggested that ulcer recurrence should be considered as an outcome 
domain.  Ulcer recurrence was not initially included in the list of outcome 
domains because the focus of the core outcome set was the treatment of open 
venous leg ulcers.  Ulcer recurrence was once again discussed by the research 
team in light of feedback at the meeting and it was concluded that it would not 
be included in the consensus because it is not possible for the scope of the 
research to cover all aspects of venous leg ulcer management.  The scoping 
review of open ulceration revealed that this in itself (open ulceration) was a 
significant endeavour. 
A number of people raised concerns and questions relating to methodological 
and statistical issues in venous leg ulcer trials more generally but not 
specifically associated to the core outcome set.  It was highlighted that the 
research aimed to develop the core outcome set only and would not be 
advising on the conduct and reporting of trials, including; duration of follow up, 
baseline prognostic variables, and target number of trial participants.  We 
emphasised the need for future research on the conduct and reporting in 











The aim of stage two was to gain consensus on the candidate outcome 




A two-round electronic Delphi (eDelphi) was conducted to gain consensus on 
the outcome domains that were extracted from RCT’s and qualitative research 
during the scoping review (stage 1).  A two-round eDelphi was chosen instead 
of a three round eDelphi.  Although more rounds increase the likelihood that 
there is a convergence of opinion, too many rounds can result in participant 
fatigue.  Figure 6 displays the overall methods used in this PhD.  It displays 
stage one which was the scoping review, stage two which was the eDelphi on 
the outcome domains (explained in this chapter), and stage three which was 
the eDelphi on the outcomes (explained in the next chapter).  The box 
emphasised in red highlights the stage this chapter explains (stage 2).  Figure 7 
















Figure 7 The eDelphi consensus process on the candidate outcome domains  
 
 
















The flow chart in Figure 8 displays how participants accessed the round one 
survey via a link on an email and through Twitter.  Participants were shown an 
introduction page after they accessed the Bristol Online Survey.  Participants 
were asked questions which sought their consent to take part and gain 
information on their background for example whether they were a patient, 
carer, healthcare professional or researcher.  Once the questions were 
completed participants were directed to the main page which asked participants 
to rate the outcome domains.  A thank you page was shown at the end on 
completion of the survey which included contact details for any questions.   
 
 
Participants asked to rate the 
importance of each outcome 
domain identified during the 
scoping review 
Round 1 
The overall group scores and scores for each group for 
each outcome domain rated in round one were 
presented to participants. Each participant was asked 
to rate the outcome domains in light of others feedback  




























The flow chart in Figure 9 displays how participants accessed the round two 
survey via a link on an email.  Participants were shown an introduction page 
after they accessed the Bristol Online Survey.  Once participants completed 
information which sought their consent to take part and gain information on 
their background for example whether they were a patient, carer, healthcare 
professional or researcher they were directed to the main page which displayed 
Survey main section 
Participants rated the importance of each of the 11 outcome domains for inclusion in the core 
outcome set. 
 
Participants were asked if the outcome domain should be in the core set (yes or no). 
 
Participants had an opportunity to suggest up to 2 outcome domains not included in the survey. 





An explanation on how to complete the survey was provided.  A question asked 
participants: Are you happy to continue to take part in the survey? (‘yes’ required to 
continue). 
Participants were asked to select a term which best described their background from 
the following; patient, carer, researcher, researcher from the industry sector, 













Thank you page 
 
Results of  round 1 were analysed and combined.  Suggested outcome domains  were 
discussed by the research team.  Any irrelevant (i.e. suggestions relating to interventions 
rather than outcome domains) outcome domains were excluded 
 
Analysis 
All outcome domains carried forward into round two for rating 
Participants invited via gatekeepers 
and through networks of the research 
team and steering group 
People invited to enquire about the 
consensus study via a Tweet.  For 
people that wanted to take part an 
email containing the survey link and 





summarised findings from round one for each outcome domain.  Participants 
were asked to rate each outcome domain in light of others feedback.  A thank 
you page was shown at the end on completion of the survey which included 
contact details for any questions.  
























An explanation on how to complete the survey was provided.  A question asked 
participants: Are you happy to continue to take part in the survey? (‘yes’ required to 
continue). 
Participants were asked to select a term which best described their background from the 
following;  patient, carer, researcher, researcher from the industry sector, healthcare 
professional, or an option to type in a free-text box.   
 
Survey main section 
Summarised findings from round 1 were presented in round  2; specifically the average 
group score and the score by stakeholder group for each outcome domain.  The outcome 
domains were rated, including any additional suggested outcome domains. 
Participants were asked if the outcome domain should be in the core set (yes or no). 
 














The results were analysed for consensus Analysis 
Thank you page 
 
Consensus was defined using the following criteria (discussed in sections 2.7.5 and 4.4.9): 
Consensus INː 70% or more rated the item 7-9 and 15% or less rated the item 1-3 
Consensus OUT: 70% or more rated the item 1-3 and 15% or less rated the item 7-9 
No Consensus: Anything that did not meet the above criteria for consensus IN/OUT 
 
Participants invited via gatekeepers 
and through networks of the research 
team and steering group 
People invited to enquire about the 
consensus study via a Tweet.  For 
people that wanted to take part an 
email containing the survey link and 









There are no set sample size requirements for a Delphi study (Powell, 2003; 
Boers et al., 2016).  Instead, Powell (2003) states that the representativeness 
of a Delphi panel is based upon the qualities of the panel members and not the 
number on a panel.  Similarly, Okoli and Pawlowski (2004) state that the size of 
the panel cannot be determined by a statistical power calculation but on the 
dynamics of the group.  A heterogeneous panel ensures that all stakeholders 
affected by and involved in venous leg ulceration research are involved in the 
development of the core outcome set.  When it can be demonstrated that the 
participants are representative of the area of interest then content validity can 
be assumed (Goodman, 1987).   Participants from a variety of backgrounds 
were invited to take part in the two eDelphi’s which included wound care 
researchers, researchers from industry, healthcare professionals, patients and 
carers.  The composition of the panel is essential to ensure that the consensus 
reached is representative of all relevant stakeholders.  The credibility of the 
core outcome set can be enhanced when the full range of participants reflect 
stakeholders.  Venous leg ulceration affects people across the globe therefore 
involvement of international stakeholders was important.  It is intended that the 
core outcome set will be used internationally so it was crucial that international 
stakeholders took part. 
Purposive sampling was used to recruit participants.  Purposive sampling is 
used to recruit participants with particular characteristics, or an interest in a 
particular field therefore it is a deliberate non-random method (Bowling, 2009). 
Participants were recruited internationally using the ‘snowballing’ technique, 
therefore it was not possible to predict the overall number of respondents.  
Snowball sampling is a form of purposive sampling which allows the selection 
of difficult to reach groups (Newell and Burnard, 2011).  The ‘snowballing’ 
technique allows existing participants to recruit potential participants through 
their contacts (Vogt, 1999).  An initial group of potential participants are asked 





to forward the survey invitations onto people they think may have been 
interested in taking part, and gatekeepers of organisations were asked to 
circulate the invitations to their members.  This form of sampling was done to 
optimise the number of participants invited to take part in the consensus. 
The stakeholder groups that were invited to take part in the consensus 
included:   
(i) People with experience of venous leg ulcers 
(ii) Carers of people with venous leg ulcers 
(iii) Healthcare professionals whose practice included venous leg ulcer care 
(iv) Researchers within wound care 
(v) Wound care industry researchers 
It was essential to invite as many stakeholders affected by venous leg ulcer 
research as possible, whether as a patient, carer, healthcare professional or 
researcher.  By inviting a wide variety of stakeholders it increases the 
probability that the opinions of those who are affected or have expertise in 
venous leg ulceration are involved in the development of the core outcome set. 
Potential participants were identified through network gatekeepers, and 
contacts of the research team and the steering group.  A network gatekeeper 
was an appointed person (i.e. chairperson, secretariat, journal editor, clinical 
trial manager or committee member) who was asked to forward the recruitment 
emails and participant information sheet on to the members of their network, for 
example a wound care society.  The gatekeepers of the following networks 
were approached and asked to invite their members to take part in the 
consensus: 
• Patients and informal carers invited via the charity; the Lindsay Leg Club 
Foundation (https://www.legclub.org/), which has 30 Leg Clubs in the 
UK, 1 in Germany and 8 in Australia. 
• Healthcare professionals; nurses, physicians, surgeons and 
physiotherapists were invited through steering group contacts.  





next section) were also invited to take part (via gatekeepers of the 
networks). 
• Leg ulcer researchers identified through the European Wound 
Management Association, Vascular Surgeons Imperial College, Society 
of Vascular Nurses, Alliance for Research and Innovation in Wounds 
and the Wounds Research Network were invited to participate. 
• Leg ulcer researchers identified through wound care journals were 
invited to take part. 
 
4.4.4 Recruitment Process 
4.4.4.1 Round One 
 
The following five recruitment routes were chosen to optimise the recruitment of 
people affected by venous leg ulceration across the globe whilst maintaining 
anonymity. 
 
1. Gatekeepers of leg ulcer societies were sent an email which gave details 
about the study, and sought their permission to support the study by 
distributing recruitment emails, participant information sheets and 
reminders by email.  The gatekeepers were asked to send a letter 
attached to an email or an email which included their organisational logo 
and official contact details, confirming that they are willing to support the 
project by forwarding the email invitations, participant information sheets 
and email reminders to the members of their organisation.  All letters and 
emails were forwarded to the School of Healthcare Research Ethics 
Committee (SHREC), University of Leeds, UK.  Ethics approval was 
granted providing the evidence of permission and support from the 
organisations’ gatekeepers to send out the recruitment material was sent 
to the ethics committee. 
Once the gatekeepers provided evidence for their support of the study a 
covering email containing a recruitment email and participant information 





The same recruitment email was sent to the members of the Lindsay Leg 
Club but included the following sentence: ‘Your participation in this study 
will not affect any care you are receiving’.  The same participant 
information sheet was sent to all participants. 
 
2. Steering group members who are gatekeepers (i.e. committee members) 
of organisations including the Alliance for Research and Innovation in 
Wounds and the Wounds Research Network (WReN) were sent a 
permission request email.  Once the gatekeepers provided evidence for 
their support of the study, a covering email containing a recruitment email 
and participant information sheet was sent to the gatekeepers for 
circulation to their members.   
 
3. Gatekeepers (i.e. editors) of wound care journals were sent the 
permission request email.  Once the gatekeepers provided evidence for 
their support of the study a covering email containing a recruitment email 
and participant information sheet was sent to the gatekeepers for 
circulation to their members.   
 
4. The following tweet was shared on Twitter two to four times a day:  
 
@VLUcoreven Would you like to help develop a core set of outcomes for 
venous leg ulceration? Please contact us for more info by sending a direct 
message. 
 
A recruitment email and participant information sheet was sent to the 
potential participants who asked for more information via a direct 
message on Twitter. 
 
5. Members of the steering group and research team (not including SH) 
sent out recruitment emails and participant information sheets to 
healthcare professionals and researchers.   An accompanying covering 
letter was sent to the steering group explaining that is was not possible to 





individuals identified because of their use of UK NHS services; carers of 
the latter, and; healthcare professionals identified because of their 
employment by the UK NHS. 
 
Participants were invited to forward the recruitment email and participant 
information sheet onto people they thought might be interested in taking part.   
A reminder was sent out approximately two weeks after the launch date via 
gatekeepers, members of the steering group and the research team.   
An example recruitment email and participant information sheet can be found in 
appendix 4 and 5. 
 
4.4.4.2 Round Two 
 
The same recruitment processes detailed in the previous section (section 
4.4.4.1) were used to recruit participants in round two.  A recruitment email and 
participant information sheet were circulated using the same methods detailed 




Ethical laws and regulations are designed to protect the rights and interests of 
all participants involved in research.  Although the study was not of a highly 
sensitive nature, it was still essential to ensure all participants were safe, and 
the research was conducted in an ethical manner.   
Ethics approval was obtained from the School of Healthcare Research Ethics 
Committee (SHREC), University of Leeds, UK [HREC16-031].  The ethics 
approval letter can be found in appendix 6.  It was thought that the invitation of 
members of the Lindsay Leg Club, which is a charity, would recruit an adequate 
number of participants for the patient and carer group therefore NHS ethics 





Due to conditional ethics approval arrangements it was not permitted to recruit 
individuals identified because of their use of UK NHS services; carers of the 
latter, and; healthcare professionals identified because of their employment by 
the UK NHS.  The steering group members and all gatekeepers were made 
aware of the ethics approval arrangements before they forwarded the 
recruitment emails. 
 
4.4.5.1 Informed Consent and Right to Withdraw 
 
Informed consent is the process of obtaining agreement from a participant who 
has received and understood all the relevant information to allow them to make 
an informed decision to take part in the research.  An individual should be able 
to determine what participation entails especially what potential harms and 
benefits may arise (Moules et al., 2017).  People should be informed of their 
right to withdraw and they should be made aware that withdrawal will not 
adversely affect their relationships (such as with care providers or researchers) 
or affect any care they may be receiving (General Medical Council, 2018). 
All participants were fully informed what the research entailed on the 
recruitment email and participant information sheet.  Participants were not 
under any obligation to take part and they were informed of this on the 
recruitment email.  
Participants were informed that they would not be able to withdraw their 
responses after completing the survey because their responses were 
anonymous therefore their data could not be identified for it to be withdrawn.  
The participants were informed of this on the participant information sheet.  
Participants were able to withdraw at any point before submission of the 
survey.  In order for the survey to be submitted, the participant was required to 
select “finish” at the end of the survey.  Participants were informed of this on 
the survey introduction page. 
Instructions on how to complete the survey was provided on the survey 
introduction page.  Informed consent was gained by informing the participants 





The question “Are you happy to continue to take part in this survey?” was also 
included at the beginning of the survey.  
A contact email address and phone number was provided on the recruitment 
email, participant information sheet and at the end of the survey for any 
questions. 
 
4.4.5.2 Confidentiality and Anonymity  
 
The ethical principle of justice is concerned with confidentiality and anonymity 
(Keeney et al., 2011).  Confidentiality should be maintained, meaning 
participants’ names are not ascribed to any comments or results in any report 
or publication (Keeney et al., 2011).  Anonymity means that a participant’s data 
cannot be identified.    
Self-administered questionnaires have the potential to maintain participant 
anonymity which is advantageous because participants can provide their 
opinions without being identified, providing the questionnaires are not coded or 
numbered (Parahoo, 2006).   
All participants were informed that any information that they provided would be 
dealt with in the strictest of confidence and privacy.  Participants were informed 
that their details would be anonymised and no details were passed on to third 
parties (i.e. name and email address).  There were no questions requesting the 
participant’s personal details, other than a question asking participants about 
their background, for example whether they were a patient, carer, healthcare 
professional or researcher.  Healthcare professionals were asked to type their 
role as a healthcare professional in a free text box. Participants were provided 
with a link and a password to access the Bristol Online Survey. 
The Bristol Online Survey enables anonymity of participants to be maintained 
throughout.  It does not use cookies for survey completion, external software is 








4.4.5.3 Privacy and Data Storage 
 
Data was stored on the password protected Bristol Online Survey website 
which is fully compliant with UK data protection laws.   
After completion of the survey data were exported and stored on a password 
protected university PC which is on a secure university system, using the 




The Bristol Online Survey (Bristol Online Bristol Online Survey, 2017) tool was 
used to collect data.  Since the launch of the first eDelphi, the Bristol Online 
Survey has changed its name to ‘Online Survey (formerly BOS)’ 
https://www.onlinesurveys.ac.uk/ (Jisc, 2018).  The change to the tool’s name 
did not affect the research or software, for example the ways in which the 
survey tool collated and formatted data was the same, and it’s security and 
data protection was not affected.   
 
4.4.7 Rating of the Outcome Domains 
4.4.7.1 Round One Survey 
 
Participants accessed the first round online survey via a link on the recruitment 
email.  Participants were directed to the survey’s front page which requested 
the password that was provided on the recruitment email.    
Once participants entered the survey they were shown an introduction page.  
To gain consent participants were asked if they were happy to continue to take 
part in the study.  In order for participants to continue they needed to consent 
by selecting ‘yes’.  Participants were asked to select a term which best 
described their background which included; patient, carer, researcher from the 





type in a free-text box.  Healthcare professionals were prompted to type their 
job role in a free-text box.   
Participants were asked to rate each of the following 11 candidate outcome 
domains in terms of how important they are for inclusion in the core outcome 
set: 
1.   Healing 
2. Patient reported symptoms 
3. Clinician reported symptoms 
4. Carer reported symptoms 
5. Life impacts 
6. Clinical signs 
7. Clinical measurement 
8. Performance of the intervention 
9. Resource use: supplies 
10. Resource use: clinician time 
11. Adverse events 
Examples of specific outcomes which may fall under each outcome domain 
were provided on the survey to give participants an idea of what the outcome 
domain represents, for example the outcomes; number of ulcers that 
completely healed, percentage of completely healed ulcers, and rate of 
reduction in ulcer area were provided for the ‘healing’ outcome domain.   
The use of rating scales has been recommended when measuring preferences 
on health issues (Bowling, 2005; McDowell, 2006).  A 9 point interval scale was 
chosen for use in the eDelphi surveys because attitudinal issues often lie on a 
continuum and are not easily dichotomised (Bowling, 2005).  They have been 
used to measure attitudes, because attitudes are complicated and hold an 
array of properties it makes them difficult to capture, however if the evaluative 
property is measured, i.e. how positively or negatively a person feels towards 
an attitude then it makes it easier to measure (Ostrom et al., 1994; Jamieson, 





The Likert rating scale of 1 to 9 where 1 indicated ‘not important’ and 9 
indicated ‘extremely important’ which was used in the surveys is displayed in 
Figure 10.   
Figure 10 Nine point Likert scale 

























Nine point Likert scales are the most commonly used psychometric scales 
because smaller scales do not give as much information about the levels on 
consensus, and scale sensitivity is increased as the number of scale points 
increase (Cummins and Gullone, 2000; Keeney et al., 2011).  A 9 point Likert 
scale has been used by many core outcome set developers such as Schmitt et 
al. (2011), Potter et al. (2015), van 't Hooft et al. (2016), MacLennan et al. 
(2017), and Millar et al. (2017). 
A variety of labels have been applied to the 9 point Likert scales in core 
outcome set development studies for example HOME (Schmitt et al., 2011) 
used a scale with the labels ‘not important’ (1-3), ‘equivocal’ (4-6) and 
‘important’ (7-9), Coulman et al. (2016) used a scale where 1 indicated ‘not 
important’ to 9 which indicated ‘extremely important’, Millar et al. (2017) 
labelled their scale ‘limited importance’ (1-3), ‘important but not critical’ (4-6) 
and ‘critical’ (7-9), Iorio et al. (2018) used a scale where 1 indicated ‘not 
important to include in the core set’ to 9 ‘essential to include’, and Meher et al. 
(2019) used ‘not important’ (1-3), ‘important but not critical’ (4-6) and ‘critically 
important’ (7-9).   
Wildt and Mazis (1978) tested whether the labels on Likert scales affected 
responses.  Four hundred and seventy-nine questionnaires were randomly 
assigned to undergraduate students.  Six different scales were tested: 
Scale 1: Extremely good ----------------------------------------------- Extremely poor 
Scale 2: Extremely good- Good- Average- Moderately poor- Extremely poor 





Scale 4: Extremely good- Very good- Good- Average- Extremely poor 
Scale 5: Extremely good- Very good- Average- Very poor- Extremely poor 
Scale 6: Extremely good- Slightly good- Average- Mediocre- Extremely poor 
 
Wildt and Mazis (1978) conclude their study by stating that there was no 
consensus in the results but that the scale labels and their position influenced 
responses.  Wildt and Mazis (1978) found a greater reluctance for participants 
to move to the negative side of a scale compared to the positive side. The 
researchers do not indicate which of the scales is the best one to use.  The 
researchers did not test whether the labels at the ends of the scale affected 
responses, for example if they are worded differently or if the ends were 
flipped.   
The researchers do not explain how the questionnaires were randomised 
therefore subjective bias of the researchers cannot not be assessed, i.e. 
whether the participants were ‘hand-picked’ to receive the questionnaires 
containing a certain scale (Parahoo, 2006).  Also, the researchers relationship 
with the undergraduates is not described therefore it cannot be determined 
whether the participants had an ‘obligation’ to take part which can affect results 
such as a desire to be seen as agreeing with someone that is senior (Sinha et 
al., 2011).   
In a more recent study by Moors et al. (2014) concluded that end labelling 
evoked extreme response style than labelling each point on a scale.  Extreme 
response style refers to a participant’s tendency to choose the extreme end-
point of a rating scale (Hurley, 1998).  Thus supporting Wildt and Mavis’s 
(1978) claim that participants are reluctant to move towards the negative side 
of a scale.  An online questionnaire was distributed amongst a random sample 
of 5,351 participants from a Longitudinal Internet Studies for Social Sciences 
household panel.  Five labelling formats were randomly allocated to a 
subsample of 3,266 participants using a split-ballot technique.  The five formats 
were: 
Format 1: full labelling with numerical values 
Format 2: full labelling without numerical values 
Format 3: end labelling with numerical values 





Format 5: end labelling with bipolar numerical values 
The fully labelled scales used the labels “totally disagree”, “disagree”, “disagree 
somewhat”, “nether disagree or agree”, “agree somewhat”, “agree” and “totally 
agree”, and the end-labelled scales used “totally disagree” and “totally agree”.  
The numerical scales ranged from -3 to 3 in the bipolar scale and 1 to 7 in the 
numerical values.  Moors et al. (2014) point out that extreme response style 
was consistently present despite the formatting of the scales and suggests that 
extreme response style is a personal style of participants rather than an issue 
with the scales.  Again, the researchers did not test whether the labels at the 
ends of the scale affected responses, for example if they are worded differently 
or if the ends were flipped.   
Evidence suggests that there is little difference in labelling the scales with 
adjectives under each rating number and end-anchored labels (labels at each 
end of the scale) (Dixon et al., 1984; Newstead and Arnold, 1989).  However 
Frisbie and Brandenburg (1979) found that participants are influenced by the 
labels on the ends of the scales.  Frisbie and Brandenburg (1979) tested 
various scales containing different labels which were randomly distributed to 
college freshman.  Similarly to Wildt and Mazis (1978), Frisbie and 
Brandenburg (1979) did not provide adequate information on how the 
questionnaires were randomised. 
The Likert scale used in the eDelphi surveys used end-anchored labels; ‘Not 
important’ and ‘Extremely important’ (Figure 10) to indicate how important the 
outcome domain was for inclusion in the core outcome set.  Because 
international stakeholders were invited to take part it was thought that the 
wording ‘extremely important’ would be better understood compared to such 
wording as ‘critically important’ or ‘critical’.  The labels were the same for each 
outcome domain as not to cause confusion. 
Participants were asked to rate each outcome domain on the 9 point Likert 
scale or select ‘no opinion’.  Comments relating to the outcome domains were 
invited using an optional free-text box.  Participants were asked, on a separate 
page, whether they thought each outcome domain should be in the core set 





Participants were given the opportunity to suggest up to two additional outcome 
domains which were not in the survey.  The option to suggest two outcome 
domains instead of an unlimited amount was chosen because there was 
potential for a long list of outcome domains to be produced if participants were 
able to provide an unlimited amount.   A free-text box was provided for any 
comments regarding the additional outcome domains.   
The survey ended with a thank you page and contact details for any questions.  
The survey was in an online format, for reference purposes a facsimile of the 
survey can be found in MS Word format in appendix 7. 
Participants had the option to download their responses (which could be saved 
to a computer or printed).  Participants were advised to download their 
responses to remind them of their rating scores when completing the second 
round survey.  Participants were advised to download their responses because 
their individualised data could not be presented in round two due to 
anonymised aggregation of data within Bristol Online Survey. 
All outcome domains, including any relevant suggested outcome domains, 
were carried forward into round two to be rated.  Many core outcome set 
developers have carried over all of the outcomes into round two (Waters et al., 
2014; Harman et al., 2015; van 't Hooft et al., 2016; Byrne et al., 2017; Egan et 
al., 2017).  Others have used pre-specified criteria for dropping outcomes 
between rounds for example Sahnan et al. (2018) carried outcomes forward 
between rounds if more than 70% of all participants scored them as ‘really 
important’ (7–9), and Potter et al. (2015) retained outcomes for round two if 
more than 50% of participants in either the patient or the professional group, or 
both groups combined scored the item 7-9, and less than 15% of either group 
or both combined scored the outcome as not important (1-3).   
All outcome domains were carried forward into round two to enable participants 
to score the list of outcome domains as a whole.  The dropping of outcome 
domains between rounds risked dropping outcome domains that are 
considered core by some participants who did not complete the survey in the 





example any suggestions relating to interventions rather than outcome domains 
were not carried over into round two.   
 
4.4.7.2 Round Two Survey 
 
The link and password for the second round survey was provided on the 
recruitment emails which were circulated by the same gatekeepers detailed in 
section 4.4.4, the same participants that enquired about the research through 
Twitter and the same participants invited by the steering group members and 
the research team.  Covering emails were sent to the gatekeepers and steering 
group members asking them to forward the recruitment email and participant 
information sheet. 
Participants were reminded to look at their responses that they had 
downloaded or printed after completing the first round survey to assist them in 
re-rating the outcome domains in the second round survey.   
A main characteristic of the Delphi method involves the feeding back of the 
‘collective’ wisdom into the eDelphi.  A table containing the median scores per 
stakeholder group and overall scores for each outcome domain were given to 
participants in round two of the eDelphi surveys.  The overall group scores and 
scores for each group for each outcome domain were presented to participants 
in round two and participants were asked to rate each outcome domain in light 
of others feedback.  Any suggested outcome domains were also rated.  The 
percentage of participants who thought the outcome domain should be in the 
core set or should not be in the core set was provided along with the group 
scores.   
The same 1 to 9 rating scale (1 being ‘not important’ and 9 being ‘extremely 
important’) was used to rate the outcome domains.  The option to select ‘no 
opinion’ was not included.  An optional free-text box was provided for 
comments relating to the outcome domains. 
Once again, participants were asked, on a separate page, whether each 





Another optional free-text box was provided for comments relating to the 
outcome domains. 
The survey ended with a thank you page and contact details for any questions. 
 
4.4.8 Data Analysis 
4.4.8.1 eDelphi Round One Analysis 
 
Data were exported from each participant’s response on the Bristol Online 
Survey and inputted into Excel.   
The first round eDelphi survey responses were analysed using descriptive 
statistics IBM SPSS Statistics version 22.   
Histograms displaying the distribution curve for each outcome domain were 
produced.  Visual inspection of the histograms demonstrated that the data for 
every outcome domain was not normally distributed and negatively skewed.  
The histograms can be found in appendix 8.   
Because the data was not normally distributed the median for each outcome 
domain per stakeholder group and groups overall was calculated for feedback 
purposes in round two.  When data is not normally distributed the median 
should be used and not the mean (Black, 2006).  The median can be used 
when outliers distort the data because the median is not skewed by outliers 
compared to the mean (Scott and Mazhindu, 2014).   
The number of participants who selected ‘no opinion’ was calculated.  The 
percentage of participants rating each outcome domain as ‘yes’ or ‘no’ to the 
question asking if the outcome domain should be in the core set was also 
calculated.   
The suggested new outcome domains were reviewed by members of the 
research team to check for duplication with previously identified outcome 
domains and to exclude any irrelevant suggestions, for example any 






4.4.8.2 eDelphi Round Two Analysis 
 
Data were exported from each participant’s response on the Bristol Online 
Survey and inputted into Excel.  An example of the data inputted into Excel for 
the researcher stakeholder group is presented in Figure 11.  Researcher 1, 2, 3 
etc. indicates participants’ responses from the researcher stakeholder group.   
Figure 11 Screen shot of data entered into excel 
 
The second round eDelphi survey responses were analysed using descriptive 
statistics IBM SPSS Statistics version 22 and they were also analysed by 
calculating the percentage of participants rating each outcome domain as 7, 8 
or 9 (extremely important), 4, 5, or 6, OR 1, 2 or 3 (not important).   
The percentage of participants rating each outcome domain as ‘yes’ or ‘no’ to 
the question asking if the outcome domain should be in the core set was also 
calculated.   
The following section explains how consensus was defined. 
 
4.4.9 Consensus Definition 
 
Defining the consensus criteria was important because a too accommodating 
criteria could have resulted in too many outcome domains therefore creating a 
long list of outcomes, whereas a too stringent criteria risked excluding 
fundamental outcome domains that may have otherwise been included 
(Williamson et al., 2017). 
Outcome domain Researcher  
1
Researcher 
1 should it 





2 should it 





3 should it 





4 should it 





5 should it 
be core yes 
or no
Healing 9 yes 9 yes 9 yes 9 yes 8 yes
Patient reported symptoms 9 yes 9 yes 9 no 7 no 9 yes
Clinician reported symptoms 6 no 5 no 6 no 9 yes 2 no
Carer reported symptoms 6 no 6 no 6 no 7 no 8 yes
Life impacts 7 yes 9 yes 9 yes 7 yes 9 yes
Clinical signs 6 no 9 yes 6 no 9 yes 7 yes
Clinical measurement 3 no 7 yes 9 yes 9 yes 8 yes
Performance of the intervention 7 yes 7 yes 7 no 9 yes 9 yes
Resource use: supplies 3 no 7 yes 7 no 5 no 8 yes
Resource use: clinician time 3 no 6 no 7 no 8 no 8 yes





For any outcome domain to be included as core, one of the following three 
conditions was required:  
The overall group (all stakeholders combined) reach consensus that the 
outcome domain is core,  
OR  
The ‘patient and carer’ sub-group ((i) Patients & (ii) Carers combined) deemed 
the outcome domain core,  
OR  
The ‘professionals’ sub-group ((iii) Healthcare professionals, (iv) Researchers 
within wound care, and (v) Other types of professionals combined) deemed the 
outcome domain core.  
By using these three conditions it meant that there was not a group that did not 
have their opinions on what should be in the core outcome domain set 
included. 
The consensus definition is outlined below: 
 
Other ways to define consensus have been used by core outcome set 
developers, such as Schmitt et al. (2011) who stated that “at least 60% of all 
members of at least three stakeholder groups including consumers recommend 
including a domain” (p. 629) for the domain to be included.  Whereas, Millar et 
al. (2017, p. 4) defined consensus as “≥70% of respondents scoring an 
outcome 7-9 and <15% scoring the outcome 1-3”.  Eleftheriadou et al. (2015) 
Consensus INː 70% or more rated the item 7-9 and 15% or less rated the 
item 1-3 
Consensus OUT: 70% or more rated the item 1-3 and 15% or less rated the 
item 7-9 







stated at least 75% of participants from two stakeholder groups separately 
rated an outcome as being ‘very important’ or ‘important’ for it to be included. 
The consensus definition of 70% of participants scoring the item 7 to 9 has 
been used by other core outcome set developers such as Wylde et al (2015), 
Potter et al (2015), Blazeby et al (2015) and Boers et al (2016).  Williamson et 
al (2017) suggest that the 70/15% (70% or more rate the item 7-9 and 15% or 
less rate it 1-3) consensus definition means that the majority believe that the 
item should be in the core outcome set and only a small minority think it is of 
little or no importance.  
4.5 Results 
4.5.1 eDelphi Round One 
 
Fifty-one participants took part in the first eDelphi round involving 2 carers, 7 
researchers, 4 researchers from the industry, and 38 healthcare professionals.  
Of the 38 healthcare professionals that took part there were 14 nurses, 12 
tissue viability nurses, 3 vascular surgeons, 3 nursing management personnel, 
2 nurse consultants, 2 Doctors, 1 podiatrist and 1 microbiologist.  Table 13 
displays the overall number of participants, and participants per stakeholder 
group that participated in round one.    
Table 13 Participant response numbers per stakeholder group in round one 
 Respondents in 
Stakeholder group Round 1 
Patients and Carers 2 
Researchers and Healthcare professionals 49 
Total number of participants 51 
 
The first round was open between 5th October 2017 and 14th November 2017.  
Eleven outcome domains were rated by participants.  The results from round 





per stakeholder group and the overall median scores for each outcome domain.  
All 11 outcome domains were rated extremely important (rated 7-9) overall.  
The median scores for 5 outcome domains; healing, carer reported symptoms, 
clinical measurement, resource use: supplies and resource use: clinician time 
rated by the researcher in industry group fell within 4-6 (thus classified as 
uncertain).  The patient and carer, researcher, and healthcare professional 
group median scores all fell between 7-9 (extremely important) on the rating 
scale.     
Table 14 also displays the percentage of stakeholders that selected either ‘yes’ 
or ‘no’ to whether they think the outcome domain should be in the core set.  
The number and percentage of participants that selected ‘yes’ when asked if 
each outcome domain should be in the core set are as follows (in descending 
order); clinical signs (n=50, 98%), healing (n= 48, 94%), patient reported 
symptoms (n= 48, 94%), life impacts (n= 48, 94%), performance of the 
intervention (n=46, 90%), adverse events (n=46, 90%), clinical measurement 
(n=43, 84%), clinician reported symptoms (n=38, 75%), resource use: clinician 
time (n=35, 69%), resource use: supplies (n=31, 61%), and carer reported 





























Percentage of participants  
who thought the outcome 
domain should be in the 
core set (selected yes) 
Percentage of 
participants who thought 
the outcome domain 
should NOT be in the 
core set (selected no) 
Healing 9 7 6 8 9 94% 6% 
Patient reported 
symptoms 
9 9 7.5 8 8.5 94% 6% 
Clinician reported 
symptoms 
7.5 7 7.5 7 7.25 75% 25% 
Carer reported 
symptoms 
7.5 7.5 5.5 7 7.25 53% 47% 
Life impacts 8.5 9 7 8 8.25 94% 6% 
Clinical signs 8 7 7 8 7.5 98% 2% 
Clinical 
measurement 
7.5 8 5.5 8 7.75 84% 16% 
Performance of 
the intervention 
8.5 7 7 8 7.5 90% 10% 
Resource use: 
supplies 
7.5 7 6 7 7 61% 39% 
Resource use: 
clinician time 
8 7 6 7 7 69% 31% 






The number of participants that selected ‘no opinion’ when asked to rate each 
outcome domain is displayed in Table 15.  
Table 15 Number of participants that selected ‘no opinion’  







Healing  1 
Patient reported symptoms 1 3 
Clinician reported symptoms 1 1 
Carer reported symptoms 1 1 
Clinical measurement  1 
Performance of the 
intervention 
 1 
Resource use: supplies  1 
Adverse events  1 
 
The following were suggested under the item asking if there were any 
additional outcome domains that participants thought should be considered for 
inclusion.   All of the suggestions were already in the list of outcomes to be 
entered into the stage three consensus process. 














Clinical signs of infection 
Mental health 
 
Ulcer recurrence was again suggested as an outcome domain, however it was 
previously decided (discussed in section 4.3) that ulcer recurrence would not 
be included because it is not possible for the scope of the research to cover all 
aspects of venous leg ulcer management.  Therefore the suggestions relating 
to ulcer recurrence were not included in the round two survey. 
The qualitative comments and suggested outcome domains that participants 
provided in the round one survey are displayed in Table 16.  The suggested 
outcome domains are the outcome domains that participants provided when 
asked if there were any additional outcome domains that should be considered 
other than what was listed in the survey.  Some participants however 
suggested outcome domains in the free text comment box for qualitative 
comments; in this instance the suggested outcome domains were considered 
part of the suggested outcome domain list.  The comments are discussed in 
chapter 6 section 6.2.2.1. 




Comment (verbatim) Suggested outcome 
domains (verbatim) 
1 The QOL measures are often very general 
and a specific measure such as veinesqol 
may be more appropriate 
 
 Combinations of outcomes presented  
2 Health economic would be very important 
given the current challenges in healthcare 
today. Patient and carer feedback is more 
significant that the nurse treating the ulcer 




 Location of treatment intervention i.e. at a 









3  Clinical signs of infection 
NB 
  Patient centred concerns 
  Pain, sleep quality, 
exudate management.  
Expenses to patient- drg 
[drug] coats etc 
4 The selection of domains compliment one 
another - some measures can be very 
subjective, even when using a validated 
scoring system (e.g. carer reported 
symptoms) but are worthwhile to include as 
often times the patient may not be telling 
the clinician the full story. In terms of 
chronic venous ulceration, healing should 
not be the overall objective, quality of life is 
paramount. Treatment options and costing 
are vital - empirical evidence is necessary 
to ensure treatment options are made 
available as "money talks" and clinicians 
need to be able to have the evidence to 
support the cost effectiveness of various 
treatment options. This empirical evidence 
may also support the fact that VLU in 
particular is a chronic illness and make 
these treatment options more easily 
available to all patients. 
 
 While there are a number of 
contemporaneous guidelines available to 
the clinicians of differing 
disciplines/professions caring for patients 
with leg ulceration, there is a paucity of 
evidence to demonstrate if these 
guidelines are being implemented and the 
outcomes related to same.  There is very 
loose interpretation, adaption and 
implementation in certain areas meaning 
the standard of care differs across sectors. 
 
 Application of current guidelines across the 







5 I believe specific questions relating to 
compliance and concordance with 
treatment should be essential domains as 
they directly impact on outcomes and cost. 
 
  Psychological impacts from 
poverty, barriers to 
engagement, operational 
timings (out of hours/ 
patient travel, clinic 
availability, childcare 
issues etc)…mental 
health….and number one 
for venous improvement is 
client engagement and 
participation in their care 
package.  Anything that 
improves this I believe will 
help outcomes 
  Compliance 
  Concordance 
6 Important questions concerning trials: 
a) Inclusion and exclusion criteria, 
b) unblinded, single-blinded, double-
blinded, 
c) statistical aspects (alpha-error 
adjustment, was a calculation of sample 
size done ahead of the beginning of the 
trial?) 
 
 Statistical aspects of the trial  
7 As they are all individually so important it is 
difficult to give priority to one over another 
 
 I think the domains above are all relevant.  
I’m not so sure about the relevance of 
clinical signs domain but I’m sure there are 
good reasons to keep it in but maybe it’s 
one to seek more consensus on 
 
8 How about having patient adherence to 






9 Concerning the severity of the wounds, it is 
more important as a Baseline data than as 
a final outcome. 
Concerning the pain of the patient, the 
evaluator should be specified but I do not 
know who would be the more relevant to 
answer. Too much evaluators may reduce 
the interest to the evaluation. 
 
10 Two problems - First, the survey tool 
doesn't allow one to deselect "no opinion" 
option once chosen. Second, it is not clear 
what is meant by Core Domain? It is not 
defined in PIS and it is not clear if one is 
being asked whether or not the domain 
must be included in all trials, or whether it 
should be included in trials as appropriate 
to the research question. 
 
11  Pain score is very 
important 
12  Self efficacy 
13  Management rather than 
healing 
  Compliance 
14 Recurrence should be able to capture long 
term effectiveness of treatment, as well as 
ensure trials include an adequate follow-up 
period 
Recurrence 
15  Mobility can be helpful 
16  Has there been any 
imaging performed to aid 
diagnosis and treatments? 
  Patient and clinicians 
expectations 
17  Does a patient want to be 
healed? 
18  Patient reported 
experience not only 
outcomes 
19  Pain level 
  Recurring ulceration 





21  Ulcer re occurrence rates 
following healing 
  Whether the patient is 
being considered for 
surgical intervention 
22  Clinician Competence ie; 
Bank Nurses 
23  Systemic treatment 
  Diagnostic 
  Phlebotropic treatment.  
Antibiotics.  Which tests 
should be performed 
before treatment. 
24  Ulcer recurrence - time to 
ulcer recurrence 
  Ulcer free time 
25  Patients wellbeing 
  Environment patient lives 
e.g. climate 
 
All 11 outcome domains were carried over into round two to be rated by 
participants. 
 
4.5.2 eDelphi Round Two 
 
Forty-four participants took part in the second round involving 1 patient, 1 carer, 
5 researchers, and 37 healthcare professionals.  Of the 37 healthcare 
professionals that took part there were 8 tissue viability nurses, 7 nurse 
consultants, 6 nurses, 6 Doctors, 4 vascular surgeons, 4 nursing management 
personnel, 1 podiatrist and 1 microbiologist.  Table 17 displays the overall 
number of participants, and participants per stakeholder group that participated 
in round two.  Because participants were anonymised it could not be 
determined whether the same participants that took part in round one took part 







Table 17 Participant response numbers per stakeholder group 
 Respondents in  
Stakeholder group Round 1 Round 2 
Patients and Carers 2 2 
Researchers and Healthcare professionals 49 42 
Total number of participants 51 44 
 
The second round was open between 2nd January 2018 and 23rd February 
2018.  The results of round two are presented in Table 18.  Table 19 displays 
the percentage of stakeholders that answered either ‘yes’ or ‘no’ to whether 
they think the outcome domain should be in the core set.  There was no 
missing data. 
Of the 11 outcome domains that were rated by participants, 10 outcome 
domains met the criteria for consensus IN (70% or more rate the item 7-9 and 
15% or less rate the item 1-3):   
1. Healing 
2. Patient reported symptoms 
3. Clinician reported symptoms 
4. Life impacts 
5. Clinical signs 
6. Clinical measurement 
7. Performance of the intervention 
8. Resource use: supplies 
9. Resource use: clinician time 
10. Adverse events  
The outcome domain ‘carer reported symptoms’ did not meet the criteria for 
consensus IN (70% or more rated the item 7-9 and 15% or less rated the item 
1-3) or consensus OUT (70% or more rated the item 1-3 and 15% or less rated 








Table 18 Results from round two: rating of the outcome domains stratified by stakeholder group  
a Professionals: Healthcare professionals and researchers , b Patients and carers, and professionals combined, c 1-3= Not important, d7-9= Extremely important 
Outcome domain Patients and carers (N=2) 
N (%) 





Rating  1-3c      4-6 7-9d  1-3c      4-6 7-9d  1-3c      4-6 7-9d   
Healing 0 1 (50) 1 (50) 0 2 (5) 40 (95) 0 3 (7) 41 (93) IN 
Patient reported symptoms 0 0 2 (100) 0 4 (10) 38 (90) 0 4 (9) 40 (91) IN 
Clinician reported symptoms 0 1 (50) 1 (50) 1 (2) 10 (24) 31 (74) 1 (2) 11 (25) 32 (73) IN 
Carer reported symptoms  0 1 (50) 1 (50) 1 (2) 16 (38) 25 (60) 1 (2) 17 (39) 26 (59) No consensus 
Life impacts 0 0 2 (100) 0 2 (5) 40 (95) 0 2 (5) 42 (95) IN 
Clinical signs 0 0 2 (100) 0 3 (7) 39 (93) 0 3 (7) 41 (93) IN 
Clinical measurement 0 0 2 (100) 2 (5) 3 (7) 37 (88) 2 (5) 3 (7) 39 (89) IN 
Performance of the 
intervention 
0 0 2 (100) 0 3 (7) 39 (93) 0 3 (7) 41 (93) IN 
Resource use: supplies 0 0 2 (100) 2 (5) 9 (21) 31 (74) 2 (5) 9 (20) 33 (75) IN 
Resource use: clinician time 0 0 2 (100) 2 (5) 6 (14) 34 (81) 2 (5) 6 (14) 36 (82) IN 






Table 19 Percentage of stakeholders that selected either ‘yes’ or ‘no’ to 





thought it should 






thought it should 






thought it should 






thought it should 




 % (n) % (n) % (n) % (n) 












53% (27) 47% (24) 50% (22) 50% (22) 
Life impacts 94% (48) 6% (3) 98% (43) 2% (1) 
Clinical signs 98% (50) 2% (1) 95% (42) 5% (2) 
Clinical 
measurement 




90% (46) 10% (5) 93% (41) 7% (3) 
Resource 
use: supplies 




69% (35) 31% (16) 73% (32) 27% (12) 
Adverse 
events 






The data for each outcome domain in round two were negatively skewed 
indicating rare values were on the low side of the x axis towards the ‘not 
important’ end of the rating scale.  The histograms displaying the distribution 
curve and tables displaying the degree of skewness are presented in appendix 
9. 
The percentage of participants that selected ‘yes’ to all but one outcome 
domain (‘carer reported symptoms’) when asked if the outcome domains 
should be in the core set was 73% or above.  Only 50% of participants thought 
‘carer reported symptoms’ it should be in the core set.  The percentage of 
participants in round two that selected yes when asked if the outcome domains 
should be in the core set was similar to that in round one. However, the 
percentage of participants that thought the outcome domain ‘resource use: 
supplies’ should be in the core set increased from 69% in round one to 82% in 
round two.  The percentage of participants that selected yes for the following 
outcome domains increased: ‘clinician reported symptoms’ which increased 
from 75% to 84%, and ‘clinical measurement’ which increased from 84% to 
98%.  The percentage of participants that thought the outcome domain ‘patient 
reported symptoms’ should be in the core set reduced slightly by 8%. 
There were a number of outcome domains rated as extremely important but 
‘no’ was selected when asked if the outcome domains should be in the core 
set, for example a participant scored adverse events an 8 (extremely important) 
but also selected ‘no’ when asked if the outcome domain should be in the core 
set.  
The number of participants that rated the outcome domains extremely 
important (7, 8 or 9) but also selected no when asked if the outcome domain 
should be in the core set are as follows: 
• 25% (11/44) selected ‘no’ when asked if the outcome domain ‘Resource 
use: clinician time’ should be in the core set despite rating it extremely 





• 18% (8/44) selected ‘no’ when asked if the outcome domain ‘Carer 
reported symptoms’ should be in the core set despite rating it extremely 
important.   
• 9% (4/44) selected ‘no’ when asked if the outcome domains ‘Patient 
reported symptoms’, ‘Resource use: supplies’ and ‘Adverse events’’ 
should be in the core set despite rating them extremely important.   
• 5% (2/44) selected ‘no’ when asked if the outcome domain ‘Performance 
of the intervention’ should be in the core set despite rating it extremely 
important.   
• 2% (1/44) selected ‘no’ when asked if the outcome domains; ‘Clinician 
reported symptoms’ and Life impacts’ should be in the core set despite 
rating them extremely important. 
Two participants provided two qualitative comments, one being; “Expertise of 
the clinician is important factor influencing outcome” and the other participant 
said “Thank you”. 
4.6 Summary 
 
Ten out of the 11 outcome domains were rated core by participants in the stage 
two eDelphi: 
1.   Healing 
2. Patient reported symptoms 
3. Clinician reported symptoms 
4. Life impacts 
5. Clinical signs 
6. Clinical measurement 
7. Performance of the intervention 
8. Resource use: supplies 
9. Resource use: clinician time 





The next stage was to gain consensus on the outcomes that fell within the 
outcome domains that were rated as core in stage two.  The next chapter will 











The previous chapter described and discussed the method used to gain 
consensus on the outcome domains.  It presented the outcome domains rated 
core by participants, which were; healing, patient reported symptoms, clinician 
reported symptoms, life impacts, clinical signs, clinical measurement, 
performance of the intervention, resource use: supplies, resource use: clinician 
time and adverse events. 
This chapter will explain the methods used to gain consensus on the outcomes 
falling within the outcome domains rated as core in the previous eDelphi.  
Similar methods used in stage two were used in stage three, therefore to avoid 
repetition the rationale for the methods are explained in chapter 4.  It will then 




The aim of stage three was to gain consensus on the candidate outcomes that 




A two-round eDelphi was conducted to gain consensus on the outcomes 
extracted during the scoping review (stage 1).  Figure 12 shows the overall 





chapter explains (stage 3).  Figure 13 shows the eDelphi process used to gain 
consensus on the outcomes. 
 



























The flow charts in Figures 14 and 15 display how participants accessed the 
round one and round two surveys via the link on an email and a Tweet.    
Participants were shown an introduction page after they accessed the Bristol 
Online Survey.  For the participants that accessed the survey via the Tweet the 
introduction page included the information that was on the participant sheet that 
other participants received via email.  Participants were asked questions which 
sought their consent to take part and gain information on their background for 
example whether they were a patient, carer, healthcare professional or 
researcher.  Once participants completed the information they were directed to 
the main page which asked participants to rate the outcomes.  A thank you 
Agreed core outcome 
domain set and 
outcomes  
Participants were asked to rate each 
outcome (falling within the outcome 
domains agreed as core in the previous 
eDelphi) identified during the scoping 
review 
Round 1 
The overall group scores and scores for each group for 
each outcome rated in round one were presented to 
participants. Each participant was asked to rate the 
outcomes in light of others feedback. 







page was shown at the end on completion of the survey which included contact 
details for any questions.   






















Survey main section 
Participants rated the importance of each of the 120 outcomes for inclusion in the core 
outcome set. 
 
Participants were asked their opinion on the preferred unit of analysis (patient, ulcer or limb). 
Participants had an opportunity to suggest up to 2 outcomes for each outcome domain not 
included on the survey. 





An explanation on how to complete the survey was provided.  A question asked 
participants: Are you happy to continue to take part in the survey? (‘yes’ required to 
continue). 
Participants were asked to select a term which best described their background from 
the following; patient, carer, researcher, researcher from the industry sector, 
healthcare professional, or an option to type in a free-text box.   













Thank you page 
 
Results of round 1 were analysed and combined with the results from the survey 
accessed via the Tweet.  Suggested outcomes discussed by the research team, any 
irrelevant (i.e. suggestions relating to interventions rather than outcomes) were excluded 
 
Analysis 
All outcomes carried forward into round two for rating 
Participants invited via gatekeepers and through networks of the research team and steering 
group OR via the Tweet:  @VLUcoreven Help develop a core set of outcomes for venous leg 
ulceration.  Online survey 1: https://leeds.onlinesurveys.ac.uk/coreven-bristol-online-survey-1-v11  



























An explanation on how to complete the survey was provided.   A question asked 
participants: Are you happy to continue to take part in the survey? (‘yes’ required to 
continue). 
Participants were asked to select a term which best described their background from 
the following;  patient, carer, researcher, researcher from the industry sector, 
healthcare professional, or an option to type in a free-text box.   
             
 
Survey main section 
Summarised findings from round 1 were presented in round  2; specifically the average 
group score and the score by stakeholder group for each outcome.  The outcomes  were 
rated, including any additional suggested outcomes. 
Participants had the option to provide qualitative comments at the end of each outcome 
domain section. 















Results of round 2 were combined with the results from the round 2 surveys 
accessed via the Tweet and the  meeting paper survey.  The combined results 
were analysed for consensus. 
Analysis 
Thank you page 
 
Participants invited via gatekeepers and through networks of the research team and steering group OR 
via the Tweet: @VLUcoreven Help develop a core set of outcomes for venous leg ulceration.  Online 
survey 2: https://leeds.onlinesurveys.ac.uk/coreven-core-outcome-set-bristol-online-survey-round-2-vi-
4 Link to the survey and participant information sheet sent via email or the Tweet 
 
Consensus was defined using the following criteria (more information available in sections 2.7.5 
and 4.4.9): 
Consensus INː 70% or more rated the item 7-9 and 15% or less rated the item 1-3 
Consensus OUT: 70% or more rated the item 1-3 and 15% or less rated the item 7-9 









The same strategy to identify participants used in stage two was used in stage 
three with the addition of the following: 
• Leg ulcer researchers identified through national guideline development 
organisations were invited via editors. 
• Stakeholders (healthcare professionals, wound care researchers and 
researchers from industry) attending the EWMA conference in Krakow, 
Poland on the 10th May 2018 were invited to take part in round two.. 
 
5.2.4 Recruitment Process 
5.2.4.1 Round One 
 
The same recruitment strategy that was used in stage two (section 4.4.4) was 
used in stage three, with the addition of the following: 
 
1. Instead of asking people on Twitter to get in contact via a private Twitter 
message, the following tweet was shared two to four times a day:  
 
@VLUcoreven Help develop a core set of outcomes for venous leg 
ulceration.  Online survey 1: https://leeds.onlinesurveys.ac.uk/coreven-
bristol-online-survey-1-v11  
 
The information contained in the participant information sheet sent to 
participants who were recruited via email was included on the 
introduction page of the online survey.   
 
A Tweet with a direct link to the survey was used to make it easier for 






2.  A news item (appendix 10) was published on the Tissue Viability Society 
website.  The news item contained information on the research and 
contact details for people wanting more information.  Recruitment email 
and participant information sheets were sent to people who expressed 
their interest in taking part. 
 
Again, participants were invited to forward the recruitment email and participant 
information sheet onto people they thought might be interested in taking part.   
 
5.2.4.2 Round Two 
 
The same recruitment processes detailed in the previous section (section 
5.2.4.1) were used to recruit participants in round two.   
The following Tweet was shared two to four times a day: 
@VLUcoreven Help develop a core set of outcomes for venous leg 
ulceration.  Online survey 2: https://leeds.onlinesurveys.ac.uk/coreven-core-
outcome-set-bristol-online-survey-round-2-vi-4 
 
Recruitment meeting at the EWMA conference 
A permission request email was sent to the secretariat of EWMA to gain 
permission to recruit participants and collect data at the meeting held at the 
EWMA conference.  The meeting was advertised in the EWMA handbook.  




Ethics approval was obtained from the School of Healthcare Research Ethics 
Committee (SHREC), University of Leeds, UK [HREC17-028].  The ethics 
approval letter can be found in appendix 11.  An error occurred whereby the 
meeting at the EWMA conference was titled a consensus meeting in the ethics 





consensus meeting’.  The aim of meeting which was to invite delegates to take 
part in the round two survey was however correctly described in the ethics 
review form and accompanying documentation for example the EWMA 
permission request email.  Recruitment material for the surveys was sent prior 
to the launch of the EU General Data Protection Regulation (GDPR) which 
came into force on the 25th May 2018 (Information Commissioners Office, 
2018).   
Ethical considerations are outlined in chapter 4.  Exceptions to the ethical 
considerations are detailed in the following sections. 
 
5.2.5.1 Informed Consent and Right to Withdraw 
 
Again, informed consent was gained by informing the participants that by 
continuing to complete the survey they will be consenting to taking part.  The 
question “Are you happy to continue to take part in this survey?” was also 
included at the beginning of the survey.  
For the participants that accessed the online survey via the Tweet, the 
participant information sheet was part of the text on the survey introduction 
page.    
Participants were informed on the participant information sheet that they would 
not be able to withdraw their responses after completing the survey because 
their responses were anonymised therefore their data could not be identified for 
it to be withdrawn.    
Meeting at the EWMA conference: 
Participants at the meeting were asked to read a participant information sheet 
(appendix 12) and they were given an opportunity to ask questions and decide 
whether they wanted to take part.  A PowerPoint slide was displayed at the 
beginning of the meeting explaining to the audience that by participating in the 
meeting they were consenting to taking part.  Audience members were also 
informed on the PowerPoint slide “Once you have submitted data it cannot be 





this verbally.  A PowerPoint presentation was delivered which explained the 
purpose of the research and the meeting, and it went on to explain how to 
complete the survey.  The PowerPoint presentation can be found in appendix 
13. 
 
5.2.5.2 Confidentiality and Anonymity  
 
There were no questions requesting participant’s personal details, other than a 
question asking for their country of residence and a question on their 
background, for example researcher.  Healthcare professionals were asked to 




The Bristol Online Survey (Jisc, 2018) was used as the tool for data collection 
(https://www.onlinesurveys.ac.uk/). 
 
5.2.7 Rating of the Outcomes 
5.2.7.1 Round One 
 
Once participants entered the survey either via the link on an email or via the 
Tweet, they were shown an introduction page.   
Participants were asked to rate each of the 120 candidate outcomes (extracted 
during the scoping review) in terms of how important they are for inclusion in 
the core outcome set.  The outcomes were presented under their outcome 
domains, for example the outcomes related to healing were listed within the 







A preamble for each outcome domain section was provided.  The following text 
was the preamble to the outcomes in the ‘healing’ outcome domain section: 
We need to decide which outcomes are core and should be 
included in future trials on venous leg ulcer interventions.  An 
outcome is a measurement to assess the effect of a treatment, for 
example, its effectiveness (benefit) or the assessment of adverse 
side effects (risks). 
You will see below a list of outcomes which can broadly be called 
‘healing’.  Please rate each outcome in terms of how important, on 
a scale of 1 to 9 (1 being not important and 9 being extremely 
important).  Remember to rate the outcome as extremely 
important if you think the outcome is core and should therefore be 
in the core outcome set. 
Participants were asked to rate each outcome on a Likert rating scale of 1 to 9 
where 1 indicated ‘not important’ and 9 indicated ‘extremely important’ (Figure 
16 ).  The option to select ‘no opinion’ and the yes/no question asking if the 
outcome should be in the core set used in stage two was not included in the 
eDelphi on the outcomes (stage three) as not to add to the length of the survey.  
The option to select ‘no opinion’ and the yes/no question did not generate data 
that was more useful than the 1 to 9 Likert rating scale and produced conflicting 
results.  Comments relating to the outcomes in each outcome domain section 
were invited using an optional free-text box (an example is shown in Figure 17).  
Participants were given the opportunity to suggest up to two additional 
outcomes, for each outcome domain (Figure 18).  A free-text box was provided 
for any comments regarding the additional outcomes.  Towards the end of the 
survey, participants were asked to select their preferred unit of analysis (Figure 
19) with an optional free text box for comments. 
Figure 16  Example survey item from the first round survey 
Number of patients/ulcers/limbs that completely healed in a trial period *Required 




























Figure 17 Example of the free-text box for comments (no maximum number of 
characters) 
Optional: Please write any comments relating to the outcomes for the healing domain 
Figure 18  Example of the text box to suggest additional outcomes (no 
maximum number of characters) 
Optional: Is there an outcome relating to healing that you think should be considered, other than 
what has been listed in this survey?.  Please write the outcome in the box below. 
 
Figure 19  Survey item asking participants to select their preferred unit of 
analysis 
Which unit of analysis do you think is the most important when measuring outcomes: *Required 
 
An explanation was provided for the outcomes that were ambiguous or 
where it was thought an explanation would be helpful, for example 
‘erythema’ was described as ‘redness of the skin caused by increased 
blood flow to the superficial capillaries’.  
The survey ended with a thank you page and contact details for any questions. 
The survey was in an online format.  For reference purposes a facsimile of the 
survey section that asked participants to rate outcomes relating to healing can 
be found in MS Word format in appendix 14.  It also contains the introduction 
pages, comment boxes to suggest additional outcomes and qualitative 
o Patient  







comments, and the thank you page.  The online survey also contained 
outcomes within the following outcome domain sections; adverse events, 
symptoms, life impacts, clinical signs, clinical measurement, performance of the 
intervention and concordance/compliance.  It also contained a question on the 
preferred unit of analysis.  
Participants were advised to download their responses (which could be saved 
to a computer or printed) to remind them of their responses when completing 
the second round survey. 
All outcomes, including any relevant suggested outcomes, were carried forward 
into round two to be rated.  Duplicated outcomes and any irrelevant 
suggestions, for example any suggestions relating to interventions rather than 
outcomes were not carried over into round two.   
 
5.2.7.2 Round Two  
 
Once participants entered the second round survey either via the link on an 
email or via the Tweet, they were shown the introduction page.  The 
introduction page accessed by the link on the Tweet contained the information 
that was in the participant information sheet.  Once again, to gain consent 
participants were asked if they were happy to continue to take part in the study.  
Participants had to select ‘yes’ to continue.  Participants were asked the 
standard demographic questions as described in section 5.2.7.1 
Participants were encouraged to look at their responses that they had 
downloaded or printed following completion of the first round survey to assist 
them in rating the outcomes in the second round survey.   
Participants were asked to rate the 120 candidate outcomes on the same 1-9 
Likert scale.  A table containing the overall group scores and scores for each 
group for each outcome were presented to participants in round two and 
participants were asked to rate each outcome in light of others feedback.  Any 






A question on the preferred unit of analysis (patient, ulcer or limb) was once 
again presented to participants. 
The survey ended with a thank you page and contact details for any questions. 
 
5.2.7.2.1  Meeting at the EWMA conference 
 
A meeting was held at the EWMA conference in Krakow, Poland, on the 10th 
May 2018 11:15-12:15.   
The purpose of the meeting was to give stakeholders attending the conference 
an opportunity to rate the importance of the outcomes for inclusion in the core 
outcome set.  The purpose of the meeting was explained to the attendees at 
the beginning of the session.  It was explained that it would not be possible to 
withdraw the data collected at the meeting because it would be anonymised.  
Attendees were also informed that by participating in the meeting that they 
were consenting to take part.  Attendees were given a participant information 
sheet (appendix 12).  Attendees were able to ask questions and provide 
comments during the meeting. 
A PowerPoint presentation was delivered, the PowerPoint slides can be found 
in appendix 13. 
Participants were asked to rate each outcome on a paper copy of the online 
survey.  Attendees were also provided with a link to access the survey online if 
they did not want to complete the paper survey during the meeting.  
 
5.2.8 Data Analysis 
5.2.8.1 eDelphi Round One Analysis 
 
Data were exported from each participant’s response on the Bristol Online 
Survey and inputted into Excel.  An example of the extracted data can be seen 
in Table 20.  HCP 1, 2, 3 etc. indicates an extract of participants responses 







Table 20 Example of the data inputted into Excel from the round one eDelphi on the outcomes 
 Rating score     






HCP 3    
New 
Zealand 








Number of patients/ulcers/limbs that 
completely healed in a trial period 
9 9 9 9 9 8 7 
Time to complete healing - may be of a 
reference ulcer, of all ulcers on a 
reference limb, or of all ulcers on both 
limbs 
9 9 9 8 9 7 7 
Change in size of ulcer, e.g. length, 
circumference, area, volume 
6 6 9 6 9 9 8 
Number of reference ulcers achieving a 
pre-defined ulcer area change (e.g. any 
reduction, at least 50% reduction, at 
least 75% reduction) 
3 6 8 5 1 9 8 
Time to achieving a pre-defined ulcer 
area change in a reference ulcer (e.g. 
any reduction, at least 50% reduction, 
at least 75% reduction) 
3 6 8 5 1 8 8 






The first round eDelphi survey responses were analysed using descriptive 
statistics IBM SPSS Statistics version 22.   
Histograms were produced displaying the displaying the distribution curve for 
each outcome.  Visual inspection of the histograms demonstrated that the data 
for every outcome was not normally distributed and negatively skewed.  
Because the data was not normally distributed the median for each outcome 
per stakeholder group and groups overall was calculated for feedback 
purposes in round two.   
The suggested new outcomes were reviewed by members of the research 
team to check for duplication with previously identified outcomes and to 
exclude any irrelevant suggestions, for example any suggestions relating to 
interventions rather than outcomes.  All relevant suggested outcomes were 
carried forward into round two. 
 
5.2.8.2 eDelphi Round Two Analysis 
 
Data were exported from each participant’s response on the Bristol Online 
Surveys and inputted into Excel.  Data were extracted from the paper surveys 
completed at the meeting at the EWMA conference and inputted into Excel.  
Data extracted from the online surveys and the paper surveys was combined to 
produce an Excel spreadsheet containing all data from all surveys.   
The second round eDelphi survey responses were analysed using descriptive 
statistics IBM SPSS Statistics version 22.  Histograms displaying the 
distribution curve for each outcome were visually inspected and the degree of 
skewness was calculated using SPSS. 
The second round eDelphi survey responses were analysed by calculating the 
percentage of participants rating each outcome as 7, 8 or 9 (extremely 
important), 4, 5, or 6, OR 1, 2 or 3 (not important).   
The survey item asking participants what their preferred unit of analysis was 
analysed by calculating the number and percentage of participants selecting 





5.2.9 Consensus Definition 
 
The consensus definition and criteria that was applied in stage two (section 
4.4.9) was applied in stage three. 
 
5.3 Results 
5.3.1 eDelphi Round One 
 
Thirty-six participants from 16 countries took part in the first round involving 1 
carer, 10 researchers, and 25 healthcare professionals. Of the 25 healthcare 
professionals that took part there were 10 nurses, 5 Doctors, 4 tissue viability 
nurses, 3 vascular surgeons, 2 nurse consultants and 1 nursing management.  
Table 21 displays the overall number of participants, and participants per 
stakeholder group that took part in round one.  Table 22 displays the 
participants’ countries of residence.  Because participants were anonymised it 
was not possible to determine whether the same participants accessed both 
rounds. 
Four participants accessed the survey via the Tweet and 32 participants 
accessed the survey via email. 
The first round was open between 22nd March 2018 and 26th April 2018.  One 
hundred and twenty outcomes were rated by participants.   
 






 Respondents in 
Stakeholder group Round 1 
Patient and Carers 1 
Researchers and Healthcare professionals 35 






Table 22 Participants’ countries of residence (round one): 
Country Number of participants 
Australia 1 
Brazil 2 





New Zealand 2 
Portugal 1 
Spain 1 
Sri Lanka 1 
Sweden 1 
Switzerland 1 
United Kingdom 15 
United States of America 2 
 
The comments provided by participants and the suggested outcomes are 
displayed in Table 23.  The suggested outcomes are the outcomes that 
participants’ provided when asked if there were any outcomes that should be 
considered other than what was included in the survey.  Many of the suggested 
outcomes were pre-emptive of the proceeding outcomes in the survey, for 
example the outcome ‘measurement of pain’ was suggested in the section on 
‘healing’ and the outcomes on pain came after the section on healing.  





were further on in the survey.  The qualitative comments are discussed in 
chapter 6, section 6.2.3.1. 
Table 23 Comments and suggested outcomes 
Participant 
number 
Comments (verbatim) Suggested outcomes 
(verbatim) 
1 Time to healing and healing rates are 
much more important than reduction in 
surface area 
Pain score / qol 
 Many of the above appear too difficult to 
assess in a community setting [relating 
to the outcomes in the clinical 
measurement outcome domain] 
Concordance 
  Increase in pain [relating to 
adverse event] 
  Limb distortion [relating to 
adverse event] 
2 It is important that any adverse events 
are discussed with the whole clinical 
team to ensure learning from them 
Not all ulcers are treated 
entirely in Leg Clubs so might 
be useful to know how often 
they attended for treatment at 
Leg Club 
  Independent mobility 
3 Hawthorne effect QoL 
 Important to treat whole patient hence 
my choice above [question on the 
preferred unit of analysis; patient, ulcer 
or limb].  However ulcer and limb are 
also important units of analysis 
Pain at dressing change and 
overall pain score 
  Reduction in ulcer size, area, 
etc. are surrogate outcomes.  
Ideal outcomes are number of 
ulcers healed.  Feasibility of 
lengthening follow up time to 
capture these outcomes? 
  Total time for visit, include 
travel to and from, waiting to 
be seen 
  Length of time of adherence 
  Pattern of adherence? Times 
and days occasions where 





4  Quality of life 
  Who funds [relating to 
resource use] 
5  Periwound edema/ border 
edema/ periwound 
inflammatory process 
  Biofilm presence 
6 The importance of outcomes will be 
determined by the research question- 
outcomes related granulating tissue or 
fibrin maybe important if the question is 
regarding debridement, for instance, but 
may otherwise be unimportant if the 
purpose of the trial is to evaluate 
efficacy of effectiveness of an 
intervention on healing 
 
 Adverse events are typically poorly 
reported in VLU trials ………What is 
also clear is not only are adverse events 
poorly reported, but the types of 
analysis vary considerably and 
guidance on the types of analysis would 
be useful eg how should adverse events 
be reported, not just what events should 
be reported.  [This comment has been 
edited in order to maintain anonymity] 
 
 Again the importance of these outcomes 
[symptoms]  
 
 Again depends on the research 
question [life impacts] 
 
 I find this approach to establishing core 
outcomes less than useful - the 
outcomes should be driven by the 
research questions. A more useful 
approach might to have included 
scenarios with research questions so 
that in some circumstances some 
outcomes are core but in other 
circumstances they are. 
 
7 Outcome measure is highly dependent 






 Some of these measures are required 
for cost-effectiveness valuations 
[performance of the intervention] 
 
8  Disability from adverse events  
  Negligent events 
  Time-trade-off specific to 
VLUs and QOL 
  Compliance to care 
  Cost of noncompliance 
compression 
  Cost of pain medications 
9  Sleep disturbance due to pain 
  Maceration around the wound 
10 Patients with leg ulcers are often 
experts on their condition and can 
provide valuable input to this topic 
Patient factors impacting 
compliance eg allergy 
reaction, itch heat from 
bandage, discomfort/irritation, 
difficulty tolerating the 
treatment 
11  % Epithelialisation tissue or 
increased new edge 
12  Exudate 
13  Reduction in pain 
14  Measurement of pain 
15  Relação tratamento vs custo 
[Relationship treatment vs 
cost] 
16 Preferred unit depends on most 
appropriate to design and outcome of 
study and may be any of the 3 
mentioned above 
 
17  Technical success or 
compliance (depending on 
intervention) 
  Time to healing and 
recurrence but other than that 
patient opinion 
18 The holistic care of the pt [patient] 
includes the ulcer and limb 







No suggested outcomes were included in round two because the suggested 
outcomes had either been included further on in the round one survey, or they 
were intervention specific or trial specific and therefore not relevant to every 
research evaluation of interventions used for venous leg ulceration. 
All outcomes were carried over into round two to be rated by participants. 
 
5.3.2 eDelphi Round Two  
 
Thirty participants from 15 countries took part in the second round involving 9 
researchers, 4 researchers from industry, and 17 healthcare professionals.  Of 
the 17 healthcare professionals that took part there were 8 nurses, 3 Doctors, 2 
tissue viability nurses, 1 vascular surgeon, 1 pharmacist, 1 nursing 
management personnel and 1 nurse consultant.  Table 24 displays the overall 
number of participants, and participants per stakeholder group that took part in 
round two.  Table 25 displays the participants’ countries of residence.  Because 
participants were anonymised it was not possible to determine whether the 
same participants accessed both rounds. 
Three participants accessed the survey via the Tweet, 12 participants accessed 
the survey via email and 15 participants completed the paper survey at the 
meeting at the EWMA conference. 
The second round was open between 5th May 2018 and 5th June 2018.   
Table 24 Participant response numbers per stakeholder groups in round one 
and two 
 Respondents in  
Stakeholder group Round 1 Round 2 
Patient and Carers 1 0 
Researchers and Healthcare professionals 35 30 







Table 25 Participants’ countries of residence (round two): 











Sultanate of Oman 1 
Sweden 1 
Switzerland 2 
United Kingdom 7  
United States of America 1 
Not specified (paper survey) 2 
 
There was no missing data for the online surveys.  One participant did not 
complete 13 items on a paper survey at the meeting at the EWMA conference 
meaning the ratings for the following outcomes were missing for that 
participant: 
Time required for ulcer dressing changes 






Percentage of the ulcer surface area covered with necrotic tissue 
Change in necrotic tissue during the trial period 
Number of patients with necrotic tissue 
Change in the scoring/rating of exudate during the trial period 
Time to cessation of exudate (e.g. number of days, weeks) 
Rate of change in exudate 
Number of ulcers with exudate 
Change in the severity of malodourous exudate during the trial period 
Number ulcers with lymphangitis (inflammation or infection of the 
lymphatic channels-part of the circulatory system) 
Number of patients with abnormal skin changes 
Number of patients with hyperpigmentation (darkening of an area of the 
skin) during the trial period 
Another participant did not complete one item on a paper survey at the 
meeting: 
Change in the scoring/rating of tingling or pins and needles during the 
trial period 
Another participant did not complete one item on a paper survey at the 
meeting: 
Number of reference ulcers achieving a pre-defined ulcer area change 
(e.g. any reduction, at least 50% reduction, at least 75% reduction) 
The results of the round two survey are presented in Table 26 and Table 27.  
Forty-six outcomes met the criteria for consensus IN meaning 70% or more 
rated the outcomes 7-9 (extremely important) and 15% or less rated the 
outcomes 1-3 (not important).  Table 26 displays the outcomes that met the 
criteria for consensus IN. 
Seventy-four outcomes did not meet the criteria for consensus IN (70% or more 
rated the item 7-9 and 15% or less rated the item 1-3) or OUT (70% or more 
rated the item 1-3 and 15% or less rated the item 7-9), and were therefore 
deemed to have ‘no consensus’.  Table 27 displays the outcomes with ‘no 





Table 26 Outcomes that met the criteria for consensus IN  
Outcome Rating 1-3 
% (No of 
responses) 
Rating 4-6 
% (No of 
responses) 
Rating 7-9 
% (No of 
responses) 
Healing (outcome domain)    
Number of patients/ulcers/limbs that 
completely healed in a trial period 
7% (2) 13% (4) 80% (24) 
Time to complete healing - may be of a 
reference ulcer, of all ulcers on a reference 
limb, or of all ulcers on both limbs 
3% (1) 10% (3) 87% (26) 
Change in size of ulcer, e.g. length, 
circumference, area, volume 
7% (2) 10% (3) 83% (25) 
    
Adverse events (outcome domain)    
Number of adverse events (type of adverse 
event/s to be detailed in the paper) 
3% (1) 3% (1) 93% (28) 
Number of patients that experience an 
adverse event (type of adverse event/s to be 
detailed in the paper) 
10% (3) 7% (2) 83% (25) 
Number of patients that withdrew due to an 
adverse event (type of adverse event to be 
detailed in the paper) 
10% (3) 7% (2) 83% (25) 
Number of serious adverse events (type of 
adverse event/s to be detailed in the paper) 
10% (3) 3% (1) 87% (26) 
Number of patients that had episodes of 
clinically diagnosed infection 
3% (1) 10% (3) 87% (26) 
Number of patients with sepsis (also known as 
blood poisoning) 
10% (3) 10% (3) 80% (24) 
Number of patients with cellulitis 13% (4) 3% (1) 83% (25) 
Change in the severity of cellulitis during the 
trial period 
13% (4) 10% (3) 77% (23) 
    
Pain (outcome domain)    
Number of patients/ulcers/limbs with pain 3% (1) 3% (1) 93% (28) 
Number of patients reporting a pre-specified 
level of change in pain score during the trial 
period (e.g. any reduction, at least 50% relief) 





Change in patient reported pain score/rating 
during the trial period 
10% (3) 3% (1) 87% (26) 
    
Life impacts (outcome domain)    
Change in the Quality of Life score during the 
evaluation period 
0 3% (1) 97% (29) 
Activities of living (outcome domain)    
Change in activities of daily living score 7% (2) 0 93% (28) 
Ability to wear/find suitable clothes and shoes 10% (3) 17% (5) 73% (22) 
    
Clinical signs / symptoms (outcome 
domain) 
   
Change in oedema during the trial period – on 
a trial leg / both legs 
3% (1) 3% (1) 93% (28) 
Number of patients with oedema 7% (2) 17% (5) 77% (23) 
Number of patients with the presence of 
malodour of the ulcer 
7% (2) 13% (4) 80% (24) 
Number of patients/ulcers/limbs with a change 
in slough during the trial period 
10% (3) 13% (4) 77% (23) 
Percentage of ulcer surface covered in slough 10% (3) 20% (6) 70% (21) 
Change in the scoring/rating of necrotic tissue 
during the trial period 
7% (2) 17% (5) 77% (23) 
Change in the scoring/rating of exudate during 
the trial period 
10% (3) 7% (2) 80% (24) 
Time to cessation of exudate (e.g. number of 
days, weeks)  
7% (2) 20% (6) 70% (21) 
    
Clinical measurement (outcome domain)    
Change in venous blood flow 10% (3) 10% (3) 80% (24) 
Number of limbs with a pre-specified change 
in venous insufficiency (e.g. any improvement) 
7% (2) 17% (5) 77% (23) 
Change in venous pressure 13% (4) 13% (4) 73% (22) 
Change in ankle/arm pressure ratio during the 
evaluation period 
7% (2) 20% (6) 73% (22) 





Resource use (outcome domain)    
Number of dressing changes (e.g. per week, 
to healing) 
7% (2) 7% (2) 87% (26) 
Time between dressing changes, in days 7% (2) 13% (4) 80% (24) 
Time required for ulcer dressing changes 7% (2) 10% (3) 80% (24) 
Number of debridements required to obtain a 
clean ulcer 
7% (2) 20% (6) 73% (22) 
Cost to heal patient/ulcer/limb completely 3% (1) 7% (2) 90% (27) 
Cost per given time frame (e.g. week, month, 
year) 
7% (2) 13% (4) 80% (24) 
Total costs to the end of the study 7% (2) 10% (3) 83% (25) 
Nursing or clinician time required per 
patient/ulcer/limb (cost and/or time) 
13% (4) 3% (1) 83% (25) 
Number of work days lost 7% (2) 13% (4) 80% (24) 
Patient expenses 3% (1) 13% (4) 83% (25) 
    
Performance of the intervention (outcome 
domain) 
   
Ease of application- Reported by the patient 3% (1) 7% (2) 90% (27) 
Ease of removal - Reported by the patient 7% (2) 13% (4) 80% (24) 
Patients scoring of satisfaction with the 
performance of the intervention 
10% (3) 13% (4) 77% (23) 
Healthcare professionals scoring of 
satisfaction with the performance of the 
intervention 
10% (3) 20% (6) 70% (21) 
Rating of exudate handling by dressing 13% (4) 17% (5) 70% (21) 
Number of dressing changes with exudate 
leakage 
10% (3) 13% (4) 77% (23) 
OTHER     
Number of patients that adhered to treatment 
advice 






Table 27 Outcomes with no consensus (did not meet the criteria for consensus 
IN or OUT) 
Outcome Rating 1-3 
% (No of 
responses) 
Rating 4-6 
% (No of 
responses) 
Rating 7-9 
% (No of 
responses) 
Number of reference ulcers achieving a pre-
defined ulcer area change (e.g. any reduction, 
at least 50% reduction, at least 75% reduction) 
13% (4) 17% (5) 67% (20) 
Time to achieving a pre-defined ulcer area 
change in a reference ulcer (e.g. any 
reduction, at least 50% reduction, at least 75% 
reduction) 
10% (3) 30% (9) 60% (18) 
Change in ulcer severity score 10% (3) 40% (12) 50% (15) 
Number of ulcers with granulating tissue 20% (6) 40% (12) 40% (12) 
Number of ulcers with: a. healthy granulation 
b. at least 75% clean granulation c. unhealthy 
granulation 
20% (6) 37% (11) 43% (13) 
Quantity of granulation tissue measured at a 
given time point 
20% (6) 43% (13) 37% (11) 
Time to a pre-specified level of granulation 
tissue (e.g. 50%, 75%, 100%)  
17% (5) 40% (12) 43% (13) 
Percentage change in granulating tissue 
during the trial period 
13% (4) 33% (10) 53% (16) 
Quantity of fibrin on the ulcer measured at a 
given time point 
23% (7) 47% (14) 30% (9) 
Percentage change in fibrin during the trial 
period 
23% (7) 43% (13) 33% (10) 
Investigator reported level of pain 20% (6) 60% (18) 20% (6) 
Pain level during mobilisation 10% (3) 33% (10) 57% (17) 
Change in ‘comfort’ score/rating during the trial 
period 
10% (3) 33% (10) 57% (17) 
Comfort rating during dressing change (e.g. 
dressing removal) 
10% (3) 30% (9) 60% (18) 
Change in ‘ache’ scores/rating during the trial 
period 
17% (5) 43% (13) 40% (12) 
Change in heavy legs sensation score/rating 
during the trial period 





Change in the scoring/rating of tiredness of the 
lower limbs during the trial period 
13% (4) 40% (12) 47% (14) 
Number of patients reporting heavy leg 
sensation 
10% (3) 40% (12) 50% (15) 
Change in the scoring/rating of cramps during 
the trial period 
17% (5) 40% (12) 43% (13) 
Number of patients with cramps 20% (6) 40% (12) 40% (12) 
Change in venous claudication severity score 
during the trial period 
13% (4) 37% (11) 50% (15) 
Change in the scoring/rating of skin tenseness 
around the ulcer during the trial period 
13% (4) 30% (9) 57% (17) 
Change in the scoring/rating of restless lower 
limbs during the trial period 
17% (5) 37% (11) 47% (14) 
Change in the scoring/rating of heat/burning 
during the trial period 
13% (4) 23% (7) 63% (19) 
Change in the scoring/rating of itching during 
the trial period 
10% (3) 33% (10) 57% (17) 
Number of patients reporting itching during the 
trial period 
10% (3) 33% (10) 57% (17) 
Change in the scoring/rating of tingling or pins 
and needles during the trial period 
20% (6) 30% (9) 43% (13) 
Change in the scoring/rating of tenderness 
(area i.e. limb or ulcer) during the trial period 
17% (5) 37% (11) 47% (14) 
Change in fatigue scores/rating during the trial 
period 
23% (7) 43% (13) 33% (10) 
Patients perception of their body image 13% (4) 20% (6) 67% (20) 
Number of ulcers with suppuration (pus) 10% (3) 27% (8) 63% (19) 
Absolute or relative change in pus during the 
trial period 
10% (3) 30% (9) 60% (18) 
Severity of odour (from the ulcer) 17% (5) 20% (6) 63% (19) 
Change in the scoring/rating of erythema 
during the trial period 
10% (3) 27% (8) 63% (19) 
Number of ulcers that had a change in 
erythema (e.g. decreased, increased) 
10% (3) 23% (7) 67% (20) 
Number of ulcers with new areas of slough 13% (4) 20% (6) 67% (20) 
Percentage of the ulcer surface area covered 
with necrotic tissue 





Change in necrotic tissue during the trial 
period 
7% (2) 30% (9) 60% (18) 
Number of patients with necrotic tissue 7% (2) 27% (8) 63% (19) 
Rate of change in exudate 10% (3) 33% (10) 53% (16) 
Number of ulcers with exudate 7% (2) 23% (7) 67% (20) 
Change in the severity of malodourous 
exudate during the trial period 
10% (3) 20% (6) 67% (20) 
Number ulcers with lymphangitis (inflammation 
or infection of the lymphatic channels-part of 
the circulatory system) 
17% (5) 20% (6) 60% (18) 
Number of patients with abnormal skin 
changes 
13% (4) 20% (6) 63% (19) 
Number of patients with hyperpigmentation 
(darkening of an area of the skin) during the 
trial period 
23% (7) 33% (10) 40% (12) 
Time to re-pigmentation (skin regains normal 
colour) 
23% (7) 50% (15) 27% (8) 
Change in the surface area of 
lipodermatosclerosis (inflammation of the layer 
of fat under the epidermis) during the trial 
period 
20% (6) 40% (12) 40% (12) 
Number of patients with denuded peri-wound 
skin (loss of the top layer of skin on the 
surrounding skin) 
17% (5) 30% (9) 53% (16) 
Changes in valvular competence 10% (3) 23% (7) 67% (20) 
Number of limbs with superficial femoral 
incompetence 
13% (4) 27% (8) 60% (18) 
Diameter of the superficial femoral vein (mm) 17% (5) 50% (15) 33% (10) 
Change in venous distensibility (swelling) 20% (6) 23% (7) 57% (17) 
Change in transcutaneous partial pressure of 
oxygen (mmHg) 
17% (5) 47% (14) 37% (11) 
Change in pCO2 (partial pressure of carbon 
dioxide) 
30% (9) 57% (17) 13% (4) 
Change in blood biochemistry (e.g. Urea and 
electrolytes) 
30% (9) 53% (16) 17% (5) 
Change in a pre-specified haematological 
parameter (for example; Red blood cells, 
White blood cells, Erythrocyte sedimentation 
rate) 





Change in glycaemia (blood glucose) 20% (6) 47% (14) 33% (10) 
Change in cholesterol (blood test) 37% (11) 53% (16) 10% (3) 
Change in systolic blood pressure 17% (5) 67% (20) 17% (5) 
Change in diastolic pressure 17% (5) 63% (19) 20% (6) 
Change in heart rate 30% (9) 57% (17) 13% (4) 
Number of patients that had microbiologically 
determined presence of a particular 
pathogen/s on the ulcer bed (type of micro-
organism to be specified by the trialist) 
10% (3) 30% (9)  60% (18) 
Change in mASEPSIS score (wound infection 
score) 
13% (4) 20% (6) 67% (20) 
Number of patients that achieved 7 day wear 
time 
13% (4) 27% (8) 60% (18) 
Ease of application- Reported by the 
researcher 
10% (3) 27% (8) 63% (19) 
Ease of removal - Reported by the researcher 10% (3) 33% (10) 57% (17) 
Number with traumatic dressing removal 
(trauma to the ulcer bed or the surrounding 
skin) 
10% (3) 23% (7) 67% (20) 
Time required to debride the ulcer 13% (4) 27% (8) 60% (18) 
Number of patients that required surgical 
debridement 
10% (3) 33% (10) 57% (17) 
Number of visits where debridement was 
needed 
13% (4) 27% (8) 60% (18) 
Cost per pre-specified reduction in ulcer area 13% (4) 33% (10) 53% (16) 
Cost of dressings 13% (4) 23% (7) 63% (19) 
Number of dressing treatments per group 13% (4) 23% (7) 63% (19) 
Costs required to achieve debridement 17% (5) 33% (10) 50% (15) 
 
A table displaying the degree of skewness for each outcome is presented in 
appendix 15.  The data for each outcome in round two were negatively skewed 
indicating rare values were on the low side of the x axis towards the ‘not 
important’ end of the rating scale.  There were however 17 outcomes that were 
approximately symmetric (skewness was between -0.5 and 0.5), these were: 





Number of ulcers with: a. healthy granulation b. at least 75% clean 
granulation c. unhealthy granulation 
Quantity of granulation tissue measured at a given time point 
Time to a pre-specified level of granulation tissue (e.g. 50%, 75%, 
100%) 
Quantity of fibrin on the ulcer measured at a given time point 
Investigator reported level of pain 
Number of patients with cramps 
Change in fatigue scores/rating during the trial period 
Number of patients with hyperpigmentation (darkening of an area of the 
skin) during the trial period 
Time to re-pigmentation (skin regains normal colour) 
Diameter of the superficial femoral vein (mm) 
Change in blood biochemistry (e.g. Urea and electrolytes) 
Change in a pre-specified haematological parameter (for example; Red 
blood cells, White blood cells, Erythrocyte sedimentation rate) 
Change in glycaemia (blood glucose) 
Change in cholesterol (blood test) 
Change in diastolic pressure 
Change in heart rate 
Participants were asked what their preferred unit of analysis is; either patient, 
limb or ulcer.  Sixty percent of participants chose the patient as their preferred 
unit of analysis, 27% chose ulcer and 10% chose limb (Table 28).  
Table 28 Preferred unit of analysis 
Question Unit of analysis % (N) 
Which unit of analysis do you think 















The qualitative comments provided by participants in round two are displayed 
in Table 29.  One participant suggested some outcomes but because round two 
was the last round the outcomes were not carried forward into a further round 
of rating.  The qualitative comments are discussed in chapter 6, section 6.2.3.1. 





 Pain, eczema, itching 
 Pain at night/ position changes/ pain from bandage 
 Dependency on others, malodour, heavy secretion, 
leakage embarrassment 
 Surgical debridement- unusual in venous leg ulcers 
 Time off from work and travel costs for next of kins 
accompanying the patient and patient 
 Healing time is most important 
2 I suggest using a parameter that compares the center with 
respect to the edges of the skin lesion as an indicator of 
the healing trajectory 
 Many symptoms are not related to Venous Leg Ulceration 
 Some questions are related to infected or rheumatic ulcer. 
In fact the target of this survey are, mainly non-infected, 
Venous Leg or lymphatic stasis Ulcers 
 Some questions are related to arterial or infected ulcer, in 
fact the target are mainly non-infected venous ulcers 
 There is a need for robust health economics studies as a 
primary (non-secondary) endpoint 
 
5.4 Steering Group Consultation 
 
Forty-six outcomes met the criteria for consensus IN which is a large number of 
outcomes to have in a core outcome set.  It would not be feasible to report on 





interventions.  If 46 outcomes were to be included in the core outcome set then 
the inconsistency of reporting across trials would remain an issue because a 
large number of outcomes would still be reported on.  Whereas if the core 
outcome set contained a more manageable number of outcomes, there would 
be a greater probability of the outcomes in the core outcome set being reported 
across trials thus facilitating treatment comparisons across different sources of 
evidence and expediting the production of systematic reviews, meta-analyses 
and evidence-based clinical guidelines.  The option to perform another eDelphi 
round to refine the outcomes was an option however it would have required an 
ethics application delaying the research, and in the meantime participants may 
have forgotten about the project which risked lack of engagement.  Another 
round also risked burdening participants, especially after they had completed 
the lengthy surveys in rounds one and two.  An additional round did not 
guarantee that the outcomes would be refined, therefore it was decided that a 
third round would not be done, instead the findings were presented to the 
steering group who have experience in venous leg ulcer research. 
A conference call was held with members of the steering group to discuss the 
results of the eDelphi on the outcomes. The aim of the conference call was to 
discuss the results, determine if the steering group agreed that the outcomes 
with ‘no consensus’ (Table 27) should not be considered for inclusion in the 
core outcome set and discuss how the list of 46 outcomes (that met the criteria 
for consensus IN) should be refined to produce a manageable list of outcomes.  
A discussion amongst the steering group and research team then took place.  
Each outcome in the consensus IN was discussed in turn.   
In light of the results of the eDelphi the following was agreed by the steering 
group and research team in order to produce a feasible number of outcomes: 
 
It was suggested that the outcomes; ‘Change in activities of daily living score’ 
and ‘Ability to wear/find suitable clothes and shoes’ are encompassed within 
the outcome ‘Change in the Quality of Life score during the evaluation period’, 
therefore it was proposed that the ‘Change in the Quality of Life score during 





It was proposed that the following outcomes are sub-components of the 
outcome; ‘Cost to heal patient/ulcer/limb completely’ when a societal 
perspective is used: 
Nursing or clinician time required per patient/ulcer/limb (cost and/or time) 
Number of work days lost 
Patient expenses 
The three outcomes listed above are contributory factors to calculating the cost 
to heal a patient, ulcer or limb outcome therefore they are encompassed by the 
outcome ‘Cost to heal patient/ulcer/limb completely’. 
The following outcomes on adverse events were condensed into one outcome; 
‘Incidence and type of adverse event/s during the trial period (including number 
of events and number of people)’ because it captures all elements of the eight 
outcomes:  
Number of adverse events (type of adverse event/s to be detailed in the 
paper) 
Number of patients that experience an adverse event (type of adverse 
event/s to be detailed in the paper) 
Number of patients that withdrew due to an adverse event (type of 
adverse event to be detailed in the paper) 
Number of serious adverse events (type of adverse event/s to be 
detailed in the paper) 
Number of patients that had episodes of clinically diagnosed infection 
Number of patients with sepsis (also known as blood poisoning) 
Number of patients with cellulitis 
Change in the severity of cellulitis during the trial period 
The following outcomes were considered to be intervention specific and 
therefore not core for every research evaluation of interventions used for 
venous leg ulceration, for example the outcome ‘Change in oedema during the 





measuring oedema.  A trial on debridement may not be concerned with 
measuring oedema thus demonstrating that the outcome is not for use by every 
research evaluations of interventions used for venous leg ulceration.  Also not 
everyone with venous leg ulceration has oedema.  Another example includes 
‘Time between dressing changes, in days’; this outcome would only be relevant 
for research on dressings and would not be useful for a drug trial.  It was 
therefore proposed that the following outcomes were not for inclusion: 
Change in oedema during the trial period – on a trial leg / both legs 
Number of patients with oedema 
Number of patients with the presence of malodour of the ulcer 
Number of patients/ulcers/limbs with a change in slough during the trial 
period 
Percentage of ulcer surface covered in slough 
Change in the scoring/rating of necrotic tissue during the trial period 
Change in the scoring/rating of exudate during the trial period 
Time to cessation of exudate (e.g. number of days, weeks) 
Number of dressing changes (e.g. per week, to healing) 
Time between dressing changes, in days 
Time required for ulcer dressing changes 
Number of debridement’s required to obtain a clean ulcer 
We noted that the outcomes within the outcome domains ‘clinical 
signs/symptoms’ and ‘clinical measurement’ were highly rated by respondents 
and given that they are in some cases interim outcome measures with the 
actual impact of patients being seen through healing and quality of life.  The 
outcomes within ‘clinical signs/symptoms’ and ‘clinical measurement’ are: 
Change in oedema during the trial period – on a trial leg / both legs 
Number of patients with oedema 





Number of patients/ulcers/limbs with a change in slough during the trial 
period 
Percentage of ulcer surface covered in slough 
Change in the scoring/rating of necrotic tissue during the trial period 
Change in the scoring/rating of exudate during the trial period 
Time to cessation of exudate (e.g. number of days, weeks) 
Change in venous blood flow 
Number of limbs with a pre-specified change in venous insufficiency 
(e.g. any improvement) 
Change in venous pressure 
Change in ankle/arm pressure ratio during the evaluation period 
Given that some of the outcomes are population and/or intervention specific 
rather than applicable across all populations and all interventions, we were 
unable to reach consensus during the conference call to whether they should 
be in the core outcome set.  It was decided by the research team that they 
would not be included in the core outcome set but we will recommend that 
trialist select them dependent upon their population and intervention type. 
Inclusion of healing in the core outcome set may encourage its reporting in 
trials of interventions such as debridement which have not always reported 
healing.  It was therefore agreed amongst the research team and the steering 
group that the following outcomes that met the consensus IN, within the healing 
outcome domain, are core: 
Number of patients/ulcers/limbs that completely healed in a trial period 
Time to complete healing - may be of a reference ulcer, of all ulcers on a 
reference limb, or of all ulcers on both limbs 
Change in size of ulcer, e.g. length, circumference, area, volume 
It was agreed amongst the research team and steering group that the outcome 





outcomes that are core for reporting across all trials, therefore the following 
outcomes were retained: 
Number of patients/ulcers/limbs with pain 
Number of patients reporting a pre-specified level of change in pain score 
during the trial period (e.g. any reduction, at least 50% relief) 
Change in patient reported pain score/rating during the trial period 
Cost to heal patient/ulcer/limb completely 
Cost per given time frame (e.g. week, month, year) 
Total costs to the end of the study 
It was suggested that the outcome domain ‘life impacts’ is ambiguous, 
therefore it was decided that it should be called ‘quality of life’.  Additionally, the 
majority of studies that report on quality of life and the tools that assess quality 
of life all use the term ‘quality of life’. 
Because adherence is part of the CONSORT guidelines, it was decided that it 
should not be in the core outcome set but trialists should be directed to the use 
of CONSORT (CONSORT, 2018).  CONSORT gives an evidence-based, 
minimum set of recommendations for reporting RCTs with an aim to improve 
the reporting in RCTs.  It provides guidelines on how to design and conduct an 
RCT; it provides advice on how to analyse and interpret results, and how to 
assess the validity of the results.  Concerns were raised at the session at 
EWMA (section 4.3) over the methodological and statistical issues in venous 
leg ulceration trials, specifically baseline prognostic variables and number of 
participants. The CONSORT checklist provides guidance on such 
methodological and statistical issues including the specifying of primary and 
secondary outcomes.    
5.5 Summary 
To summarise, the consensus study on the outcomes helped refine the 





evaluations of interventions used for venous leg ulceration.  The core outcome 
domain set comprises of five outcome domains: 
1. Healing 
2. Adverse events 
3. Pain 
4. Quality of life 
5. Resource Use 
The following candidate outcomes, which fell within the five outcome domains 
listed above, and met the consensus IN criteria now require a systematic 
appraisal of their performance characteristics i.e. whether the outcomes are 
reliable, valid and responsive (discussed further in section 6.9.3): 
Number of patients/ulcers/limbs that completely healed in a trial period 
Time to complete healing – may be of a reference ulcer, of all ulcers on a 
reference limb, or of all ulcers on both limbs 
Change in size of ulcer, e.g. length, circumference, area, volume 
Incidence and type of adverse event/s during the trial period (including 
number of events and number of people) 
Number of patients/ulcers/limbs with pain 
Number of patients reporting a pre-specified level of change in pain score 
during the trial period (e.g. any reduction, at least 50% relief) 
Change in patient reported pain score/rating during the trial period 
Change in the Quality of Life score during the evaluation period 
Cost to heal patient/ulcer/limb completely 
Cost per given time frame (e.g. week, month, year) 
Total costs to the end of the study 
The primary use of CONSORT will be recommended for RCTs on interventions 
used for venous leg ulceration.  
The next chapter will summarise the key findings of all three stages of the PhD.  





challenges that arose and the limitations to the research.  The chapter will then 
discuss dissemination of the core outcome domain set and recommendations 
for future research.  Finally, the chapter will conclude with the implications of 























Chapter 6 Discussion 
6.1 Introduction  
The PhD set out to develop a core outcome set for use in research evaluations 
of interventions used for venous leg ulceration.  A core outcome domain set 
and a set of candidate outcomes have been developed over three distinct 
stages comprising of a scoping review (stage one) which identified outcome 
domains and outcomes that have been reported in RCTs on venous leg 
ulceration interventions and qualitative research, a consensus study on the 
outcome domains (stage two) and a consensus study on the outcomes (stage 
three).  A detailed account of each stage is provided in the previous chapters.  
This chapter will therefore summarise the key findings of this PhD and it will 
discuss the strengths and limitations to the methodological approaches.  It will 
also discuss the challenges that arose.  It will then go on to explain changes to 
the protocol.  Finally, the chapter will discuss ideas for future research, 
including dissemination of the core outcome domain set, the development of 
the core set of measurement instruments and the systematic appraisal of the 
candidate outcomes. 
6.2 Summary of Findings 
6.2.1 Stage One: Scoping Review 
 
In stage one, a scoping review was performed which provided the foundation 
for the consensus process.  The scoping review identified the outcome 
domains and outcomes reported in RCTs and qualitative research on venous 
leg ulceration.  The scoping review identified 258 eligible studies of which 230 
were RCTs and 28 were qualitative studies.  A total of 822 (following de-
duplication) outcomes were identified, of which 807 outcomes were identified 





The 822 outcomes were grouped into 11 outcome domains which are 
presented below: 
1.   Healing 
2. Patient reported symptoms 
3. Clinician reported symptoms 
4. Carer reported symptoms 
5. Life impacts 
6. Clinical signs 
7. Clinical measurement 
8. Performance of the intervention 
9. Resource use: supplies 
10. Resource use: clinician time 
11. Adverse events 
The 822 outcomes that were extracted during the scoping review were 
condensed into 120 outcomes, further information on the condensing process 
is available in chapter 3.   
The findings of the scoping review support claims that the outcomes reported in 
venous leg ulceration RCTs are heterogeneous thus highlighting the need for 
standardisation of the outcomes (Franks et al., 2003; Dwan et al., 2008; 
Gottrup et al., 2010; Gethin et al., 2015b; Liu et al., 2017).   
It is evident that there are a vast number of outcomes reported in RCTs posing 
difficulties for decision makers in recognising the trials purpose, identifying what 
outcomes have been reported, and collating usable information which is 
relevant to them.  It also poses challenges in evidence synthesis.  There is 
evidence of potential outcome reporting bias with 24% of the RCTs included in 
the scoping review stated an outcome or outcomes at the start of the paper but 
failed to report them in the results.  Four percent of the RCTs introduced an 
outcome in the discussion when it had not been stated in any other part of the 
paper.   
Deciphering what outcomes were reported in the RCTs was a challenge; in 





the trial report making it unclear whether the outcome stated in the results was 
the same as the intended outcome that was stated in the methods.   
When reading the trial report it was not always clear which outcomes were 
primary and secondary, which is not in keeping with the recommendations 
made by CONSORT (2010) which states that the primary and secondary 
outcomes should be pre-specified.  When primary and secondary outcomes are 
not adequately reported it can cause ambiguity over the overall point of the 
study (Gethin et al., 2015b).  In many cases there was not sufficient information 
on the outcomes making it difficult to fully understand what had been assessed.  
Nineteen percent of the RCTs failed to provide any information on the 
instruments used to measure the outcomes.  Similarly to Gethin et al’s (2015b) 
findings that the majority of venous leg ulcer trials (95%, 97/102) failed to make 
a reference to the reliability or validity of their measurement methods, the 
scoping review found that 74% (83/112) of the RCTs that measured an 
outcome relating to quality of life, signs and symptoms (e.g. pain, discomfort 
and heavy leg sensation) used trial specific scales.  It is not clear if the trial 
specific scales were assessed for validity, reliability and sensitivity.  Similarly to 
Gottrup et al. (2010) and Gethin et al. (2015b), the scoping review also found a 
lack of healing definitions; 45% (63/140) of RCTs included in the scoping 
review did not provide a definition of ‘healing’ or ‘healed’.  In addition, there was 
frequent use of un- defined outcomes such as ‘acceptability’ and ‘tolerability’.  
These types of outcomes can be interpreted in many ways adding confusion to 
the meaning of the outcomes and the purpose of the trial.  Many of the 
researchers who used these terms did not explain what they meant by them or 
how they were measured. 
 
6.2.2 Stage Two: Consensus Process for Identifying Core Outcome 
Domains (eDelphi)  
 
The second stage sought consensus on the outcome domains identified during 
the scoping review.  Patients, carers, healthcare professionals, researchers 





round eDelphi which aimed to identify which outcome domains are core for 
research evaluations of interventions used for venous leg ulceration. 
A total of 95 participants took part in rounds one and two of the eDelphi, 51 in 
round one and 44 in round two.   Patients, carers, healthcare professionals, 
researchers from industry and wound care researchers rated the outcome 
domains.  Ten out of the 11 outcome domains were rated as core by 
participants.  The outcome domain ‘Carer reported symptoms’ was not rated as 
core by participants.  The outcome domains which were rated as core by 
participants are displayed below:  
1.   Healing 
2. Patient reported symptoms 
3. Clinician reported symptoms 
4. Life impacts 
5. Clinical signs 
6. Clinical measurement 
7. Performance of the intervention 
8. Resource use: supplies 
9. Resource use: clinician time 
10. Adverse events 
The data for each outcome domain in round two were negatively skewed 
indicating rare values were on the low side of the x axis towards the ‘not 
important’ end of the rating scale.  Therefore the majority of ratings for each of 
the outcome domains were towards the ‘extremely important’ end of the rating 
scale.  The histograms displaying the distribution curve can be found in 
appendix 9.  All of the outcome domains, other than ‘clinical signs’, were highly 
skewed (less than -1).  ‘Clinical signs’ was moderately skewed (between -1 and 
-0.5). 
One carer and one healthcare professional rated healing ‘6’ and life impacts ‘9’ 
suggesting that quality of life is more important than healing.  A participant 
suggested “…In terms of chronic venous ulceration, healing should not be the 
overall objective, quality of life is paramount…” thus emphasising why some 





outcome domains are displayed in Table 14 and Table 18, and the qualitative 
comments are displayed in Table 16, chapter 4. 
The question asking if the outcome domain should be in the core set (yes or 
no) was not used to determine whether the outcome domain was included in 
the core outcome domain set because attitudinal issues often lie on a 
continuum and are not easily dichotomised (Bowling, 2005), and a dichotomous 
approach is related to a loss of information (Kottner et al., 2018).  However, 
that said, it supported the decision not to include the outcome domain ‘Carer 
reported symptoms’ in the core set because the outcome domain had the 
highest percentage (50%) of participants selecting ‘no’ when asked if it should 
be in the core set, compared to the other outcome domains.  This does not 
imply that the outcome domain is not important, but that the results of the 
eDelphi did not classify it as being ‘core’. 
The large number of outcome domains that met the consensus inclusion 
criteria meant that a very large number of outcomes were subjected to the 
subsequent consensus process.   
 
6.2.2.1 Qualitative Comments  
 
Some comments provided by participants in the round one survey reiterated 
the rating scores they gave, for example the following comment “Health 
economic would be very important given the current challenges in healthcare 
today. Patient and carer feedback is more significant that [than] the nurse 
treating the ulcer as this impacts on the patients QOL”, was provided by a 
participant that rated resource use: supplies and clinician time, and patient and 
carer reported symptoms as extremely important and rated clinician reported 
symptoms as not important.  
A participant suggested “The QOL measures are often very general and a 
specific measure such as veinesqol may be more appropriate” which is an 
important point, measurement instruments to assess the outcome domains now 






One participant highlighted issues to be addressed in the conduct of trials:  
“Important questions concerning trials: 
a) Inclusion and exclusion criteria, 
b) unblinded, single-blinded, double-blinded, 
c) statistical aspects (alpha-error adjustment, was a calculation of 
sample size done ahead of the beginning of the trial?)” 
However it was not in the scope of this PhD to address all aspects of venous 
leg ulceration research therefore the PhD was not able to address these issues 
but future research is needed on these. 
A participant stated “…is not clear what is meant by Core Domain? It is not 
defined in PIS and it is not clear if one is being asked whether or not the 
domain must be included in all trials, or whether it should be included in trials 
as appropriate to the research question.”.  The introduction page to the survey 
included the following sentence “The purpose of this study is to determine what 
outcomes are essential for patients and their clinicians to make decisions and 
therefore must be reported for all trials of venous ulcer treatments.”, the same 
sentence was included in the eDelphi on the outcomes but in light of feedback 
and the results of the eDelphi the following sentence was added at the start of 
each section to emphasise that the aim is for all outcomes in the core outcome 
set to be reported “We need to decide which outcomes are core and should be 
included in future trials on venous leg ulcer interventions.”. 
 
6.2.3 Stage Three: Consensus Process for Identifying Core 
Outcomes (eDelphi) 
 
The third stage sought consensus on the outcomes that fell within the 
outcomes domains rated as core in stage two.  The outcomes were those 
outcomes that were identified during the scoping review.  Patients, carers, 
healthcare professionals, researchers from industry and wound care 





identify which outcomes are core for research evaluations of interventions used 
for venous leg ulceration. 
A total of 66 participants from 21 countries took part in rounds one and two of 
the eDelphi, 36 participants in round one and 30 participants in round two.  
Healthcare professionals, researchers from industry, wound care researchers 
and a carer rated 120 outcomes.   
The majority of data (n=103/120) for each outcome in round two were 
negatively skewed indicating rare values were on the low side of the x axis 
towards the ‘not important’ end of the rating scale.  As to be expected, the 
outcomes in the consensus IN category were highly skewed (less than -1), 
other than the outcome ‘Change in ankle/arm pressure ratio during the 
evaluation period’ which was moderately skewed (between -1 and -0.5).  A 
table displaying the degree of skewness can be found in appendix 15. 
 
The eDelphi on the outcomes refined the original set of 10 outcome domains 
that were rated as core in the stage two eDelphi to produce a set of five core 
outcome domains.  The outcome domains which were agreed as core by 
participants and therefore comprise the core outcome domain set are displayed 
below: 
Core outcome domain set: 
1. Healing 
2. Pain 
3. Quality of Life 
4. Resource use 
5. Adverse events 
Forty-six outcomes met the criteria for consensus IN (70% or more rated the 
item 7-9 and 15% or less rated the item 1-3) and 74 outcomes did not meet the 
criteria for consensus IN or OUT thus deemed ‘no consensus’.  No outcomes 
met the criteria for consensus OUT (70% or more rated the item 1-3 and 15% 
or less rated the item 7-9).  The results of stage three are displayed in Table 26 





Seventy-four outcomes did not meet the criteria for consensus IN or OUT, 
some core outcome set developers subject the ‘no consensus’ outcomes (rated 
4-6) are subjected to another survey round, however the number of participants 
gradually declined since the start of the consensus process suggesting there 
may have been a further decline in participants if another round took place.  
The rating of such a large number of outcomes risked burdening participants 
resulting in fatigue.  The 74 outcomes had no consensus thus suggesting they 
are unlikely to be appropriate for every trial and therefore they were deemed 
not suitable for the set of candidate outcomes. 
An interesting observation was made; one healthcare professional rated the 
healing outcomes ‘2’ and quality of life impact ‘8’ suggesting that quality of life 
is more important than healing.  Whereas one researcher rated the outcomes 
on quality of life ‘5’ and the outcomes relating to healing a ‘9’.    
Because it would not be feasible to report 46 outcomes in every trial a 
consultation meeting was held with the steering group to discuss the results 
(discussed in chapter 5).  Each of the 46 outcomes were discussed in-turn and 
after consideration 35 outcomes were either formed to produce an outcome 
that incorporates other outcomes, for example the eight outcomes on adverse 
events were incorporated into the outcome ‘Incidence and type of adverse 
event/s during the trial period (including number of events and number of 
people)’, or the outcomes were excluded from inclusion because they are 
intervention/trial specific (discussed in section 5.4).  This resulted in 11 
outcomes which are proposed as candidate outcomes.  The candidate 
outcomes now require a systematic appraisal of their performance 
characteristics i.e. whether the outcomes are reliable, valid and responsive.  





Table 30 Candidate outcomes 
Number of patients/ulcers/limbs that completely healed in a trial period 
Time to complete healing – may be of a reference ulcer, of all ulcers on a 
reference limb, or of all ulcers on both limbs 
Change in size of ulcer, e.g. length, circumference, area, volume 
Incidence and type of adverse event/s during the trial period (including 
number of events and number of people) 
Number of patients/ulcers/limbs with pain 
Number of patients reporting a pre-specified level of change in pain score 
during the trial period (e.g. any reduction, at least 50% relief) 
Change in patient reported pain score/rating during the trial period 
Change in the Quality of Life score during the evaluation period 
Cost to heal patient/ulcer/limb completely 
Cost per given time frame (e.g. week, month, year) 
Total costs to the end of the study 
 
The results do not mean that the outcomes excluded from the list of candidate 
outcomes are not important or relevant but that the candidate outcomes (as 
displayed in Table 30) are agreed as core by stakeholders that took part in the 
eDelphi surveys.  Trialists can report on additional intervention specific 
outcomes relevant to their trial (Schmitt et al., 2015). 
Some of the candidate outcomes also require a suitable measurement 
instrument which is reliable, valid and responsive.  Consensus is needed on 
what definition of healing is used in the core outcome set.  There are existing 
definitions of ‘healing’ used in the literature for example, complete 
epithelialisation (Kerihuel, 2010), fully epithelized with the absence of drainage 
and without the need for a dressing (Alvarez et al., 2012), and complete 
epithelialization of the ulcer with no scab (Michaels et al., 2009).  After a recent 
review by Gould and Li (2019) on how wound closure is determine in clinical 
trials and real-world wound literature, Gould and Li (2019) state that the 
widespread adoption of a wound healing definition and measurement method is 
needed for better comparisons of treatment effects across trials.  Gould and 





and 9 real-world studies (studies based on electronic health records and 
patient/wound registry data).  The review highlights the variance in the 
definition of ‘healed’; five RCTs used the FDA definition of healing which is 
“skin reepithelialization without drainage or dressing requirements confirmed at 
two consecutive study visits 2 weeks apart” (FDA, 2006, p. 12), four RCTs used 
a similar definition to the FDA’s, 26 RCTs used a simpler definition (e.g. 
complete/full/100% (re)epithelialization or closure without discharge), 11 RCTs 
defined healing as complete epithelialization or closure, and 18 RCTs did not 
define healing.  Only three out of nine real-world studies defined healing which 
included; ‘complete epithelialization at 24 weeks’, ‘complete epithelialization of 
all wounds without any major amputations 1 year post treatment’ and one study 
referred to an algorithm to determine whether an ulcer has healed but no 
further details were given. 
After consultation with the steering group and research team the following is 
recommended for researchers planning and reporting on research evaluations 
of interventions for venous leg ulceration: 
1. All trialists follow the CONSORT guidelines (http://www.consort-
statement.org/)  
2. All venous leg ulcer trialists report on the five outcome domains in the 
core outcome domain set which are; healing, pain, quality of life, 
resource use and adverse events. 
Future research is now needed to systematically appraise the 11 candidate 
outcomes (displayed in Table 30).  Once they have been appraised and an 
accompanying core set of measurement instruments has been developed the 
core outcome set (which includes what outcome domains and outcomes should 
be measured and how the outcome domains and outcomes should be 
measured) will be recommended.  Future research on the development of a set 
of measurement instruments is discussed further in section 6.9.3. 








6.2.3.1 Qualitative Comments  
 
Many qualitative comments provided by participants in the surveys reiterated 
the rating scores given to the outcomes, for example one participant that rated 
‘Time to complete healing – may be of a reference ulcer, of all ulcers on a 
reference limb, or of all ulcers on both limbs’ extremely important and outcomes 
relating to the reduction in surface area not important commented “Time to 
healing and healing rates are much more important than reduction in surface 
area”. 
One participant included a comment which said “Reduction in ulcer size, area, 
etc. are surrogate outcomes.  Ideal outcomes are number of ulcers healed.  
Feasibility of lengthening follow up time to capture these outcomes?”.  It was 
not in the scope of this PhD to address all aspects of venous leg ulceration 
research therefore the PhD was not able to address these issues, it does 
however highlight that future research is needed on minimum follow up time. 
A participant stated “Adverse events are typically poorly reported in VLU 
trials……What is also clear is not only are adverse events poorly reported, but 
the types of analysis vary considerably and guidance on the types of analysis 
would be useful eg how should adverse events be reported, not just what 
events should be reported”, the core outcome set has the potential to improve 
the reporting of adverse events in venous leg ulcer trials.  The candidate 
outcome ‘Incidence and type of adverse event/s during the trial period 
(including number of events and number of people)’ has been proposed for 
inclusion in the core outcome set following a systematic appraisal of its 
performance characteristics thus if trialist report the outcome fully then both the 
incidence and type of adverse event/s will be reported. 
A participant stated that many of the outcomes relating to symptoms are not 
related to venous leg ulceration however the outcomes included in the survey 
are those that have been reported in RCTs on venous leg ulceration therefore 






6.3 Validity and Reliability 
 
A ‘good’ judgement cannot be determined therefore the use of a rigorous 
method can increase the likelihood that a ‘good’ judgement is derived (Murphy 
et al., 1998).  The principles of a rigorous method were applied in the planning 
and deliverance of the consensus process.  Patient organisation 
representatives, various healthcare professionals and researchers were 
consulted in the planning phase of the consensus methods at the session at 
the EWMA conference (see section 4.3).  The careful preparation of the 
methods through the development of a protocol strengthened the principles of 
good research practice.   
Threats to external validity include the selection of the sample, and threats to 
internal validity include the situation (i.e. number of rounds and type of 
feedback provided), attrition and researcher bias (Keeney et al., 2011).  Rowe 
et al. (1991) suggest that the validity of a study is influenced by the number of 
participants and their relative expertise.  By involving participants with expert 
knowledge, the content validity can be enhanced (Goodman, 1987).  The 
snowballing technique was used to optimise recruitment of participants with 
different expertise from various countries.  The sample size and characteristics 
of a sample impact the generalisability of the findings to venous leg ulceration 
research (Parahoo, 2006).  The findings however cannot be generalised to the 
wider context (outside of venous leg ulceration research) because the purpose 
of the research is to gain consensus on venous leg ulcer outcome domains and 
outcomes.  The eDelphi panel was composed of ‘experts’ in venous leg 
ulceration and thus may not be typical of the general population outside of this 
context.   
Consideration was given to the number of survey rounds because reliability 
increases as the number of rounds increase, however too many rounds can 
result in participant fatigue (Hasson et al., 2000), and successive rounds can 
lead to an increased number of drop outs (Simoens, 2006).  It was decided that 
the survey would involve two rounds so that participants would not become 
fatigued which would have increased attrition.  The audience members at the 





The opportunity to provide participants with explicit input ensures face and 
content validity by identifying any gaps in what has been measured (Kirwan et 
al., 2007).  Participants who took part in the eDelphi surveys were able to 
suggest outcome domains and outcomes, and qualitative comments on the 
surveys, thus providing participants with an opportunity to give explicit input 
whilst identifying any missing outcome domains and outcomes.  
 
While reliability was not assessed in this PhD, one way of assessing the Delphi 
method for reliability is to compare two or more Delphi studies which are on the 
same subject.  The results are than analysed for intra-group agreement using 
Pearson correlation coefficient (Kastein et al., 1993).  However, Kastein et al. 
(1993) highlight that although a study may demonstrate reliability, it cannot be 
generalised to an “Ideal Delphi”.  Future research is needed on the reliability of 
the Delphi method, however variations in Delphi studies will always exist 
therefore every Delphi study will be different, for example the level of expertise, 
size of the panel, clarity of the survey items and the number of rounds will be 
different, posing difficulties in assessing reliability. 
6.4 Strengths of the PhD 
6.4.1 Scoping Review  
 
The scoping review generated a comprehensive list of outcomes which were 
extracted from RCTs on venous leg ulceration interventions and qualitative 
research.  The scoping review enabled the breadth of the literature to be 
searched in a relatively time efficient way.  Many (n=358) of the outcomes 
extracted from the RCTs and qualitative research papers were duplicated 
suggesting the extraction of the outcomes became saturated, implying that 
further searching may not have led to the retrieval of further outcomes.  
Some core outcome set developers recommend asking open questions to 
generate the list of outcomes (Sinha et al., 2011).  Evidently the number of 
patients and carers that participated in both eDelphi’s was low thus meaning if 





some outcomes and outcome domains important to this stakeholder group may 
have been missed.  Trials have been criticized for not including outcomes that 
are important to patients and carers (Gandhi et al., 2008; Chalmers and 
Glasziou, 2009; Sinha et al., 2009).  Therefore, solely relying on the outcomes 
reported in RCTs to generate the list risked missing outcomes that are 
important to patients and carers.  It was therefore essential to include outcomes 
that are important to this stakeholder group.  It was hypothesised that the 
inclusion of outcomes identified in qualitative research would capture the 
outcomes regarded as important to patients and carers.  The inclusion of 
qualitative studies reporting on outcomes expressed by patients and carers in 
the scoping review, and by including an option to suggest two additional 
outcome domains and outcomes in the surveys it was intended that the eDelphi 
surveys included outcomes that have been identified by patients and carers.  
The identification of patients’ perspectives by including outcomes reported in 
qualitative research to inform the ‘list’ of outcomes is supported by Gorst et al. 
(2019).  Gorst et al. (2019) carried out a rapid review on qualitative research.  
MEDLINE was searched for qualitative studies on type 2 diabetes with no date 
restrictions.  The rapid review identified 458 individual outcomes from 26 
studies which either involved qualitative interviews (69%) or focus groups 
(31%).  The identified outcomes contributed to the development of the ‘long list’ 
of outcomes to be entered into a consensus process for the development of a 
core outcome set (Gorst et al., 2019).  Gorst et al. (2019) demonstrated that a 
large number of outcomes which are important to patients can be identified 
through a review of qualitative studies. 
 
6.4.2 International Involvement  
 
Participants from 22 different countries took part in the eDelphi on the 
outcomes (stage three).  International involvement is important because 
venous leg ulceration is a condition which is experienced world-wide and 
research on venous leg ulceration is carried out in various countries.  
International involvement increases the probability that the core outcome 





and validity of the results is increased by the involvement of stakeholders from 
different cultures (Boers et al., 2017).  The external validity of the core outcome 
domain set and candidate outcomes is increased by the involvement of 
international participants that took part in the eDelphi surveys.   External validity 
is concerned with the extent to which the findings can be applied to the wider 
population (Creswell and Plano Clark, 2011).  In a systematic review by 
Hutchings and Raine (2006) it was found that there were international 
differences in the overall and chance-corrected agreement on healthcare 
interventions between different countries (Switzerland, US, UK, Israel, 
Netherlands).  Hutchings and Raine (2006) suggested that the difference may 
have been due to differences in healthcare resources between the countries, 
thus highlighting the importance of international involvement in the 
development of a core outcome set because there are potential differences in 
healthcare between countries.  However cultural differences in the rating of the 
outcomes for research evaluations of interventions for venous leg ulceration 




The anonymity of participants was maintained throughout.  Being able to inform 
participants that their responses would be anonymous potentially increased the 
likelihood of open and honest opinions in the rating of the outcome domains 
and outcomes, and in the qualitative feedback.  One characteristic of the Delphi 
method is anonymity which is advantageous because it encourages true 
opinions which are not affected by peer pressure (Goodman, 1987).  Subject 
bias is eliminated when participants are not known to each other (Jeffery et al., 
1995).  Subject bias, also known as participant bias or social desirability bias, 
occurs when participants want to respond in a socially acceptable way 
(Bowling, 2009).  Therefore by maintaining anonymity it potentially meant that 
participants did not give responses they thought it were expected from them, 






The following example demonstrates that participants were potentially able 
to express open and honest opinions.   
I find this approach to establishing core outcomes less than useful - 
the outcomes should be driven by the research questions. A more 
useful approach might to have included scenarios with research 
questions so that in some circumstances some outcomes are core 
but in other circumstances they are [not]. [Participants number 6] 
The participant raised a useful suggestion, however it was decided that 
scenarios would not be included for each outcome because the survey was 
already very long, adding scenarios for participants to read would have 
added to it length thus risking participant burden.   
 
6.4.4 Opportunity for Participants to Suggest Outcome Domains 
and Outcomes 
 
Consultation with stakeholders provides the opportunity to gain additional 
insights and allows for knowledge transfer and exchange by allowing additional 
sources of information and opinions to be offered (Levac et al., 2010).  
Participants were given an opportunity to suggest additional outcome domains 
and outcomes not included in the eDelphi surveys, and provide qualitative 
comments thus adding to the comprehensive list of outcomes. 
Some outcomes were suggested in the eDelphi on the outcome domains 
(stage two) but they were already included on the list of outcomes to be 
subjected to the consensus process in stage three.  There were no outcomes 
suggested in the eDelphi on the outcomes (stage three) that were relevant for 
inclusion i.e. suggestions that were not related to interventions or they were 
trial specific, or they were duplicated outcomes.  This suggests that because 
there were no outcome domains or outcomes that participants suggested in 
addition to those that were already on the survey, that the survey captured the 






6.5 Summary of the Strengths of the PhD 
 
The scoping review generated a comprehensive list of outcomes for the 
consensus process, which included outcomes that have been reported in 
venous leg ulceration RCTs and qualitative research.  There was international 
involvement in the consensus to develop the core outcome domain set and 
candidate outcomes.  Participants had an opportunity to suggest outcome 
domains and outcomes that were not included in the eDelphi surveys.  
Anonymity was maintained throughout the consensus process. 
The next section will discuss the methodological challenges that arose in the 
development of the core outcome domain set and set of candidate outcomes, 
and the limitations to the findings of the PhD. 
 
6.6 Challenges and Limitations of the PhD 
6.6.1 Terminology 
 
The different terminology used by core outcome set developers posed 
challenges in the development of the definitions used in this PhD.  Table 12 in 
section 4.2 displays examples of how the different terminology has been used.   
Many discussions took place amongst the research team to discuss how an 
outcome domain and outcome would be defined.  It was important to establish 
definitions that are not only relevant to core outcome set terminology but also to 
venous leg ulceration research.  After many discussions and re-iterations the 
definitions presented in Table 1 (section 1.13) were decided upon.   
Although the option of titling this PhD ‘the development of a core outcome 
domain set’ was possible, the term ‘core outcome set’ is well-recognised and 
therefore people are more likely to search for this term, which is crucial for its 
dissemination and implementation.  Therefore the title of this PhD uses ‘core 





Conceptual frameworks and guidance on core outcome set development has 
continued to grow and develop since the start of this PhD, for example the 
OMERACT filter 2.0 which was used to help guide the grouping of the 
outcomes into outcome domains has now been updated to filter 2.1.  The filter 
was updated by OMERACT in order to address ambiguous wording and 
terminology (Boers et al., 2019).  The OMERACT handbook has also been 
updated since the start of the PhD and they have developed a workbook 
(OMERACT, 2019).  The COMET handbook (Williamson et al., 2017) was 
published towards the end of the planning phase for the stage two consensus 
process.  The continual development of core outcome set guidance is positive 
and crucial for developers but the evolving guidance during the time this PhD 
has been carried out was challenging.  The changing goal posts made them 
difficult to meet because the methods and ethics applications had already been 
developed and submitted.    
 
6.6.2 Scoping Review Search Strategy 
 
 
The search strategy retrieved 258 studies of which 230 were RCTs and 28 
were qualitative studies.  Two of the retrieved qualitative studies (Cullum et al., 
2016; Burke, No date) were identified by members of the research team. The 
qualitative study by Cullum et al (2016) was part of a larger 5 year funded 
programme of research.  Cullum et al’s (2016) programme of research was not 
retrieved during the database searches which led to an investigation into 
whether the search strategy was sufficient in identifying relevant studies.  A 
search (strategy can be found in appendix 16) was run to find out if the 
research by Cullum et al. (2016) was indexed in any of the four databases; 
MEDLINE, Scopus, Embase and CINAHL searched during the scoping review.  
The search did not locate Cullum et al’s (2016) research thus suggesting the 
reason for not retrieving it in the scoping review was because the research is 
not indexed in the databases that were searched rather than the search 






6.6.3 Language Bias 
 
Language bias arises when researchers and readers only use scientific studies 
reported in English (Egger et al., 1997).  Egger et al. (1997) found that RCTs 
with statistically significant results are more likely to be published in English.  
However Jüni et al. (2002) found that non-English trials produced significant 
results (p<0.05) and the estimates of effects were 16% more beneficial 
compared to English-language trials.  Jüni et al. (2002) looked at 303 meta-
analyses of which 50 included at least one published non-English trial.  
However, Jüni et al. (2002) point out that non-English trials included fewer 
participants compared to trials in English and the methodological quality of the 
trials was lower. 
Due to lack of funding for translation services it meant English only RCTs and 
qualitative studies were included in the scoping review therefore language bias 
is a limitation to this PhD.   
There were no additional outcomes or outcome domains suggested by 
participants from countries where English is not their first language suggesting 
the outcomes and outcome domains considered to be core to international 
stakeholders that took part in the consensus were captured.   
 
6.6.4 Grouping of Outcomes into Outcome domains 
 
 
The grouping of a large number of outcomes into outcome domains was 
challenging.  There were many outcomes that had high degrees of overlap with 
other reported outcomes therefore making the grouping process challenging.  
Outcome domains contain many different outcomes, such as the 111 outcomes 
contained within the outcome domain ‘healing’ which the scoping review 
identified.  The 111 outcomes are displayed in Table 10 (section 3.5.2).  The 
111 outcomes demonstrate that there can be a large number of outcomes 
within an outcome domain.  By only recommending core outcome domains in a 





combined to facilitate systematic reviews and meta-analyses.  Trialist’s can 
report on any outcome within an outcome domain, for example one trial may 
choose to report on ‘Number of patients with the presence of malodour of the 
ulcer’ as their primary outcome and another trial may choose ‘Severity of odour 
(from the ulcer)’ as their primary outcome, the two outcomes cannot be 
combined for a meta-analysis, whereas if trials report on the same outcomes in 
the same way they can be combined.   
Taxonomy can facilitate the grouping of the outcomes into outcome domains.  
Taxonomy is a controlled vocabulary.  It is a classification scheme to control 
the naming of groups within a hierarchical structure (American Society for 
Indexing, 2019).  Since the launch of the consensus process a taxonomy was 
developed by Dodd et al. (2018) for outcomes in medical research.  Conceptual 
models on taxonomy or classification schemes are not new; models exist such 
as Wilson and Cleary’s (1995) conceptual model which groups health related 
quality of life outcomes into five areas: biological and physiological, symptoms, 
functioning, general health perceptions and overall quality of life.  Wilson and 
Cleary’s (1995) model was later revised by Ferrans et al. (2005).  Ferrans et al. 
(2005) expanded the explanation of the five areas outlined in Wilson and 
Cleary’s model.  The areas depicted by Wilson and Cleary’s (1995), and 
Ferrans et al’s (2005) models are similar to the areas in the OMERACT filter 
2.0 (Boers et al., 2014), which was used to guide the grouping of the outcomes 
extracted during the scoping review into outcome domains. 
However, the new taxonomy by Dodd et al. (2018) provides a more detailed 
approach. The taxonomy contains 38-categories for classifying trial and 
systematic review outcomes.  It was developed following a literature review by 
Dodd et al. (2018) who found that there was not a suitable outcome taxonomy 
for trial outcomes.  The taxonomy was tested by applying it to the classification 
of outcomes recorded within 299 published core outcome sets on the COMET 
database, 3,515 Cochrane reviews and 30 studies identified from a search of 
US National Institutes of Health clinical trials registry (Dodd et al., 2018).  The 
outcome taxonomy can be used to annotate core outcome sets.  The COMET 
initiative promotes the use of Dodd et al’s (2018) 38-category scale taxonomy 





the 38 outcome domains on their website (http://www.comet-
initiative.org/OutcomeClassification/Taxonomy).   
Dodd et al’s (2018) 38-category taxonomy would have been useful for the 
grouping of the outcomes into outcome domains but the taxonomy was not 
available at that time.   
 
6.6.5 Rating of the Outcome Domains 
 
Ten out of 11 outcome domains were rated as core by participants in the 
eDelphi on the outcome domains (stage two).  One reason for this may have 
been because outcome domains containing many different, more specific 
outcome domains and outcomes within them, for example the outcome domain 
‘clinical signs’ contains 14 outcome domains of which contains 28 specific 
outcomes.  The 14 outcome domains and specific outcomes are displayed in 
Table 31. 
Table 31 List of outcome domains and their specific outcomes within ‘clinical 
signs’ 
Outcome domain Outcome 
Oedema Change in oedema during the trial period – on a 
trial leg / both legs 
 Number of patients with oedema 
Pus Number of ulcers with suppuration (pus) 
 Absolute or relative change in pus during the 
trial period 
Odour Number of patients with the presence of 
malodour of the ulcer 
 Severity of odour (from the ulcer) 
Erythema Change in the scoring/rating of erythema during 
the trial period 
 Number of ulcers that had a change in erythema 
(e.g. decreased, increased) 





 Change in the severity of cellulitis during the trial 
period 
Slough Number of patients/ulcers/limbs with a change in 
slough during the trial period 
 Number of ulcers with new areas of slough 
 Percentage of ulcer surface covered in slough 
Necrotic tissue Change in the scoring/rating of necrotic tissue 
during the trial period 
 Percentage of the ulcer surface area covered 
with necrotic tissue 
 Change in necrotic tissue during the trial period 
 Number of patients with necrotic tissue 
Exudate Change in the scoring/rating of exudate during 
the trial period 
 Time to cessation of exudate (e.g. number of 
days, weeks) 
 Rate of change in exudate 
 Number of ulcers with exudate 
 Change in the severity of malodourous exudate 
during the trial period 
Lymphangitis Number ulcers with lymphangitis (inflammation 
or infection of the lymphatic channels-part of the 
circulatory system) 
Abnormal skin changes Number of patients with abnormal skin changes 
Hyperpigmentation Number of patients with hyperpigmentation 
(darkening of an area of the skin) during the trial 
period 
Re-pigmentation Time to re-pigmentation (skin regains normal 
colour) 
Lipodermatosclerosis Change in the surface area of 
lipodermatosclerosis (inflammation of the layer 
of fat under the epidermis) during the trial period 
Denuded peri-wound skin Number of patients with denuded peri-wound 







The refinement of the list of outcome domains in the eDelphi on the outcomes 
(stage three) proved to be more effective at gaining consensus on the outcome 
domains.  One reason for this could have been because participants were able 
to see which specific outcomes are contained within each of the outcome 
domains.   
On reflection, it may have been better to have included more specific outcome 
domains in the first eDelphi on the outcome domains, rather than the 11 broad 
outcome domains. 
 
6.6.6 Rating of the Long List of Outcomes 
 
There was a loss of 29 participants between the consensus study on the 
outcome domains (stage two) and the consensus study on the outcomes (stage 
three).  One reason for this may have been due to the length of the online 
surveys in the eDelphi on the outcomes (stage three).  Participants were asked 
to rate 120 outcomes; meaning it was a long survey for participants to 
complete.  This could therefore have resulted in participant fatigue.  Participant 
fatigue can arise when participants get tired of completing a survey (Lavrakas, 
2008).   
Edwards et al. (2002) performed a systematic review on RCTs of any method 
to influence response to postal questionnaires and found that the shorter the 
questionnaire, the more likely the response (odds ratio 1.86; confidence interval 
1.55 to 2.24). The review included 292 trials of which 40 reported on the effect 
of questionnaire length.    
Meta-analyses of published studies suggest lower response rates are 
associated with longer surveys (Heberlein and Baumgartner, 1978; Yammarino 
et al., 1991).  However, the studies included in the meta-analyses are based on 
paper-based mail surveys.  A meta-analysis by Sheehan (2001) was carried 
out on 31 studies that used e-mail surveys.  Sheenan (2001) reported on; 
number of questions in the survey, number of pre-survey notifications, year of 





informed participants of how long the survey would take to complete.  Sheenan 
(2001) did not find a correlation between survey length and response rate.   
Galesic and Bosnjak (2009) tested whether the information given to participants 
on the length of a survey affected response rates.  They found that the longer 
the stated length of time to complete the survey the less respondents took part 
compared to a quicker survey.   
In the stage two and stage three eDelphi surveys participants were given an 
approximate length of time each survey would take on the survey introduction 
page and participant information sheet.  Participants were informed of the 
length of time in order to make an informed decision whether to take part, thus 
reducing participant burden.  Efforts went into making the eDelphi surveys as 
succinct as possible, for example the outcomes were grouped under their 
outcome domains i.e. the outcomes related to healing were displayed under the 
title ‘healing’.  The same Likert scale was used for each outcome to make it 
more straight forward for participants to use.   
 
6.6.7 Ordering of Survey Items 
 
The ordering of the questions which asked participants to rate each outcome 
domain on a Likert scale of 1 to 9 was considered.  Research suggests that the 
ordering of questions can influence response rate and participant’s responses 
to questions (Bradburn et al., 2004; Galesic and Bosnjak, 2009; Krosnick and 
Presser, 2010; Brookes et al., 2018).  The questions at the start of the survey 
can influence whether a person decides to take part or not because the initial 
questions give the participant an idea of what the survey entails (Krosnick and 
Presser, 2010).   
Brookes et al. (2018) carried out a study on the impact of question order on the 
prioritisation of outcomes for a core outcome set.  A parallel RCT, nested within 
a Delphi survey to test three hypotheses; the ordering of items impacts on the 
following: response rates, participants’ responses and influences the items 
retained at the end of the first Delphi round (Brookes et al., 2018).  One 
hundred and eighty seven participants took part, of which 116 were patients 





professionals who were members of the Association of Upper Gastro Intestinal 
Surgeons of Great Britain and Ireland.  Participants were randomised to receive 
a survey with clinical and patient-reported outcomes, where patient-reported 
outcomes appeared either first or last.  Participants rated a 68-item survey.  
Brookes et al. (2018) found that the ordering of the questions did not impact on 
response rates for the surveys sent to patients, but fewer healthcare 
professionals participated when the survey gave clinical items first and patient-
reported items last.  The importance of patient-reported outcomes were rated 
higher by patients when patient-reported outcomes came last in the survey, 
whereas healthcare professionals rated clinical outcomes higher when they 
appeared last on the survey.  Brookes et al. (2018) also found that the order of 
questions impacted upon the number of outcomes retained at the end of round 
one.  Discrepancy was found in the items retained by one stakeholder group 
and not by the other stakeholder group.  Brookes et al. (2018) conclude that the 
ordering of outcomes in a Delphi survey can affect participants’ ratings. 
Galesic and Bosnjak (2009) found that questions posed later on in a survey 
were given shorter response times.  Because the nature of the questions in the 
eDelphi surveys were the same throughout it may have meant participants 
spent less time on the questions posed later on in the survey as they became 
fatigued with completing the rating scales for each outcome.  Alternatively, 
participants may have become accustomed to the framing of the items and thus 
did not need to spend as much time reading the questions.  The length of time 
participants spent on each item is not known as the Bristol Online Survey did 
not time how long participants spent completing the surveys. 
Guidance on question order in Delphi studies developing core outcome sets is 
lacking.  Brookes et al. (2018) point out that further research is needed on the 
area of question order in core outcome set development and that there is little 
guidance on the best way to structure Delphi surveys. 
The option to select ‘no opinion’ and the yes/no question asking if the outcome 
should be in the core outcome set which was asked in stage two was not 
included in the eDelphi on the outcomes (stage three) as not to add to the 





did not generate data that was more useful than the 1 to 9 Likert rating scale 
(explained in chapter 4).  
In order to make the survey shorter it would have meant omitting outcomes 
from the survey which would have introduced subjective bias of the 
researchers, whereby the researchers would have made judgements on which 
outcomes to omit.   A shorter survey would have meant there was less 
possibility that people were put off from starting it or participants becoming 
fatigued completing it.  The number of participants starting but not finishing the 
survey was not recorded by the Bristol Online Survey tool.   
 
6.6.8 Selection of ‘Experts’ 
 
The selection of participants was important because reliability can be affected 
by the judgements made by ‘experts’ taking part in an eDelphi.  What makes an 
‘expert’ has been debated over the years (discussed in chapter 2).  Experts for 
the eDelphi surveys were thought of as being those that have either 
experienced a venous leg ulcer, cared for a person that has experienced a 
venous leg ulcer, decision makers, guideline developers or those involved in 
research on venous leg ulceration.  Therefore recruitment aimed to invite these 
groups of stakeholders to take part in the development of the core outcome set 
because they have an in-depth understanding of which outcomes should be 
reported in research. 
Purposive sampling was used to recruit participants belonging to venous leg 
ulcer and wound care networks, for example Alliance for Research and 
Innovation in Wounds and the European Wound Management Association.    
There is potential for subjective bias of the researchers as the participants were 
purposefully selected.  The subjectivity of researchers selecting the type of 
participant is a potential for bias (Jones and Hunter, 1995), and threatens 
validity of the conclusions (Jupp, 2006).  In an attempt to minimise subjective 
bias, the uptake of the eDelphi surveys was promoted through gatekeepers of 





outcome set to be representative of venous leg ulceration, it was important to 
involve people who hold knowledge in this area. 
 
6.6.9 Patient and Carer Participation 
 
Two carers participated in round one of the eDelphi on the outcome domains, 
and one patient and one carer took part in round two of the eDelphi on the 
outcome domains.  One carer took part in round one of the eDelphi on the 
outcomes, and no patients or carers took part in round two.  The inclusion of 
five participants from the patient and carer group may limit its representation of 
patients’ and carers’ perspectives on the outcomes.   
Low numbers for patient and carer participation have been reported in core 
outcome set development.  In a systematic review by Davis et al. (2018) which 
included the findings from three previous systematic reviews (Gargon et al., 
2014; Gorst et al., 2016a; Gorst et al., 2016b), it was found that of the 225 
studies that provided details on the stakeholder groups that participated in 259 
studies to develop a core outcome set, only 28% (62/225) included public 
representatives (i.e. patients, carers, service users and patient support group 
representatives).  There are various reasons for this; public representatives 
were not recruited, public representatives did not respond to invitations, only a 
small number responded, and because of attrition.  Attrition is the loss of 
participants over time (Bowling and Ebrahim, 2005).  Attrition bias can occur in 
core outcome set development when the participants that do not take part in 
subsequent rounds have different views to other participant groups that 
continued to take part (Williamson et al., 2017).  Attrition bias can lead to an 
over-estimation of the degree of consensus (Mullen, 1983; Bardecki, 1984; 
Williamson et al., 2017).  However Harman et al. (2015) found that attrition bias 
did not affect the results in their Delphi study.  One hundred and four 
healthcare professionals took part in round one of Harman et al’s (2015) study, 
85 completed round two and 74 completed round three. Participants in Harman 
et al’s (2015) study were asked to rate outcomes (n=49).  Harman et al (2015) 





scores for participants completing Delphi rounds one and two.  Round three 
scores were compared with round two scores in the same manner.  Harman et 
al (2015) found that the people that did not take part in round two or three did 
not represent extreme views therefore stating that bias was not an issue 
caused by attrition.  However, no parents of children with cleft palate, or adults 
or children with cleft palate took part in the eDelphi’s instead 35 parents, eight 
adults and eight children were interviewed.   
Williamson et al. (2017) suggest that core outcome set developers should 
examine the presence of potential attrition bias.  Because no patients or carers 
took part in round two of the eDelphi on the outcomes (stage three), the 
consensus in round two was dependent upon the participants within the 
‘professionals’ stakeholder group (researchers, researchers from industry and 
healthcare professionals).   
Attempts were made to recruit patients and carers by inviting members of the 
Lindsay Leg Club Society which has 39 clubs (30 Leg Clubs in the UK, 1 in 
Germany and 8 in Australia), and through a Tweet which was Tweeted two to 
four times a day.  The use of Twitter increased the opportunity for public 
involvement.   
Some core outcome set developers have used a combination of a systematic 
review or a literature review with interviews and/or focus groups to generate the 
list of outcomes (Millar et al., 2017; Sahnan et al., 2018).  The use of interviews 
or focus groups may have generated a richer insight into the outcomes that are 
core to patients and carers and is worth considering in future core outcome set 
development.  However that said, the scoping review identified a large number 
of outcomes that have been reported in RCTs and it identified outcomes that 
have been expressed by patients and carers in qualitative research which were 
included in the consensus.  Therefore the inclusion of interviews or focus 
groups may not have generated outcomes that were not already identified 
during the scoping review, in which case interviews or focus groups may result 







6.6.10 Online Surveys Only 
 
The surveys were only available to complete online, other than at the meeting 
at the EWMA conference where paper surveys were also available.  The 
surveys were in English therefore only people literate in English could take part 
and those with access to the internet.  A limitation to the research is therefore 
that the surveys were only available in English and mainly in an online format.  
In addition to the online surveys, paper versions of the surveys may have 
reached more participants.  A meta-analysis by Manfreda et al. (2008) found 
that web surveys had an 11% lower response rate than other modes (e.g. mail, 
telephone, face to face survey or fax), suggesting paper surveys may generate 
better response rates than online surveys.  The meta-analysis included 24 
studies, but because some studies contained more than one comparison 
between the questionnaire modes there were 45 comparisons in total. 
Members of the Lindsay Leg Club were invited to take part in the eDelphi 
surveys.  There are 30 Leg Clubs in the UK, 1 in Germany and 8 in Australia 
therefore it was thought that by inviting Lindsay Leg Club members to take part 
online it would capture a large sample of people who have had experience of 
having a venous leg ulcer or carers of people with venous leg ulceration.  It 
also meant that an equal opportunity to participate was given to all members of 
the Lindsay Leg Club rather than a select few being offered paper versions of 
the surveys which were also not guaranteed to recruit participants. 
An error in the formatting of the online survey arose which was identified by 
one participant who provided the following qualitative comment on the online 
survey; “the survey tool doesn't allow one to deselect "no opinion" option once 
chosen”.  In this instance the score on the Likert scale was included in the data 
analysis. 
 
6.6.11 Tracking of Survey Responses 
 
All participants received the same link to each survey sent via gatekeepers of 





Bristol Online Survey.  Therefore because participant’s responses could not be 
linked to an individual it meant it was not possible to track whether the same 
participant took part in each round of the eDelphi studies.  It also meant that 
attrition rates could not be accurately calculated.  An advantage of this 
approach, however, was that anonymity was maintained throughout.   
Because participant’s responses could not be identified it also meant that 
participant’s responses could not be presented to them in the second round 
survey.  To help overcome this participants were recommended to download or 
print their responses after completing the first survey so that they could see 
their ratings when completing the second survey.  They were able to see how 
other stakeholder groups (i.e. patients and carers, researchers, and healthcare 
professionals) rated the outcome domains and outcomes in the first round.  
Participants were able to view a statistical summary of the stakeholder groups’ 
views before rating the outcome domains and outcomes in round two. 
 
6.6.12 Important Versus Core  
 
All outcome domains were rated extremely important (7-9) apart from one 
(‘carer reported symptoms’) in stage two which meant all 120 outcomes were 
entered into the eDelphi on the outcomes (stage three).  The large number of 
outcome domains rated as core could be due to the labelling on the Likert 
scale.  The labelling of the Likert scale may have influenced participants rating; 
studies by Wildt and Mazis (1978), Frisbie and Brandenburg (1979) and Moors 
et al. (2014) found that adjective on the ends of the scales are more influencing 
than the labels in between.  Therefore participants are more likely to be pulled 
towards the ends of end-anchored scales (Streiner and Norman, 2008), thus 
suggesting participants who took part in the eDelphi surveys may have been 
influenced by the extreme end of the scale.   Acquiescence bias is the 
tendency of participants to endorse a survey item without considering its 
opposite (Watson, 1992), often called ‘yes-saying’ to items (Bowling and 
Ebrahim, 2005).  Thus participants may have been pulled towards the positive 
end of the scale (‘extremely important’).  Bowling and Ebrahim (2005) suggest 





labels are swapped.  Reversed-scored items have been used in surveys in an 
attempt to overcome acquiescence (Cronbach, 1950; Paulhus, 1991).  
Conversely, Barnette (2000) found that reversing response options became too 
confusing for participants and therefore recommended against it.  Barnette 
(2000) conducted a study to assess what the effects of wording on item and 
item response direction had on consistency reliability.  Reversing response 
direction, for example instead of 1 indicating ‘not important’ it would indicate 
‘extremely important’, was not tested in the eDelphi surveys because it was 
thought that it would be confusing for participants, especially with the number of 
outcomes that they were asked to rate in stage three.  In addition, continually 
changing the scales throughout a lengthy survey risked participants selecting 
the wrong rating score, however further research on reversing response 
options in core outcome set development using the eDelphi is required.   
Conversely, end- aversion bias, also called central tendency bias, is the 
reluctance of a participant to use the extreme categories of a scale (Streiner 
and Norman, 2008).  End-aversion bias is one explanation to why many 
outcomes (74/120) were defined as ‘no consensus’ (Anything else that did not 
meet the criteria for consensus IN/OUT) in the eDelphi on outcomes (stage 
three) instead of falling within the consensus OUT category (70% or more rated 
the item 1-3 and 15% or less rated the item 7-9). 
Additionally, attitudes towards questions on a survey can be influenced by the 
fact that participants are being asked to answer that question, sometimes 
called ‘reactivity’.  Reactivity is concerned with the degree to which the act of 
measuring something changes the thing that is being measured (Punch, 2005).  
Therefore the fact that a participant was asked to rate an outcome domain or 
outcome may have influenced their rating score, changing it in some way. 
Another explanation to why the majority of outcome domains and a large 
number of outcomes were rated as core could be because the difference in the 
concepts ‘important’ and ‘core’ were not clear to participants.  The majority of 
outcomes rated extremely important (7-9) were by healthcare professionals and 
carers whereas researchers were more selective to which outcomes they rated 
as extremely important.  The difference between healthcare professionals and 





suggests that researchers are more familiar with the concept of core outcome 
sets and the implications of reporting many outcomes in a trial.  Alternatively, 
researchers by nature of their job may be more critical and also more familiar 
with ratings scales thus taking longer to consider the options. 
The development of a core outcome set in leg ulcer research is new for its 
discipline therefore healthcare professionals who took part in the consensus 
may have not been familiar with its concept.  The findings of this PhD suggests 
more information on core outcome sets in nursing based journals would be 
useful, especially since core outcome sets are on the increase in various 
healthcare fields meaning healthcare professionals may be invited to take part 
in the development of core outcome sets. 
In a qualitative comment provided in the round one eDelphi on the outcome 
domains, a participant highlighted “As they are all individually so important it is 
difficult to give priority to one over another” and “I think the domains above are 
all relevant…” thus emphasising that participants struggled to differentiate 
between which outcome domains were core versus those that were important 
but not core. 
6.7 How the Findings Compare to Previous Research 
 
This PhD supports findings reported by other researchers who have highlighted 
that multiple outcomes are reported in venous leg ulcer research.  Gethin et al. 
(2015b) concluded in their systematic review that the outcomes reported in 
RCTs on venous leg ulceration are highly heterogeneous with 79 of the 102 
RCTs reporting different outcomes.  Liu et al. (2017) also found a variation in 
the reported outcomes in trials.  Liu et al (2017) analysed outcomes pre-
specified in Cochrane Wounds systematic reviews and found a large number 
(n=126) of different outcome domains were specified.  The scoping review in 
this PhD found that 230 RCTs had reported 807 different outcomes thus 
supporting Gethin et al’s (2015b) conclusion that the outcomes reported in 
RCTs on venous leg ulceration interventions are highly heterogeneous.  When 
outcomes are heterogeneous it means they cannot be compared and 





result, the findings from this body of research might not always reliably inform 
clinical decision making. 
Gethin et al. (2015b) found that 39% (40/102) of RCTs did not report any 
outcomes in the methods section.  Dwan et al. (2008) found that 40-62% (16 
included studies in their systematic review) of wound care studies had a 
primary outcome that was either changed, omitted or introduced in the studies 
publication compared to the protocol.  Similarly, Kirkham et al. (2010) found 
that only 55% (157/283) of trials in a cohort of Cochrane reviews included full 
data for primary outcomes.  As previously reported in chapter 3, the scoping 
review found 24% (54/230) of the RCTs on venous leg ulceration stated an 
outcome or outcomes in the introduction and/or methods but failed to report 
them in the results.  Also, 4% (9/230) of the RCTs introduced an outcome in the 
discussion when it had not been stated in any other part of the paper.  Such 
issues suggest that RCTs on venous leg ulcer interventions are at risk of 
outcome reporting bias. 
Gethin et al. (2015b) found that only 5% (5/102) of the RCTs made a reference 
to the reliability or validity of the measurement methods.  Gottrup et al. (2010) 
found that 76% (134/176) of the studies that defined their measurement 
instruments did not meet the reproducibility criteria defined as (p.262);  
the inclusion of a verifiable source of data, e.g. photos, to secure 
the possibility of validation from an external source by reproducing 
the study, or the involvement of an external validation source as 
part of the study design 
Gottrup et al. (2010) also found that 30% (53/176) of instruments were not 
robust (the adequacy of information on the measurement method used in order 
for another to replicate the data collection).  In this scoping review it was found 
that 19% (44/230) of the RCTs failed to provide any information on the 
instruments used to measure outcomes.  Also, 74% (83/112) of the RCTs that 
measured an outcome relating to quality of life, signs and symptoms (e.g. pain, 
discomfort and heavy leg sensation) used trial specific scales therefore it is not 





The scoping review found a lack of wound healing definitions with 45% 
(63/140) of RCTs not providing a definition of healing, similarly Gethin et al 
(2015b) found that 61% (62/102) of the RCTS did not provide a definition of 
healing.  Likewise, Gottrup et al. (2010) found that 45% of 176 articles in a 
literature review on chronic wounds and ulcer endpoints did not predefine their 
endpoints or their definition was not sufficient; for example of the 53 articles 
whose endpoint included wound closure, 36% did not define what was meant 
by wound closure. 
6.8 Changes to the Protocol 
 
To increase recruitment potential in the eDelphi on the outcomes, a news item 
(appendix 10) was published on the Tissue Viability Society website.  The news 
item contained information on the research and contact details for people 
wanting to take part.  Viewers of the news item were able to request more 
details via email before deciding to participate. 
The option for participants to select ‘no opinion’ in round one of the eDelphi on 
the outcome domains (stage two) was not used in the second round eDelphi on 
the outcome domains and in the eDelphi on the outcomes (stage three).  It’s 
inclusion in the first eDelphi did not prove to be useful because it was unclear 
how its use could contribute to the consensus; did no opinion mean that it is not 
thought of enough and therefore should not be in the core outcome set? And 
did it hold the same weight as the outcomes in the ‘uncertain’ category (4-6 on 
the Likert scale)?.  The option to select ‘no opinion’ did not generate data that 
was more useful than the 1 to 9 Likert rating scale (discussed in chapter 4).  
The yes/no question asking if the outcomes should be in the core set was not 
asked in the eDelphi on the outcomes (stage three).  There were conflicting 
results when the ratings for the outcome domains were compared to the results 
of the yes/no question; for example 25% (11/44) selected ‘no’ when asked if the 
outcome domain ‘Resource use: clinician time’ should be in the core set 
despite rating it as extremely important (further information can be found in 
section 4.5).  Because a dichotomous approach can be related to a loss of 





because the eDelphi survey on the outcomes was already very long it was 
decided that the yes/no question would not be included in the eDelphi on the 
outcomes. 
Because a large number of outcomes (46/120) remained in the consensus IN 
group (70% or more rated the item 7-9 and 15% or less rated the item 1-3) 
following the second round eDelphi on the outcomes (stage three), consultation 
with the steering group to refine the number of outcomes took place.  The 
steering group consultation was not in the protocol because it was done ad hoc 
following the large number of outcomes that remained after round two.   
Generally, when outcomes remain in the ‘no consensus’ category another 
round to rate the outcomes for a third time is done (COMET, 2017).  However it 
was decided that another round would not be justifiable.  An additional round 
may have caused participant burden because four rounds (two for the eDelphi 
on the outcome domains and two for the eDelphi on the outcomes) had already 
taken place.  Also, gradual attrition rates had occurred since the first eDelphi 
survey suggesting the number of participants may have reduced further.  An 
amendment or another ethics application would have been required creating a 
time gap between the last eDelphi survey and the additional eDelphi survey 
potentially leading to a loss participant engagement.   A large number of 
outcomes in the consensus IN category and no outcomes in the consensus 
OUT category suggested that the likelihood of participants rating a substantial 
number of outcomes so that they were in the consensus OUT category would 
have been unlikely. 
6.9 Future Research 
6.9.1 Patient and Carer Validation of the Core Outcome Domain Set 
and Candidate Outcomes 
 
Because a low number of patients and carers took part in the eDelphi studies, 
future research on the validation of the core outcome domain set and set of 





core to patients and carers are missing.  However detailed planning of this is 
essential as not to burden patients and carers. 
 
6.9.2 Dissemination and Implementation  
 
Dissemination of the core outcome domain set is now needed so that it is 
accessible.  It is essential that trialists and researchers can access the core 
outcome domain set so it can be used for research evaluations of interventions 
for venous leg ulceration.  Knowledge of the recommendations becomes more 
widespread as the usage of the core outcome set increases (Copsey et al., 
2016), thus highlighting the importance of dissemination.   
Engagement with clinical guideline developers, journal editors, Cochrane 
Review Groups, research funders, regulators and trial registries is needed to 
increase the uptake of the core outcome domain set.  Publication of the results 
will be promoted through social media, for example Twitter, and uploaded to 
the COMET database.  Considerations need to be given to potential barriers 
and cost implications in its implementation. 
Kirkham et al’s. (2016) Core Outcome Set- STAndards for Reporting (COS-
STAR) will be utilised so that a clear and transparent presentation of the results 
is provided.  Kirkham et al. (2016) have produced a checklist for the reporting 
of core outcome set development.   The checklist will be used when a 
publication of the results is composed.  Kirkham et al. (2016) performed a two-
round Delphi and a consensus meeting involving core outcome set developers, 
methodologists, journals editors, core outcome set users, and patient 
representatives.  One hundred and eighty-three international participants were 
involved in the development of an 18 item checklist comprising of standards for 
reporting a core outcome set. 
The core outcome domain set will need to be periodically reviewed to check 
that the outcome domains in the set are still relevant and core to stakeholders.  
Audits are then required to assess the uptake and adherence to the core 
outcome domain set recommendations.  This can be done by means of a 





needs to be tracked.  By assessing uptake it indicates if the promotion of the 
core outcome domain set has been effective and if more needs to be done to 
promote it. 
 
6.9.3 Development of a Core Set of Measurement Instruments 
 
Some core outcome set developers gain consensus on the outcome domains 
(sometimes called domains) then perform a systematic review on the 
measurement instruments (Boers et al., 2014).  A systematic review on all of 
the measurement instruments available to measure the outcome domains rated 
as core in this case would be unnecessarily lengthy and would waste 
resources.    
It is evident from the second eDelphi on the outcomes (stage three) that not all 
the outcomes within each outcome domain are core to stakeholders, for 
example the outcome ‘Time to achieving a pre-defined ulcer area change in a 
reference ulcer (e.g. any reduction, at least 50% reduction, at least 75% 
reduction)’ falls within the outcome domain ‘healing’ which was agreed as core 
by participants but the specific outcome was not deemed core.  The eDelphi 
surveys identified which of the outcomes are core to stakeholders who took 
part.   
The development of a core outcome domain set alone may not solve the 
problems that exist, for example the inability to combine results for a meta-
analysis.  Schmitt et al. (2019) found that there is agreement amongst trialists 
at the outcome domain level but there is still a lack of reporting on specific 
outcomes.  Schmitt et al. (2019) systematically assessed concordance on 
outcomes between 220 dermatology trials and 10 Cochrane Skin systematic 
reviews.  They conclude that there is a low degree of overlap in outcomes 
between trials and reviews which facilitates weaknesses in conclusions of 
systematic reviews because of insufficient data.   
Even if the core outcome domain set went to the level of sub-outcome 
domains, for example odour (sub-outcome domain in clinical signs) it still 





of patients with the presence of malodour of the ulcer’ or ‘Severity of odour 
(from the ulcer)’.  Therefore specific outcomes are needed along with their 
accompanying measurement instrument. 
The specific outcomes (candidate outcomes) which were rated as core by 
stakeholders in the eDelphi on the outcomes (stage three) now require a 
systematic appraisal of their performance characteristics.  Once appraised, 
consideration over how the outcomes are defined and measured will be 
required, for example two of the 11 candidate outcomes require definitions and 
five require an accompanying measurement instrument (Table 32).  A core 
outcome set is comprised of what to measure and how to measure, therefore 
the next step in the development of the core outcome set requires the 
development of a core set of outcome measurements.  
Table 32 Requirement for each candidate outcome 
Candidate outcome  Definition or measurement 
instrument required 
Number of patients/ulcers/limbs that 
completely healed in a trial period 
Definition of ‘healed’ 
Time to complete healing – may be of a 
reference ulcer, of all ulcers on a reference 
limb, or of all ulcers on both limbs 
Definition of ‘complete healing’ 
Change in size of ulcer, e.g. length, 
circumference, area, volume 
Measurement instrument 
needed 
Number of patients/ulcers/limbs with pain Pain measurement instrument 
needed 
Number of patients reporting a pre-specified 
level of change in pain score during the trial 
period (e.g. any reduction, at least 50% relief) 
Pain measurement instrument 
needed 
Change in patient reported pain score/rating 
during the trial period 
Pain measurement instrument 
needed 
Change in the Quality of Life score during the 
evaluation period 







The scoping review identified some of the measurement instruments which 
have been used to measure the outcomes reported in the RCTs.  Many of the 
RCTs used trial specific instruments which is problematic because it is not clear 
if they were assessed for validity, reliability and feasibility, and they can be a 
source of bias (Marshall et al., 2000).  When the reliability, validity and 
feasibility of measurement instruments are low or not clear it is a barrier to 
evidence based decision making (Chalmers and Glasziou, 2009).   
OMERACT and HOME state that when there is no applicable (i.e. truthful, 
discriminative and feasible) instrument then a new one needs to be developed 
(Boers et al., 2014; Schmitt et al., 2015).  Once the instrument is developed it 
requires a validation study to test whether it is valid and reliable.   
Measurement instruments may need to be developed for the core outcome set 
if there are no applicable existing instruments. 
There is published guidance on assessing measurement instruments in the 
development of the core set of measurement instruments.  Mokkink et al. 
(2010b) have developed taxonomy on measurement properties.  The taxonomy 
was developed following a lack of consensus in the literature on which 
measurement proprieties are relevant.  The taxonomy contains three quality 
domains on measurement properties; reliability, validity and responsiveness 
(ability of an outcome measure to detect change over time).  Reliability contains 
the measurement properties; measurement error, internal consistency and 
reliability (test-retest, inter-rater and intra-rater).  Validity contains content 
validity, criterion validity and construct validity.   The COSMIN checklist is a tool 
to assess the methodological qualities of studies on measurement properties 
(outlined on the previous page), and it can also be used when designing a 




Recurrence is an outcome domain that audience members at the EWMA 
conference suggested for inclusion in the core outcome domain set.  Because 
the scoping review revealed that the outcome domains and outcomes relating 





recurrence would not be in the scope of this PhD.  Future research is needed to 
investigate how recurrence in venous leg ulceration research is investigated. 
 
6.9.5 Methodological and Statistical Issues in Venous Leg 
Ulceration Research 
 
There are issues on the methodological and statistical issues in venous leg 
ulceration research that arose at the session at the EWMA conference and in 
the comments provided on the eDelphi surveys.  It was not in the scope of this 
PhD to address all aspects of venous leg ulceration research therefore the PhD 
was not able to address these issues but future research is needed.  The 
methodological and statistical issues are outlined in the following paragraphs. 
The Cochrane handbook (Higgins and Green, 2011) points out that the data on 
the change from baseline measures and final measurements can be missing 
due to missed visits and withdrawals.  Therefore causing problems for 
systematic reviews because it is difficult to identify the subset of participants 
from whom they can compute the change scores from.  A fully specified 
outcome requires a specific metric (i.e. change from baseline at a specific 
time), therefore the candidate outcomes that will be included in the core 
outcome set following a systematic appraisal of their performance 
characteristics will require a specific metric.   
The minimum follow up times varied in the RCTs included in the scoping review 
(for example 8 weeks, 12 weeks, 1 year).  Follow up time is an important part of 
a fully specified outcome (Zarin et al., 2011).  A study with short duration of 
follow-up risks missing outcome events and can be underpowered (Hodgson et 
al., 2014).  Future research is needed on the minimum follow up duration. 
The target number of trial participants in venous leg ulceration research 
requires investigation.  It is recommended that CONSORT guidelines are used 
in the reporting of venous leg ulceration trials. 
The majority of participants chose the ‘patient’ as their preferred unit of analysis 





of analysis may be intervention specific.  Further research is needed on the unit 
of analysis reported in RCTs on venous leg ulcer interventions. 
6.10 Conclusion and Implications of the PhD for Research 
 
The aim of this PhD was to develop a core outcome set for use in research 
evaluations of interventions used for venous leg ulceration.  To date, no core 
outcome set exists for venous leg ulceration research.  This PhD has 
developed a core outcome domain set and candidate outcomes through three 
stages.  In stage one a scoping review generated a comprehensive list of 
outcomes for the two consensus processes (stage two and three).  Stage two 
gained consensus from stakeholders on the outcome domains, and stage three 
gained consensus from stakeholders on the outcomes.   
The scoping review supports claims that the outcomes reported in RCTs on 
venous leg ulceration interventions are heterogeneous and outcome reporting 
bias is a problem in the RCTs.  It also highlights the lack of ‘healing’ definitions 
and the lack of valid and reliable measurement instruments used to measure 
the outcomes reported in the RCTs.  
The work of this PhD makes an important contribution to venous leg ulceration 
research, however there are limitations to the methodological approaches used 
in the PhD, which are outlined earlier on in this chapter.  It has begun work on 
developing a core set of outcomes by identifying which candidate outcomes are 
considered to be core by stakeholders that took part in the eDelphi surveys.  
The candidate outcomes now require a systematic appraisal of their 
performance characteristics.  Once appraised they will form part of the core 
outcome set along with an accompanying set of measurement instruments.  
The implementation of a core outcome set has the potential to improve the 
utility of RCTs, reduce outcome reporting bias, increase the consistency of 
outcomes reported in research, and facilitate treatment comparisons across 
different sources of evidence.  The reporting of appropriate outcomes which are 
core to stakeholders has the potential to reduce research waste.  Providing the 
core outcome set has good uptake, it will also expedite the production of 
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Appendix 1 Scoping Review Qualitative Search Strategy 
 
Ovid MEDLINE  
1. exp Varicose Ulcer/ or venous leg ulcer*.mp. 
2. crural ulcer*.tw. 
3. stasis ulcer*.tw. 
4. ulcus cruris*.tw. 
5. ulcer cruris*.tw. 
6. outcome*.tw. 
7. quality of life.tw. 
8. exp "Quality of Life"/ or QoL.mp. 
9. expert patient.tw. 
10. (((patient$ or consumer$ or parent$ or famil$ or spouse$) adj attitude$) or involvement or 













23. grounded theor*.mp. 
24. case study.mp. 






27. 1 or 2 or 3 or 4 or 5 
28. 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 
29. 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 
30. 27 and 28 and 29 
31. limit 30 to (english language and humans) 
 
Scopus 
( ( ABS ( qualitative )  OR  ABS ( interview* )  OR  ABS ( narrative )  OR  ABS ( 
ethnograph* )  OR  ABS ( phenomenolog* )  OR  ABS ( grounded  AND theor* )  OR  
ABS ( case  AND study )  OR  ABS ( focus  AND group* )  OR  ABS ( survey* ) ) )  
AND  ( ( ABS ( outcome* )  OR  ABS ( quality  AND of  AND life )  OR  ABS ( expert  
AND patient )  OR  ABS ( experience* )  OR  ABS ( patient )  OR  ABS ( perspective* )  
OR  ABS ( feeling* )  OR  ABS ( insight* )  OR  ABS ( descripti* )  OR  ABS ( explorat* 
)  OR  ABS ( impact ) ) )  AND  ( ( ABS ( varicose  AND ulcer )  OR  ABS ( crural  AND 
ulcer* )  OR  ABS ( stasis  AND ulcer* )  OR  ABS ( ulcus  AND cruris* )  OR  ABS ( 
ulcer  AND cruris* )  OR  ABS ( venous  AND leg  AND ulcer ) ) )  AND  ( LIMIT-TO ( 
LANGUAGE ,  "English" ) ) 
 
Ovid Embase 
1. exp Varicose Ulcer/ or venous leg ulcer*.mp. 
2. crural ulcer*.tw. 
3. stasis ulcer*.tw. 
4. ulcus cruris*.tw. 
5. ulcer cruris*.tw. 
6. outcome*.tw. 
7. quality of life.tw. 
8. exp "Quality of Life"/ or QoL.mp. 
9. expert patient.tw. 
10. (((patient$ or consumer$ or parent$ or famil$ or spouse$) adj attitude$) or involvement or 

















23. grounded theor*.mp. 
24. case study.mp. 
25. focus group*.mp. 
26. survey*.mp. 
27. 1 or 2 or 3 or 4 or 5 
28. 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 
29. 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 
30. 27 and 28 and 29 
31. limit 30 to (english language and humans) 
 
CINAHL 
• S1. AB ( Varicose Ulcer/ or venous leg ulcer* ) OR AB crural ulcer* OR AB 
stasis ulcer* OR AB ulcus cruris* OR AB ulcer cruris* 
 
• S2. AB outcome* OR AB quality of life OR AB expert patient OR AB ( patient$ 
or consumer$ or parent$ or famil$ or spouse$) adj attitude$) or involvement or 
desir$ or perspective$ or activation or view$ or ) OR AB preference$ OR AB 
experience* OR AB perspective* OR AB feeling* OR AB insight*  
 
• S3. AB descripti* OR AB explorat* OR AB impact OR AB QUALITATIVE OR 
AB interview* OR AB narrative OR AB ethnograph* OR AB phenomenolog* OR 
AB grounded theor*v OR AB case study OR AB focus group* OR AB survey*  
 
• S1 AND S2 AND S3 
 






Appendix 2 Outcomes Extracted from RCTs and Qualitative Research 
The information in the tables below display the outcomes extracted from RCTs.  
The outcomes are grouped by the number of times they appeared in 
descending order from 10+ appearances.  The outcomes written in red 
appeared once in the RCTs but because they related to the outcome above it 
they were placed in that group, for example “Number of healed ulcers in the 
case of multiple ulcers” appeared once but it relates to the outcome “Number of 
ulcers that completely healed” which appeared 38 times : 
Number of ulcers that completely healed  38 
















Number of patients that completely healed 42 
Number of ulcers that completely healed  38 
Number of healed ulcers in the case of multiple ulcers  1 
Number of ulcers completely healed at… 
                                 6 months 




Percentage of completely healed ulcers 36 
Percentage of patients with healed legs 
                                    At 12 weeks 
                                    At 24 weeks 





Percentage of patients completely healed 34 
Percentage of the group that had completely healed 1 
Percentage of patients completely healed over weeks 1 
Percentage of ulcer free patients over time 1 
Number of days to healing 30 
Number of days to healing quintiles  1 
Percentage reduction in ulcer area 28 
Percentage reduction in ulcer area over time 1 
Percentage of healed ulcer area 1 
Percentage reduction in ulcer area per week 2 
Number of patients that did not heal 20 
Number of weeks to complete healing 14 
Percentage change in ulcer area 
                                              Per week 




Reduction in ulcer size 12 





Ulcer healing rates 10 
Reduction in ulcer diameter 1 
 
Compliance (not specific) 26 
Change in pain score/rating 25 
Percentage of patients that experienced the difference ratings of levels of 
pain relief during wear 
1 
Change in Quality of Life scores/rating 19 
Change in Philadelphia Geriatric Morale Scale scores 1 
Change in Geriatric Depression scale scores 1 
Change in Rosenbergs Self-esteem scale scores 1 
Changes in Medical Outcomes Study support scale scores 1 
Changes in Medical Outcomes Study Pain Measures scores 1 
Pain (not specific) 16 
Percentage of ulcers with pain 1 
Tolerability (not specific) 13 
Reduction in pain 12 
Percentage of patients with a disappearance of pain 1 
Proportion of patients with a pain score of >50% of the total maximum pain 
relief score 
1 
Proportion of patients that reported >50% of the maximum daily pain relief 1 
Proportion of patients that reported a reduction in pain intensity of >50% of 
the pain intensity at baseline 
1 
Number of patients that reported slight or more pain relief 1 
Change score for pain reduction 1 
Percentage reduction in pain 1 
Number of patients pain free at the end of treatment 1 
Number of patients where pain between dressing changes decreased 1 
Percentage of patients with improvement in pain 1 
Patient comfort 11 
 
Ease of application… 
                              Reported by researcher 




Ease of removal… 
                            Reported by researcher 





Number of adverse events/ patients that experienced adverse events:  
Ulcer infection 21 
Pain 27 
 













Time to healing (not specified) 9 
Cumulative healing times 1 
Reduction in the time to complete healing 1 
Rate of healing cm2 per day  9 
Healing rate mm2 per day 1 
Rate of healing over time 1 
Closure rate (cm3) per day 1 
Percentage decrease in ulcer size 8 
Percentage reduction in ulcer size… 
                                   Per week 




Percentage improvement in ulcer size 1 
Change in ulcer area……  
                               cm2   




Change in ulcer area… 
                                Mm2 per day   




Change in ulcer area… 
                                 Per day 
 
1 
Complete healing (not specific) 7 
Percentage of patient that failed to heal/ remained unhealed 7 
Number of patients whose ulcers were still open at 24 weeks 1 
Remained unhealed (not clear) 1 
Percentage of healed ulcers over time 7 
Percentage of healed ulcers….  
                                                   Per fortnight 




Reduction in ulcer surface 
                                         Per week 
7 
1 
Percentage reduction in ulcer surface area 2 
Reduction in ulcer area… 
                      Cm2 




Reduction in ulcer area (cm2) per week 1 
Decrease in ulcer area per fortnight 1 
Number of days in the study 6 
Number of recurrences 5 
Number of extremities that showed recurrence 1 
Number of patients that reported a skin break 1 
Number of patients that had recurrent ulceration 5 
 
Pain score/rating at dressing change 7 
Change in pain severity score/rating 5 
Frequency of severity scores 1 
Relative change in pain severity  1 
Percentage of patients with a reduction in pain intensity  
Intensity of pain 1 
Change in pain intensity score 1 





Reduction in oedema 6 
Reduction in the score/rating of oedema 1 
Percentage decrease in oedema  
                                     Cm per week 
1 
1 
Number of ulcers where oedema decreased 1 
Percentage of patients with improvement in oedema 1 
Change in ankle circumference 6 
Rate of change in pus 5 
Rate of suppurate area percentage reduction per week  1 
Relative ulcer suppurate area after treatment  1 
Percentage of ulcers with suppuration   
Decrease in pus 1 
Relative change in pus covered area 1 
Percentage change in granulating tissue 6 
Quality of Life (not specific) 7 
Percentage of patients reporting an improvement in quality of life 1 
Quality of life score for patients with unhealed ulcers 5 
Change in haematology blood test 6 
Number of patients with haematological abnormalities  1 
Reduction in heavy legs sensation score/rating 5 
Percentage reduction in heavy legs 1 
Improvement in the heavy leg sensation 1 
Percentage of patients with the disappearance of heaviness 1 
Change in heavy legs sensation score/rating 9 
Percentage reduction in the scoring of heavy legs sensation 1 
Change in severity 1 
Reduction in tiredness of lower extremities/ limbs score/rating  5 
 
Number of days (wear time) 5 
Number of dressing changes 8 
Number of dressing changes per patient 1 
Frequency of dressing changes 1 
Total cost per patient 7 
Cost of dressings 5 
 
Number of adverse events/ patients that experienced adverse events:  
Maceration  7 
Eczema 6 






New ulceration 5 
Nausea 6 














Increase in ulcer size 6 
Deterioration in the ulcer 7 
Number of deaths 7 
 
2- 4 appearances 
Rate of healing per week cm2 
                                         cm 
4 
1 
Rate of healing per week cm2 
                                                                        mm 
3 
1 
Change in ulcer size cm2 
                                     Cm 
2 
1 
Change in ulcer size per week 1 
Change in surface area  
                                          Mm2 
3 
1 
Reduction in ulcer area per week cm2 3 
Reduction in ulcer area per day  2 
Reduction in limb volume 4 
Percentage reduction in leg volume 1 
Change in limb volume 3 
Absolute difference in total lower leg volume (ml) 1 
Difference in the lower leg volume change per patient (ml) 1 
Lower leg volumes 1 
Absolute change in leg volume (cm3) 1 
Percentage change in leg volume 1 
Relative change in total surface area 2 
Change in ulcer depth (cm) 2 
Improvement in the depth of the ulcer 1 
Percentage of surface area healed 
                                     Per week 
2 
1 
Percentage change in ulcer area 2 
Percentage of healing per week 4 
Percentage of ulcers healed per week 3 
Number of ulcer healed per week 1 
Percentage healed per week (not specific) 4 
Percentage healed at each visit 1 
Reduction in ankle circumference 2 
Number of limbs with complete healing 2 
Percentage of limbs with complete healing 1 
Change in calf circumference 3 
Change in leg circumference 1 
Decrease in the leg circumference 1 
Percentage of ulcer area regression 2 
Relative risk of ulcer closure at any time point 2 
Relative risk of healing at… 
                              12 weeks 








Relative rate of ulcer closure 1 
Relative chance of healing 1 
Ability to accelerate healing (not specific) 2 
Number with rapid healing 1 
Percentage with rapid healing 1 
Increased healing (not clear) 1 
Number of ulcers that improved 4 
Number of patients that improved 1 
Improvement in the ulcer 1 
Number of patients that showed clinical improvement  1 
Percentage of patients that showed clinical improvement 1 
Percentage of ulcers that improved 2 
Percentage that reported improvement (not specific) 2 
Predicted healing (not specific) 2 
Predictor of healing at 24 weeks 2 
Predictor of healing after 1 year 1 
Probability (%) that ulcers will be healed 4 
Number of patients with no varicose veins recurrence 2 
Number of patients with varicose veins 1 
Percentage of patients that had recurrence of varicose veins 1 
Percentage of patients with no varicose veins recurrence 2 
Number of patients with varicose veins recurrence <5mm 2 
Number of patients with varicose veins recurrence >5mm 2 
No change in ulcer area 4 
Increase in ulcer area cm2 2 
Reduction in volume cm3 2 
Percentage reduction of ulcer volume per week 1 
Relative change in… 
                                  Length 
                                  Width 





Change in length cm2 1 
Change in width cm2 1 
Change in ulcer volume 1 
Number of days spent in hospital 4 
Number of patients that were hospitalised  1 
Residual area remaining 2 
Percentage of the remaining area at the end 1 
Change in foot volumes (ml/100ml + refilling rate ml/min x 100ml) 2 
 
Pain on dressing removal 4 
Level of pain on dressing removal 1 
Pain post dressing change 1 
Pain on dressing application 1 
Percentage of patients with pain 2 
Number of patients with pain 2 
Number of patients that complained of pain 1 
Pain during debridement  2 
Percentage decrease in pain scores for debridement  1 
Number of patients that interrupted debridement due to pain 1 
Pain between dressing changes 4 





Decrease in pain intensity over time  1 
Percentage of total visits with pain 2 
Percentage of pain scores/rating 2 
Difference in pain scores/rating between groups 2 
Number of patients experienced a decrease in pain 2 
Percentage of patients experienced a decrease in pain 3 
Percentage reduction in pain 4 
Reduction in the scoring/rating of pain 2 
  
Change in aching scores/rating 2 
Improvement in aching score 1 
Reduction in aching scores 1 
  
Percentage of patients reporting heavy leg sensation 2 




Comfort during wear 3 
Levels of comfort 2 
Comfort during removal 3 
  
Satisfaction… 
                     Patients 




Number of patients that were satisfied aesthetically 1 
Number of patients that were not satisfied 1 
  
Change in the rating of oedema (not specific) 3 
Percentage reporting the severity of oedema 1 
Change in the severity of pitting oedema 2 
Change in the extent of oedema 2 
Percentage of patients with oedema 2 
Number of patients with oedema 2 
Oedema (not specific) 4 
  
Acceptability… 
                        Nurse 




Acceptability of the dressing 4 
Acceptance (not clear) 1 
  
Convenience (not specific) 2 
Convenience at dressing changes 1 
  
Dressing performance (not specific) 2 
  
Exudation score 2 
Decrease in exudate 2 
Number of ulcers where heavy exudation decreased  1 
Percentage of patients that had no exudate 1 





Improvement in exudates  1 
Type of exudate 2 
Percentage of visits with purulent or serosanguineous exudate 1 
Amount of exudate  4 
Percentage of visits with medium-large amount of exudate 1 
Change in the extent of exudate 2 
Ability to contain exudate 2 
Containment of ulcer drainage  1 
Number that rated the dressing absorbency as excellent 1 
Percentage that rated the dressing absorbency as excellent 1 
Exudate handling capacity  3 
Exudate absorption 3 
Reason for removal prior to visit: exudate strike through 1 
Number of days to achieve lack of exudation 2 
Time taken to cease exudation 1 
Percentage of ulcers that ceased exudation 2 
Number of patients whose exudate resolved  1 
Rate of change in exudation 4 
  
Odour (not specific) 2 
Levels of odour  1 
Percentage levels of odour 1 
Severity of odour 1 
Percentage of ulcer area affected by odour 1 
Effect of odour on general well-being 1 
Number of ulcers where foul odour decreased 1 
Number of ulcers with malodour 1 
Difference in odour scores/rating 1 
Time to no odour 1 
Percentage of patients with the presence of foul odour 2 
Number of ulcers where odour was present 3 
Change in the reporting of odour (not specific) 2 
  
Condition of surrounding skin 3 
Number of patients showing signs of abnormal or normal… 
                    Skin condition 
                    Skin tropism 






Improvement in the condition of peri ulcer skin 1 
Percentage of patients with normal peri wound skin 1 
  
Rate of change in debris 4 
  
Extent of debridement  2 
Rating of the debridement procedure in terms of difficulty 1 
Quality of debridement (percentage of rating responses) 1 
Duration of debridement (mins) 1 
Number of patients that required surgical debridement  1 
Nursing time (mins) required to achieve debridement  1 
Required more weekly debridement (not clear) 1 





Percentage reduction of debrided tissue 1 
Improvement in tissue debridement  1 
Number of debridement’s required to obtain a clean ulcer  2 
Number of days to achieve cleaning 1 
Cleaning effect (not specific) 2 
Percentage of area covered in residue following irrigation  1 
Number of patients with a clean ulcer at the end of the study 1 
Percentage of patients with a clean ulcer at the end of the study 1 
  
Number of patients with the appearance of granulation tissue 2 
Number of ulcers with unhealthy granulation  2 
Number of ulcers with healthy granulation  4 
Appearance of healthy granulation 1 
Percentage of healthy granulation tissue 1 
Number of weeks to healthy red granulation 1 
Percentage of patients with granulating tissue 2 
Amount of granulation tissue 3 
Change in granulation tissue (not clear) 1 
Percentage of ulcers with changes in granulation tissue 1 
Weekly growth of granulation tissue 1 
Number of days required to achieve a clean granulating ulcer 1 
Frequency of ulcers with at least 75% clean and granulating ulcer bed 1 
Increase in granulation tissue 2 
Formation of granulation tissue  1 
Percentage increase in granulation tissue 2 
Number of days to at least 75% granulation 2 
Number of days to 100% granulation 1 
Decrease in score/rating of granulation 2 
Change in condition score: granular tissue 1 
Percentage of granulating tissue 3 
Rate of change in granulation 2 
Percentage of ulcer surface covered with granulation 2 
  
Amount of slough 3 
Percentage of ulcer surface covered in slough 1 
Slough  1 
Percentage of ulcers with a decrease in slough 1 
Change in the amount of slough 1 
Change in the amount of ulcers with slough 2 
Percentage of slough 2 
Reduction in the percentage area of slough 2 
Reduction of at least 50% slough 3 
Reduction in slough 1 
Number of patients with a decrease in slough 1 
Percentage reduction in slough 3 
Percentage change in slough 2 
  
Number of days to at least 50% epithelialisation  2 
Presence of epithelial tissue 2 
Epithelialisation 1 
Levels of epithelial (not clear) 1 





Percentage of epithelializing tissue 3 
Percentage of ulcers with an increase in epithelising tissue 1 
Percentage change in epithelializing tissue 1 
Percentage of ulcer surface covered with re-epithelialisation 2 
Re-epithelialized to at least 90% of the initial area  1 
  
Number of patients that developed eczema 3 
Eczema (not specific) 1 
  
Reduction in erythema 3 
Number of ulcers where perilesional skin erythema decreased 1 
Change in the scoring/rating of erythema 2 
Erythema  1 
Change in the extent of erythema 1 
Rate of change in erythema 1 
Number that reported severe erythema 1 
Percentage that reported severe erythema  1 
Percentage of dressing changes where erythema was observed 1 
  
Percentage of the ulcer surface area covered with necrotic tissue 2 
  
Percentage of fibrin 2 
Percentage change in fibrin 1 
Percentage reduction in fibrin 1 
  
Maceration  3 
Percentage of patients that developed maceration  1 
Percentage of patients with maceration of the skin 1 
Extent of maceration (number and percentage of each rating) 1 
Percentage in the reporting of maceration of the surrounding skin 1 
Percentage of visits with maceration of the peri-wound skin 2 
  
Reduction in the scoring/rating of cramps  4 
Change in the scoring/rating of cramps 3 
Change in the severity of cramps 2 
  
Change in venous claudication score 2 
  
Change in tenseness score 2 
  
Change in severity of swelling 3 
Reduction in swelling 1 
Reduction in the scoring/rating of swelling 4 
Percentage reduction in the scoring of swelling 1 
Percentage of patients with a disappearance of swelling 1 
Change in the scoring/rating of swelling 3 
  
Change in the scoring/rating of tiredness of the lower extremities 3 
  
Reduction in the scoring/rating of restless lower limbs 3 
Change in the scoring of restless lower limbs 1 






Change in the scoring/rating of paraesthesia 4 
Improvement in the scoring/rating of paraesthesia 1 
Reduction in the scoring of paraesthesia 1 
Paraesthesia (not specific) 1 
  
Reduction in the scoring/rating of nocturnal cramps 2 
Percentage reduction in night cramps 1 
Change in the scoring/rating of nocturnal cramps 2 
Severity of nocturnal cramps 1 
Presence of night cramps 1 
  
Reduction of the severity of heavy legs  2 
Number of patients-heavy legs severity score 1 
  
Change in the scoring/rating of heat/burning 4 
Burning 1 
Improvement in the burning score/rating 1 
  
Change in the scoring/rating of itching 3 
Itching 1 
Number of patients that complained of itching 1 
Improvement in the itching score/rating 1 
Reduction of itching (not clear) 1 
  
Number of patients that experienced stinging sensation 2 
  
Change in the scoring/rating of tingling 3 
Improvement in the tingling score/rating 1 
  
Improvement in quality of life  2 
Quality of life scores/rating for patients with healed ulcers 4 
Change in quality of life score/rating… 
                             Social functioning  
                             Emotional  





Improvement in functional ability 1 
Change in the number of patients reporting being less sociable 1 
Percentage of the patients reporting being less sociable 1 
Change in the number of patients reporting going out to visit less frequently  1 




Change in the Comprehensive Classification System for Chronic 
Venous Disorders (CEAP) score 
4 
  
Variations in Laser Doppler flowometry (flux units) 2 
Change in systolic blood pressure 2 
Change in diastolic pressure 2 
Change in heart rate 2 
Change in venous pressure 2 






Healing by secondary intention (not specific) 2 
  
Number of patients with skin staining 2 
  
Change in transcutaneous O2 (TcPO2) measurements  4 
Variation in transcutaneous partial pressure of oxygen (mmHg) 1 
Relative change in transcutaneous O2 (TcPO2) 1 
  
Capillary filtration (ml/100ml/min/mmHg) 2 
Capillary filtration rate (ml/100ml per min) 1 
Change in capillary filtration coefficient (ml/100ml/min) 1 
  
Number of patients that had….reduced or eliminated  
                    Staphylococcus  





Incidence of infection 3 
Number of patients that had episodes of infection 2 
Number of isolated bacteriological species  4 
Frequency distribution of isolated bacteria 1 
Percentage of ulcers that developed a clinical infection 1 
Change in the severity of pruritus 2 
Percentage of patients reporting the severity of pruritus 1 
Pruritus severity score improved 1 
Pruritus (not specific) 3 
Number of patients that developed pruritus  1 
Cellulitis (not specific)  3 
Change in the severity of cellulitis 1 
Number of patients with indications of cellulitis 1 
Percentage of patients with cellulitis 1 
Percentage of dressing changes where cellulitis was observed 1 
Number of bacterial burden signs present in the ulcer  2 
  
Change in half refilling times (seconds) 2 
  
Change in refilling time (seconds) 3 
  
Number of patients that were compliant 2 
Percentage of patients that were non-compliant 2 
Percentage of patients that were compliant  3 
Number of patients that were not compliant 4 
  
Occurrence of pinhead bleeding 2 
Change in plasma fibrinogen level 3 
  
Number of patients that experienced micro bleeding 1 
  
Thyroid stimulating hormone levels 3 
Number of patients that developed abnormal thyroid hormone levels 1 
Changes in thyroid function 1 





Change in growth factors 2 
Change in biochemistry 3 
Number of patients with biochemical abnormalities  1 
 
Number of days compression devices were worn 2 
Number of patients that wore the stockings for at least 8 hours 1 
Percentage of patients that wore the stockings for at least 8 hours 1 
Frequency of dressing changes  4 
Number of days between dressing changes 2 
Number of unscheduled dressing changes 2 
Number of dressing changes needed per week 2 
Number of dressing changes to healing 1 
Time required to apply 4 
Time spent on ulcer care (mins) 1 
Time spent on a typical dressing change 1 
Time taken to apply bandages 1 
Shorter wound bed preparation time (not specific) 1 
Percentage of patients taking less time to change a dressing  1 
Number of hours per day patients wore stockings 2 
  
Bandage slippage 2 
Reason for removal prior to visit: slippage 1 
Ease of handling 2 
Ease of use 2 
Wound re-injury on dressing removal 2 
Trauma on dressing removal 2 
Non-traumatic dressing removal 1 
Conformability to ulcer site 2 
Percentage of dressing changes reporting adhesion to the ulcer bed 
on removal 
2 
Adhesion of the dressing to the ulcer bed 1 




Cost of dressings per patient 2 
Costs per percentage ulcer reduction 2 
Cost to heal ulcer completely  2 
Total costs to the end of the study 2 
Total mean costs for patients with healed ulcers compared to patients with 
unhealed ulcers 
1 
Total direct costs per group 1 
Total indirect costs per group 1 
Total cost per group 1 
Cost per healed patient 1 
  
Incremental costs 2 
Incremental Quality-adjusted life years gain 1 
Incremental cost-effectiveness ratios per Quality-adjusted life years gained 1 
Total annual cost 2 
Cost per week 3 
Material costs per week 1 





Weekly costs for unhealed ulcers 1 
Number of work days lost 2 
Number of days patients had working difficulties 1 
Nursing time (cost) 2 
Nursing time required per ulcer (cost) 1 
Cost- nurse costs 1 
Cost of nursing time to dress each patient 1 
Cost of nursing time spent doing administration per patient 1 
Nursing time spent doing administration (hours) per group (cost) 1 
Cost of nursing time spent travelling 1 
Nursing time spent travelling (hours) 1 
Nursing time spent dressing the ulcers per group (cost) 1 
Total time (hours) spent by nurses per group (cost) 1 
Distance (miles) travelled by the nurse per group (cost) 1 
 
Number of adverse events/ patients that experienced adverse events:  
Bleeding  4 
Pruritus 2 
Oedema 4 
Increased  2 
Vomiting 3 
Diarrhoea  4 









Over granulation 2 
Skin irritation 4 
Increased ulcer size 4 
DVT 3 
Urticarial  2 
Erysipelas 2 
Gastrointestinal haemorrhage 2 
 
Number of patients that withdrew and number of events causing 
withdrawal: 
 
Ulcer aggravation 2 





No progress 2 
Phlebitis 2
  





Urticarial  2 
Pruritus of the scalp 2 
Headaches 3 
Exudate 2 





Adverse drug reactions (not specific) 2 
 
 
The list below displays the outcomes extracted from qualitative research. 
Effect on family 
Limited choice of shoes 
Ability to wear clothes and 
shoes 




Avoiding trauma to the leg 
Personal hygiene 
Ability to self care 
Personal expenses e.g. laundry 
costs 
Loss of identity 
Worry [about the ulcer not 
healing] 
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Appendix 4 Recruitment Email eDelphi on the Outcome Domains 
(stage 2) Round One 
 
Dear Sir/Madam 
You are being invited to participate in a research study titled ‘Development of 
a core set of outcome measurements for use in research evaluations of 
interventions used for venous leg ulceration’.  This study is being led by 
members of the CoreVen (Core outcome set for Venous leg ulceration) project 
team who are researchers from the University of Leeds, UK and the National 
University of Ireland, Galway.  The project team includes Sarah Hallas (PhD 
student on the CoreVen project, University of Leeds), Professor Andrea Nelson 
(University of Leeds), Dr Susan O’Meara (University of Leeds) and Dr Georgina 
Gethin (National University of Ireland Galway).   
Further information about the project is provided below and on the participant 
information sheet attached to this email. 
We apologise if you have already received this from another source, please 
ignore this email if you have already received it. 
As part of this project we are seeking to include views from all people who are 
affected by venous leg ulcers whether as a patient, carer, nurse, doctor, other 
health professional or researcher.  You have been asked to participate so that 
we can learn more about peoples’ views on which domains should be included 
in future trials. 
The study is broken down into 2 rounds.  At each round an online survey will be 
presented to you.  It will take you approximately 20 minutes to complete the 
round 1 survey and approximately 15 minutes to complete the round 2 survey. 
Details of the round 2 survey will be sent via email once the results from the 
round 1 survey have been analysed.  A summary of the group responses will 
be visible on the round 2 survey. 
 
Following on from the surveys which look at which domains are important we 
will need to gain agreement on the domains’ associated outcomes.  So please 





we will be inviting your views on the importance of specific outcomes falling 
within the domains.  
We believe there are no known risks associated with this research study.  Your 
participation in this study is entirely voluntary and all results will be anonymous.   
We have been granted ethics approval [HREC16-031] from the University of 
Leeds.  If you wish to receive a copy of the approval please send your request 
to *********@leeds.ac.uk. 
By completing the Bristol Online Survey you are consenting to take part in the 
study.  If you decide to participate it would be greatly appreciated if you could 
complete the survey within the next three weeks from the date this email was 
sent.  The survey will take approximately 20 minutes to complete.  You will 
have the opportunity to download the responses you have submitted at the end 
of the survey, we recommend that you do this to allow you to see your previous 
responses when completing the round 2 survey. 
Please feel free to forward this email onto others that may be interested in 
participating in this study.  But please note that in order to comply with the 
project’s ethics approval conditions, please DO NOT forward the invitations 
to the following: individuals identified because of their use of UK NHS 
services; carers of the latter, and; healthcare professionals identified 
because of their employment by the UK NHS. 
If you have any questions please do not hesitate to contact Sarah Hallas by 
email *********@leeds.ac.uk or contact Dr Susan O’Meara by email 
*********@leeds.ac.uk or telephone ***********. 
In order to help you decide whether or not to take part in the study please read 
the participant information sheet attached to this email. If you do decide to take 
part, a Bristol Online Survey has been created for you and can be accessed 
from the following link: https://leeds.onlinesurveys.ac.uk/coreven-brsitol-online-
survey-core-domains.  You will need to enter the password:**********, as 
directed on the Bristol Online Survey website. 
With many thanks for your consideration,  







Appendix 5 Participant Information Sheet eDelphi on the Outcome 
Domains (stage 2)  
CoreVen (Core outcome set for Venous leg ulceration) 
 
Participant Information Sheet 
 
Development of a core set of outcome measurements for use in research 
evaluations of interventions used for venous leg ulceration 
 
We would like to invite you to take part in the above named study but before 
you decide it is important for you to understand why the research is being 
carried out and what it will involve.  Please ask if there is anything that is not 
clear or if you would like more information before deciding whether to take part, 
contact details are shown at the end of this document.  Please read the 
following information carefully. 
Purpose of this study 
This study is part of a project called CoreVen (Core outcome set for Venous leg 
ulceration), which aims to determine what outcomes are essential for patients 
and their clinicians to make decisions and therefore must be reported for all 
venous ulcer treatments. By doing this we will be able to see over time how 
different interventions impact on these outcomes.   
An outcome is any identifiable consequence of the exposure to a health care 
intervention, for example a dressing.  Clinical trials aim to determine how 
effective a new product, device, drug or other intervention is in helping to 
manage venous leg ulceration.  The problem is that each trial can focus on a 
different outcome and as a result it is very difficult to see which interventions 
work.  There is evidence that the number of outcomes measured in trials is so 
large that it is difficult to compare the results, meaning decision making on 
interventions used for venous leg ulcers can be challenging.  A list of core 





easier for the results of trials to be compared. This in turn will improve the 
information available to clinicians and patients.   
Before determining which outcomes are important we need to decide which 
domains are important.  Domains are broad, descriptive categories under which 
several, more specific, outcomes might be grouped.  For venous leg ulcers, 
domains might include:  
• Healing 
• Patient reported symptoms 
• Clinician reported symptoms 
• Carer reported symptoms  
• Life impacts 
• Clinical signs 
• Clinical measurement 
• Performance of the intervention 
• Resource use: supplies 
• Resource use: clinician time 
• Adverse events   
These examples of domains have been derived from a thorough review of the 
research literature. 
We would like to invite you to contribute to a two-round online survey on the 
importance of different domains in evaluations of treatments for venous leg 
ulcers. Later on we will launch a follow-up survey to explore the importance of 
different outcomes and will circulate more details in due course; but for now we 
are inviting your views on the importance of different domains.  
Who is doing the study?  
This study is being undertaken by Miss Sarah Hallas as part of a PhD in the 
School of Healthcare at the University of Leeds, UK.  Professor Andrea Nelson 
and Dr Susan O’Meara from the School of Healthcare, University of Leeds are 
supervising this research.  Dr Georgina Gethin from the School of Nursing and 
Midwifery, National University of Ireland Galway will also be supervising the 
study as a founder of the CoreVen project.  Further details on the CoreVen 






Why have I been asked to participate? 
As part of this project we are seeking to include views from all people who are 
affected by venous leg ulcers whether as a patient, carer, nurse, doctor, 
researcher or other professional related to healthcare.  You have been invited 
to participate in this study because you have been identified as belonging to 
one of these groups.   
What will be involved if I take part in this study? 
Your participation in this study is entirely voluntary.  If you choose to take part, 
we will ask you to complete online surveys which can be accessed via a link 
and login details shown in the email sent with this attachment.  On entering the 
surveys you will be asked to confirm whether you are willing to participate.  
There will be 2 rounds to the study.   
On the first survey (round 1) you will be presented with a list of potential 
domains along with a rating scale below each one.  You will be asked to rate 
each domain in terms of importance on a scale of 1 to 9 (1 being not important 
and 9 being extremely important). You will also be given an option to suggest 2 
domains that have not been included on the list.  If you decide to take part we 
would appreciate that the survey is completed within 3 weeks from the date of 
sending this email.   
You will also be asked whether each domain should be included in the core 
domain set; yes or no.  If you are uncertain, then please tick the answer closest 
to your opinion, for example if you think it probably shouldn’t be then select no. 
Following on from the first survey (round 1) you will be presented with a 
summary of the results from round 1 via a link on the invitation email.  You will 
have an opportunity to rate each domain once more on the Bristol Online 
Survey (round 2), allowing the list of domains to be refined.  You will also be 
asked to rate the additional domains suggested on the first survey. 
Please note that by completing the Bristol Online Survey you are consenting to 







What are the advantages and disadvantages of taking part? 
Your participation in this study will inform the design of future research 
addressing the effectiveness of treatments for venous leg ulcers.  In turn, this 
research will provide useful information to assist clinical decision making in 
terms of identifying the best treatment options for patients.  It is foreseen that 
by having a minimum core set of outcomes in trials it will make it easier and 
more efficient for the reader to compare and contrast the evaluations of 
interventions.  The first survey should take approximately 20 minutes to 
complete and we estimate the second survey will take 15 minutes to complete. 
Can I withdraw from the study at any time?  
You are under no obligation to take part in the study.  Once you start the online 
survey you may withdraw at any point provided you have not clicked on ‘Finish’ 
at the end.  This will mean that your responses will not be used for analysis or 
any other purpose.  You do not need to give a reason for discontinuing with the 
survey.   
If you complete the survey and click on ‘Finish’ at the end your responses will 
be merged with those from other participants and used as part of our analysis 
of data.  Once you click on ‘Finish’ it will not be possible withdraw your 
responses because they are anonymised.   
If you wish you can enter responses for part of the survey on one occasion and 
then select the ‘Finish later’ option on the survey pages in order to return to it 
later.  If you choose to do this you will be asked to provide an email address so 
that a link can be sent to you to enable you to return to the survey.  In this 
instance, your responses will still be anonymised as your email address will not 
be linked to your finished set of responses. 
If you do not click on ‘Finish’ at the end your responses will not be included in 
the analysis.  The questions on the survey that require a response will be 
highlighted with ‘*Required’ next to it.  There are some responses that are 
optional, you will be informed that it is optional at the beginning of the question. 
Will the information I give be kept confidential? 
The survey will be conducted using the Bristol Online Survey which is fully 





from you will be kept confidential at all times.  No personal data will be stored 
other than your name and email address but this cannot be linked to the 
responses you make on the Bristol Online Survey.  Your name and email 
address have been required to enable the emails with the link for the Bristol 
Online Surveys to be sent to you.  Your name and email address will not be 
passed onto third parties. 
All data will be password protected on the Bristol Online Survey and on the 
password protected secure network of the University of Leeds.  Other members 
of the CoreVen project that may have access to your name and email address 
are Professor Andrea Nelson (University of Leeds), Dr Susan O’Meara 
(University of Leeds) and Dr Georgina Gethin (National University of Ireland 
Galway).   
What will happen to the results of the study? 
Your responses from the Bristol Online Surveys will be analysed, along with 
other participant’s responses.  An email containing a password protected 
attachment showing the scores for the domains on clearly marked bar charts 
will be sent after the study.  We anticipate that it will take approximately 4 
weeks for the results of the study to be sent to you. 
Who has reviewed this study? 
Ethical approval has been granted by the University of Leeds School of 
Healthcare Research Ethics Committee reference: HREC16-031. 
 
If you would like more information or have any questions or concerns 
about the study please contact: 
Sarah Hallas, [University contact details were provided 
Dr Susan O’Meara (PhD supervisor), [University contact details were provided] 














Appendix 7 eDelphi on the Outcome Domains Round One Survey 










CoreVen Bristol Online Survey 1 
 
 




You are being invited to participate in a research study called ‘Development of a core set 
of outcome measurements for use in research evaluations of interventions used for 
venous leg ulceration’. The purpose of this study is to determine what outcomes are 
essential for patients and their clinicians to make decisions and therefore must be 
reported for all trials of venous ulcer treatments. Your participation in this study is entirely 
voluntary. 
 
On the following pages you will see a series of areas which have been described as 
'domains'. A domain is the overarching name for a group of outcomes that have been 
measured in venous leg ulcer trials. 
 
We will ask you to rate how important you consider each domain to be in venous leg ulcer 
trials using a numerical rating scale of 1 to 9 (‘1’ means ‘not important’ and ‘9’ means 
‘extremely important’). 
Below each domain we have shown examples of associated outcomes. For example, for 
the domain of ‘Healing’ we have suggested ‘Number of ulcers completely healed’ as a 
specific outcome. 
 
Once the survey is started you will be able to leave it and return to it at a later time by 
selecting the ‘finish later’ option at the end of the page. If you decide to use this option, 
you will be asked to enter your email address so that a link can be sent to you for 
returning to the survey. Your responses will be anonymous throughout the study, 
regardless of whether you use the ‘finish later’ option. 
 
We believe that there are no known risks associated with this research study; however, as with 
any online activity the risk of a breach is always possible. We have minimised risks by using 
the Bristol Online Survey which is fully compliant with all UK data protection laws and is 









By continuing onto the survey you are consenting to take part in the study. You are under no 
obligation to take part and you can withdraw from the study until you click on ‘Finish’ at the 
end. You do not need to provide a reason for withdrawal. You can stop at any point in the 
survey. In order for your responses to be used in the analysis you must answer all the 
questions and click on ‘Finish’ at the end.  Once you do this, your responses cannot be 
withdrawn and will be included in the analysis. The questions on the survey that require a 
response will be highlighted with ‘*Required’ next to it. There are some responses that are 
optional, you will be informed that it is optional at the beginning of the question. 
 
Please do not provide any personal details on the survey, other than stating your role (for 





































We anticipate that the survey will take approximately 20 minutes to complete. We very much 









Which term best describes your background? (please select only one response that best describes 




If you are a healthcare professional, please state your job role: 
 
 






















Page 2: Core domains 
 
3. Research studies often refer to healing as an outcome in 
clinical trials of treatments for venous leg ulcers. We would 
like to know how important it is, in your opinion, to have 
HEALING as a core domain in future research trials? 
Examples of outcome measures in this domain: Number of ulcers that completely healed, 
Percentage of completely healed ulcers, Rate of reduction in ulcer area. *Required 
 






























4. Research studies often refer to various  patient  reported  
symptoms  as outcomes in clinical trials of treatments for venous 
leg ulcers. We would like to  know how important it is, in your 
opinion, to have PATIENT REPORTED SYMPTOMS as a core 
domain in future research trials? Examples of outcome measures in this 
domain include: Pain score/rating (rated by the patient), Heavy legs sensation score/rating 
(rated by the patient). 
*Required 
 





































3. Research studies often refer to symptoms that have been 
reported by the clinician, for example a nurse, as an outcome 
in clinical trials of treatments for venous leg ulcers. We would 
like to know how important it is, in your opinion, to have 
CLINICIAN REPORTED SYMPTOMS as a core domain in 
future research trials? An example of an outcome measure in this domain 
includes: Pain score at dressing removal (rated by the clinician). *Required 
































Research studies often refer to symptoms of the patient  
reported by carers as an outcome in clinical trials of treatments 
for venous leg ulcers. We would like to know how important it is, 
in your opinion, to have CARER REPORTED  SYMPTOMS as a 
core domain in future research trials? An example of an outcome measure in 
this domain includes: Pain score/rating (rated by the carers) . *Required 











































7. Research studies often refer to outcomes relating to life 
impacts in clinical trials of treatments for venous leg ulcers. We 
would like to know how important it is, in your opinion, to have 
LIFE IMPACTS as a core domain in future research trials? 
The life impact domain contains outcomes that measure the patients' ability to function. It covers 
quality of life, loss of ability to work, secondary impact on their family, and social interactions. It 
also encompasses what impact the leg ulcer and the treatments required to treat the leg ulcer 
has on the patient. Examples of outcome measures in this domain include: Quality of Life 
scores/rating, Percentage of patients reporting an improvement in quality of life. *Required 































Research studies often refer to various clinical signs as outcomes 
in clinical 
trials of treatments for venous leg ulcers. We would like to know 
how important  it is, in your opinion, to have CLINICAL SIGNS 
as a core domain in future research trials? The clinical signs domain 
contains outcomes that measure the bodily function and structure, including reversible and 
irreversible symptoms such as oedema. Examples of outcome measures in this domain 
include: Severity of pitting oedema, Severity of odour. *Required 
Table 1 









































Research studies often refer to various clinical 
measurement outcomes in clinical trials of treatments for 
venous leg ulcers. We would like to know how important it is, 
in your opinion, to have CLINICAL MEASUREMENT as a 
core domain in future research trials? The clinical measurement domain 
contains outcomes that measure the bodily function including organ function and 
biomarkers (measurable indicator of the presence or severity of venous ulceration). 
Examples of outcome measures in this domain include: Deep vein reflux, Maximal venous 
outflow (ml/100ml/min). *Required 































Research studies often refer to the performance of an 
intervention as an outcome in clinical trials of treatments for 
venous leg ulcers.  We would like to  know how important it is, in 
your opinion, to have PERFORMANCE OF THE 
INTERVENTION as a core domain in future research trials? The 
performance of the intervention domain contains outcomes that measure how well the 
intervention, such as a dressing, has worked and performed. Examples of outcome measures 
in this domain include: Ease of application, Number of days between dressing changes. 
*Required 


























Select below if you do not have an opinion on whether performance of the intervention should be 
















Research studies often refer to resource use, such as 
supplies, as an outcome in clinical trials of treatments for 
venous leg ulcers. We would like to know how important it is, in 
your opinion, to have RESOURCE USE: SUPPLIES as a core 
domain in future research trials? The resource use: supplies domain contains 
outcomes that measure supply costs for example the cost of a dressing. Examples of 
outcome measures in this domain include: Material costs per week, Total single treatment cost 
per group. *Required 































Research studies often refer to resource use, such as 
clinician time, as an outcome in clinical trials of treatments for 
venous leg ulcers.  We would like to  know how important it is, in 
your opinion, to have RESOURCE USE: CLINICIAN TIME as a 
core domain in future research trials? The resource use: clinician time 
domain contains outcomes that measure costs related to clinician time for example nursing 
time. Examples of outcome measures in this domain include: Nursing time required per ulcer 
(cost), Cost of clinician contact per patient. *Required  
Table 1 









































13. Research studies often record adverse events in clinical 
trials of treatments for venous leg ulcers. We would like to know 
how important it is, in your opinion, to  have ADVERSE 
EVENTS as a core domain in future research trials? Examples of 
outcome measures in this domain include: Number of patients that experienced ulcer infection, Number 
of patients that withdrew due to an allergic reaction. *Required 























































Page 3: Core domains 
 
Should the following domains be included in the core domain set for venous leg ulceration?. *If 
you are uncertain, then please tick the answer closest to your opinion for example 'Probably 












































































































































Page 4: Additional core domains 
 
Optional: Is there a domain that you think should be considered, other than what has been 
listed in this survey?. 





Optional: Is there a domain that you think should be considered, other than what has been 
listed in this survey?. 






























Page 5: Thank you 
 
Thank you for the time you have taken to complete this survey. Your opinion is important to 
us and your assistance in producing the minimum list of outcomes for future effectiveness 
evaluations on venous leg ulcer treatments is invaluable. 
 











Appendix 8 Histograms for Each Outcome Domain Rated in the 






























Appendix 9 Histograms for Each Outcome Domain Rated in the 










Healing   
N Valid 44 
Missing 0 
Skewness -1.247 
Std. Error of Skewness .357 
Statistics 
Patient reported symptoms   
N Valid 44 
Missing 0 
Skewness -1.298 
Std. Error of Skewness .357 
 
Statistics 
Clinician reported symptoms   
N Valid 44 
Missing 0 
Skewness -1.136 















Carer reported symptoms   
N Valid 44 
Missing 0 
Skewness -1.260 
Std. Error of Skewness .357 
 
Statistics 
Life impacts   
N Valid 44 
Missing 0 
Skewness -1.250 
Std. Error of Skewness .357 
Statistics 
Clinical signs   
N Valid 44 
Missing 0 
Skewness -.624 
























Clinical measurement   
N Valid 44 
Missing 0 
Skewness -1.725 
Std. Error of Skewness .357 
Statistics 
Performance of the intervention   
N Valid 44 
Missing 0 
Skewness -1.145 




Resource use: supplies   
N Valid 44 
Missing 0 
Skewness -1.261 






















Resource use: clinician time   
N Valid 44 
Missing 0 
Skewness -1.468 






Adverse events   
N Valid 44 
Missing 0 
Skewness -1.272 






Appendix 10 News Item eDelphi on the Outcomes (stage 3) Round One 
 
Would you like to help develop a core set of outcomes for venous leg 
ulceration? 
We would like to invite you to take part in a study entitled "Development of a 
core set of outcome measurements for use in research evaluations of 
interventions used for venous leg ulceration".  This study is being led by 
members of the CoreVen (Core outcome set for Venous leg ulceration) project 
team who are researchers from the University of Leeds, UK and the National 
University of Ireland Galway.   
The CoreVen project aims to determine what outcomes are really important 
and should be included as core for any trial evaluating treatment effectiveness 
in venous leg ulceration.  An outcome is a measurement used to assess the 
effect of a treatment such as the assessment of effectiveness (benefits) or side 
effects (risk).  The current problem is that the types of outcomes reported vary 
considerably across trials and as a result it is very difficult to determine 
treatment effectiveness from the overall body of evidence.  The application of a 
core outcome set has the potential to facilitate the comparing, contrasting and 
synthesising of outcome data across trials.  This can make research evidence 
accessible to those involved in clinical decision making.  The advantage of 
easier decision making will benefit patients’ treatments by enabling a clearer 
judgement on the intervention that is being provided.   
 
It will take approximately 25 minutes to complete the round 1 survey and 
approximately 20 minutes to complete the round 2 online survey. Details of the 
round 2 survey will be sent via email once the results from the round 1 survey 
have been analysed.  
The School of Healthcare Research Ethics Committee, University of Leeds, 
UK, has granted approval (HREC17-028).  A copy of the ethics approval 
documentation can be forwarded to you on request. 
If you would like to take part or would like more information please contact 


















Appendix 12 Participant Information Sheet Meeting at the EWMA 
conference.  eDelphi on the Outcomes (stage 3) Round Two 
CoreVen (Core outcome set for Venous leg ulceration) 
 
Participant Information Sheet  
 
Development of a core set of outcome measurements for use in research 
evaluations of interventions used for venous leg ulceration 
We would like to invite you to take part in the above-named study but before 
you decide it is important for you to understand why the research is being 
carried out and what it will involve.  Please ask one of the meeting facilitators 
(Sarah Hallas or Georgina Gethin) if there is anything that is not clear or if you 
would like more information before deciding whether to take part.  Please read 
the following information carefully. 
Purpose of this study 
This study is part of a project called CoreVen (Core outcome set for Venous leg 
ulceration), which aims to determine what outcomes are really important and 
should be included as core for trials on venous leg ulcers interventions.  
Clinical trials in this field are designed to evaluate the effectiveness of 
treatment strategies for venous leg ulceration.  An outcome is a measurement 
used as part of a clinical trial to assess the effect of a treatment in terms of 
benefits and risks.  The problem is that the outcomes reported in different trials 
vary considerably and as a result it can be difficult to judge which interventions 
are most helpful.  Inclusion of a core set of outcomes in all trials evaluating 
treatments for venous leg ulcers has the potential to facilitate the comparing, 
contrasting and synthesis of outcomes across trials; this in turn can help make 
research evidence more accessible for clinical decision makers. 
A two-round online survey has explored consensus on which domains are 
important.  We now need to decide which specific outcomes, falling within the 
domains, are important.  Domains are broad, descriptive categories under 





The domains that were rated as important are as follows: 
• Healing 
• Patient reported symptoms 
• Clinician reported symptoms 
• Life impacts 
• Clinical signs 
• Clinical measurement  
• Performance of the intervention 
• Resource use: supplies 
• Resource use: clinician time 
• Adverse events 
We would like to invite you to contribute to part 2 of a two-round survey on the 
importance of different outcomes in evaluations of treatments for venous leg 
ulcers.  
Who is doing the study?  
This study is being undertaken by Miss Sarah Hallas as part of a PhD in the 
School of Healthcare at the University of Leeds, UK.  Professor Andrea Nelson 
and Dr Susan O’Meara (School of Healthcare, University of Leeds, UK) and Dr 
Georgina Gethin (School of Nursing and Midwifery, National University of 
Ireland Galway) are supervising this research.  Further details on the CoreVen 
project can be found on:   
http://www.comet-initiative.org/studies/details/680?result=true 
Why have I been asked to participate? 
As part of this project we are seeking to include views from all people who are 
affected by venous leg ulcers whether as a patient, carer, nurse, doctor, 
researcher or other professional related to healthcare.  You have been invited 
to participate in this study because you have been identified as belonging to 
one of these groups.   
What will be involved if I take part in this study? 
Your participation in this study is entirely voluntary.  If you choose to take part, 





displayed on the screen or you can complete the same survey on paper.  At the 
start of either format of the survey you will be asked to confirm whether you are 
willing to participate  
You will be presented with a list of outcomes that fall within the domains that 
were rated as important in a previous study. There will be a rating scale below 
each outcome.  You will be asked to rate each outcome in terms of importance 
on a scale of 1 to 9 (1 being not important and 9 being extremely important). 
The questions on the survey that require a response will be highlighted with 
‘*Required’ next to them.  There are some responses that are optional, you will 
be informed that they are optional at the beginning of the question. 
Please note that by completing the Survey you are consenting to take part in 
the study.   
What are the advantages and disadvantages of taking part? 
The findings from this study have the potential to inform the design of future 
research addressing the effectiveness of treatments for venous leg ulcers.  In 
turn, this research will provide useful information to assist clinical decision 
making in terms of identifying the best treatment options for patients.  It is 
foreseen that by having a core set of outcomes in trials it will make it easier and 
more efficient for the reader to compare and contrast the evaluations of 
interventions.   
The survey should take approximately 25 minutes to complete.  
Can I withdraw from the study at any time?  
You are under no obligation to take part in the study.  Once you start the online 
survey you may withdraw at any point providing you do not click on the ‘Finish' 
button at the end.  This will mean that your responses will not be used for 
analysis or any other purpose.  You do not need to give a reason for 
discontinuing the survey.   
If you complete the survey and click on ‘Finish’ at the end your responses will 
be merged with those from other participants and used as part of our analysis 
of the data.  Once you click on ‘Finish’ it will not be possible to withdraw your 






If you decide to complete the paper-based survey, please note that you will not 
be able to withdraw your responses once the survey has been collected as the 
survey will be anonymised. 
Will the information I give be kept confidential? 
The online survey will be conducted using the Bristol Online Survey which is 
fully compliant with all current UK data protection laws.  All information obtained 
from you will be kept confidential at all times.  
All data will be password protected on the Bristol Online Survey and on the 
password protected secure network of the University of Leeds.   
The paper-based surveys will be stored securely and scanned at the earliest 
opportunity. Scanned documents will be stored securely on the University of 
Leeds secure drive. The paper copies will then be destroyed. 
Other members that will have access to the data, from both the online and 
paper-based surveys, will be Professor Andrea Nelson (University of Leeds), Dr 
Susan O’Meara (University of Leeds) and Dr Georgina Gethin (National 
University of Ireland Galway).   
What will happen to the results of the study? 
Your responses from the Bristol Online Surveys will be analysed, along with 
other participant’s responses.  
If you would like to be sent the results of the consensus process please write 
you email address on the separate piece of paper we have provided at the front 
of the room.  Please do not write your email address on the survey. 
Who has reviewed this study? 
Ethical approval has been granted by the University of Leeds School of 
Healthcare Research Ethics Committee, UK, reference: HREC17-028. 
If you would like more information or have any questions or concerns 
about the study please contact: 
Sarah Hallas, [University contact details were provided] 
Dr Susan O’Meara (PhD supervisor), [University contact details were provided] 






Appendix 13 PowerPoint Presentation Meeting at the EWMA 
conference.  eDelphi on the Outcomes (stage 3) Round Two 
 











      
 
      
 










      
 
      
 
      









      
 
      
 










Appendix 14 eDelphi on the Outcomes Round One Survey 
The next pages display a facsimile in MS Word format of the survey section 
that asked participants to rate outcomes relating to healing.  It also displays the 
introduction pages, comment boxes to suggest additional outcomes and 







CoreVen core outcome set Bristol Online Survey 
1 




You are being invited to participate in a research study titled ‘Development of a core set of outcome 
measurements for use in research evaluations of interventions used for venous leg ulceration’. The purpose 
of this study is to determine what outcomes are really important and should be included as core for any 
future research trial on venous leg ulceration. Your participation in this study is entirely voluntary. 
 
On the following pages, you will see a series of outcomes. We will ask you to rate how important you 
consider each outcome to be on a numerical rating scale of 1 to 9 (‘1’ means ‘not important’ and ‘9’ means 
‘extremely important’). 
Once the survey is started you will be able to leave it and return to it at a later time by selecting the ‘finish 
later’ option at the end of the page. If you decide to use this option, you will be asked to enter your email 
address so that a link can be sent to you for returning to the survey. Your responses will be anonymous 
throughout the study, regardless of whether you use the ‘finish later’ option. 
 
By continuing the survey you are consenting to take part in the study. You are under no obligation to take 
part and you can withdraw from the study at any point providing you do not click on ‘Finish’ at the end. You 
do not need to provide a reason for withdrawal. You can stop at any point in the survey. In order for your 
responses to be used in the analysis you must answer all the ‘required’ questions and click on ‘Finish’ at the 
end. Once you do this, your responses cannot be withdrawn and will be included in the analysis. The 
questions on the survey that require a response will be highlighted with ‘*Required’ next to it. 
There are some responses that are optional, you will be informed that it is optional at the beginning of the 
question. 
 
Please do not provide any personal details on the survey, other than stating your role (for example patient, 
researcher, nurse) and country of residence on the first page of the survey. 
 
We anticipate that the survey will take approximately 25 minutes to complete. You will have the opportunity 
to download the responses you have submitted at the end, we recommend that you do this to allow you to 
see your previous responses when completing the round 2 survey. 
Once the results of this survey have been analysed a summary of the group responses for round 1 will be 
shown to you on the next, round 2, survey. 
 











Researcher from the industry sector 
Healthcare professional 
Other 





Which term best describes your background? (please select only one response that best describes your 
role)  Required 
 
 
If you are a healthcare professional, please state your job role: 
 
 
























Page 2: Healing 
We need to decide which outcomes are core and should be included in future trials on venous leg ulcer 
interventions. An outcome is a measurement to assess the effect of a treatment, for example, its 
effectiveness (benefit) or the assessment of adverse side effects (risks). 
 
You will see below a list of outcomes which can broadly be called ‘healing’. Please rate each outcome in 
terms of how important, on a scale of 1 to 9 (1 being not important and 9 being extremely important). 
Remember to rate the outcome as extremely important if you think the outcome is core and should 
therefore be in the core outcome set. 
Number of patients/ulcers/limbs that completely healed in a trial period.  
Required 
 1 2 3 4 5 6 7 8 9  
Not important                   Extremely 
important 
 
Time to complete healing - may be of a reference ulcer, of all ulcers on a 
reference limb, or of all ulcers on both limbs.  Required 
 1 2 3 4 5 6 7 8 9  
Not important                   Extremely 
important 
 
Change in size of ulcer, e.g. length, circumference, area, volume.  Required 
 1 2 3 4 5 6 7 8 9  
Not important                   Extremely 
important 
 
Number of reference ulcers achieving a pre-defined ulcer area change (e.g. any 
reduction, at least 50% reduction, at least 75% reduction).  Required 
 
 1 2 3 4 5 6 7 8 9  




Time to achieving a pre-defined ulcer area change in a reference ulcer (e.g. any 
reduction, at least 50% reduction, at least 75% reduction).  Required 
 1 2 3 4 5 6 7 8 9  




Change in ulcer severity score.  Required 
 1 2 3 4 5 6 7 8 9  









Granulation Outcomes. These outcomes are about the type of 
tissue in the ulcer. 
Number of ulcers with granulating tissue.  Required 
  1 2 3 4 5 6 7 8 9  
Not important                    Extremely 
important 
 
Number of ulcers with: a. healthy granulation b. at least 75% clean granulation c. 
unhealthy granulation  Required 
 
 1 2 3 4 5 6 7 8 9  
Not important                   Extremely 
important 
 
Quantity of granulation tissue measured at a given time point.  Required 
 1 2 3 4 5 6 7 8 9  
Not important                   Extremely 
important 
 
Time to a pre-specified level of granulation tissue (e.g. 50%, 75%, 100%). 
Required 
 1 2 3 4 5 6 7 8 9  
Not important                   Extremely 
important 
 
Fibrin outcomes. These outcomes are about the type of tissue in 
the ulcer. 
Quantity of fibrin on the ulcer measured at a given time point.  Required 
 
 1 2 3 4 5 6 7 8 9  
Not important                   Extremely 
important 
 
Percentage change in fibrin during the trial period.  Required 
 
 1 2 3 4 5 6 7 8 9  











Optional: Is there an outcome relating to healing that you think should be considered, other than what has 
been listed in this survey?. Please write the outcome in the box below. 
 
 
Optional: Is there an outcome relating to healing that you think should be considered, other than what 
















Page 13: Thank you 
 
Thank you for the time you have taken to complete this survey. Your opinion is important to us and 
your assistance in producing a core outcome set for trials on venous leg ulcer interventions is 
invaluable. 
 









Appendix 15 Degree of Skewness for Each Outcome Rated in the 




Number of patients/ulcers/limbs that completely healed in a trial period   -1.703 
Time to complete healing - may be of a reference ulcer, of all ulcers on a 
reference limb, or of all ulcers on both limbs   
-2.128 
Change in size of ulcer, e.g. length, circumference, area, volume   -1.854 
Number of reference ulcers achieving a pre-defined ulcer area change 
(e.g. any reduction, at least 50% reduction, at least 75% reduction)   
-1.189 
Time to achieving a pre-defined ulcer area change in a reference ulcer 
(e.g. any reduction, at least 50% reduction, at least 75% reduction)   
-1.271 
Change in ulcer severity score   -.926 
Number of ulcers with granulating tissue   -.383 
Number of ulcers with: a. healthy granulation b. at least 75% clean 
granulation c. unhealthy granulation   
-.437 
Quantity of granulation tissue measured at a given time point   -.075 
Time to a pre-specified level of granulation tissue (e.g. 50%, 75%, 100%)   -.283 
Percentage change in granulating tissue during the trial period   -.659 
Quantity of fibrin on the ulcer measured at a given time point   -.346 
Percentage change in fibrin during the trial period   -.532 
Number of adverse events (type of adverse event/s to be detailed in the 
paper)   
-3.530 
Number of patients that experience an adverse event (type of adverse 
event/s to be detailed in the paper)   
-2.290 
Number of patients that withdrew due to an adverse event (type of 
adverse event to be detailed in the paper)   
-2.021 
Number of serious adverse events (type of adverse event/s to be detailed 






Number of patients/ulcers/limbs with pain   -2.806 
Number of patients reporting a pre-specified level of change in pain score 
during the trial period (e.g. any reduction, at least 50% relief)   
-2.198 
Investigator reported level of pain   -.035 
Change in patient reported pain score/rating during the trial period   -2.104 
Pain level during mobilisation   -1.032 
Change in ‘comfort’ score/rating during the trial period   -1.112 
Comfort rating during dressing change (e.g. dressing removal)   -.838 
Change in ‘ache’ scores/rating during the trial period    -.565 
Change in heavy legs sensation score/rating during the trial period   -1.157 
Change in the scoring/rating of tiredness of the lower limbs during the trial 
period   
-.872 
Number of patients reporting heavy leg sensation   -1.079 
Change in the scoring/rating of cramps during the trial period   -.742 
Number of patients with cramps   -.475 
Change in venous claudication severity score during the trial period   -.806 
Change in the scoring/rating of skin tenseness around the ulcer during the 
trial period   
-.638 
Change in the scoring/rating of restless lower limbs during the trial period   -.810 
Change in the scoring/rating of heat/burning during the trial period   -.888 
Change in the scoring/rating of itching during the trial period   -1.305 
Number of patients reporting itching during the trial period   -1.271 
Change in the scoring/rating of tingling or pins and needles during the trial 
period   
-.633 
Change in the scoring/rating of tenderness (area i.e. limb or ulcer) during 
the trial period   
-.630 
Change in fatigue scores/rating during the trial period   -.437 
Change in the Quality of Life score during the evaluation period   -2.721 
Change in activities of daily living score   -2.576 





Ability to wear/find suitable clothes and shoes   1.622 
Change in oedema during the trial period – on a trial leg / both legs   -3.170 
Number of patients with oedema   -1.834 
Number of ulcers with suppuration (pus)   -1.235 
Absolute or relative change in pus during the trial period   -1.048 
Number of patients with the presence of malodour of the ulcer   -1.580 
Severity of odour (from the ulcer)   -1.033 
Change in the scoring/rating of erythema during the trial period   -.963 
Number of ulcers that had a change in erythema (e.g. decreased, 
increased)   
-1.011 
Number of patients with cellulitis   -1.672 
Change in the severity of cellulitis during the trial period   -1.526 
Number of patients/ulcers/limbs with a change in slough during the trial 
period   
-1.559 
Number of ulcers with new areas of slough   -1.374 
Percentage of ulcer surface covered in slough   -1.438 
Change in the scoring/rating of necrotic tissue during the trial period   -1.249 
Percentage of the ulcer surface area covered with necrotic tissue   -1.189 
Change in necrotic tissue during the trial period   -1.143 
Number of patients with necrotic tissue   -1.091 
Change in the scoring/rating of exudate during the trial period   -1.771 
Time to cessation of exudate (e.g. number of days, weeks)   -1.310 
Rate of change in exudate   -.631 
Number of ulcers with exudate -1.337 
Change in the severity of malodourous exudate during the trial period   -1.046 
Number ulcers with lymphangitis (inflammation or infection of the 
lymphatic channels-part of the circulatory system).   
-1.041 
Number of patients with abnormal skin changes   -1.261 
Number of patients with hyperpigmentation (darkening of an area of the 






Time to re-pigmentation (skin regains normal colour).   -.259 
Change in the surface area of lipodermatosclerosis (inflammation of the 
layer of fat under the epidermis) during the trial period.   
-.545 
Number of patients with denuded peri-wound skin (loss of the top layer of 
skin on the surrounding skin).   
-.923 
Change in venous blood flow   -1.756 
Changes in valvular competence   -1.314 
Number of limbs with superficial femoral incompetence.   -1.022 
Diameter of the superficial femoral vein (mm).   -.412 
Number of limbs with a pre-specified change in venous insufficiency (e.g. 
any improvement).   
-1.731 
Change in venous pressure   -1.391 
Change in venous distensibility (swelling).   -.732 
Change in ankle/arm pressure ratio during the evaluation period   -.910 
Change in transcutaneous partial pressure of oxygen (mmHg).   -1.153 
Change in pCO2 (partial pressure of carbon dioxide).   -.421 
Change in blood biochemistry (e.g. Urea and electrolytes)   -.272 
Change in a pre-specified haematological parameter (for example; Red 
blood cells, White blood cells, Erythrocyte sedimentation rate).   
-.350 
Change in glycaemia (blood glucose). -.444 
Change in cholesterol (blood test).   -.172 
Change in systolic blood pressure   -.529 
Change in diastolic pressure   -.482 
Change in heart rate   -.168 
Number of patients that had microbiologically determined presence of a 
particular pathogen/s on the ulcer bed (type of micro-organism to be 
specified by the trialist)   
-.952 
Number of patients that had episodes of clinically diagnosed infection   -2.242 
Number of patients with sepsis (also known as blood poisoning).   -1.739 





Number of dressing changes (e.g. per week, to healing).   -2.158 
Time between dressing changes, in days.   -1.814 
Number of patients that achieved 7 day wear time -1.001 
Time required for ulcer dressing changes   -1.538 
Ease of application- Reported by the researcher   -1.240 
Ease of application- Reported by the patient   -2.605 
Ease of removal - Reported by the researcher   -.987 
Ease of removal - Reported by the patient   -2.014 
Patients scoring of satisfaction with the performance of the intervention   -1.723 
Healthcare professionals scoring of satisfaction with the performance of 
the intervention   
-1.671 
Number with traumatic dressing removal (trauma to the ulcer bed or the 
surrounding skin).   
-1.342 
Rating of exudate handling by dressing   -1.271 
Number of dressing changes with exudate leakage   -1.584 
Number of debridements required to obtain a clean ulcer   -1.311 
Time required to debride the ulcer   -.938 
Number of patients that required surgical debridement   -1.254 
Number of visits where debridement was needed   -1.204 
Cost to heal patient/ulcer/limb completely   -2.712 
Cost per pre-specified reduction in ulcer area   -1.005 
Cost per given time frame (e.g. week, month, year).   -2.061 
Total costs to the end of the study -2.066 
Cost of dressings.   -1.214 
Nursing or clinician time required per patient/ulcer/limb (cost and/or time). -1.801 
Number of dressing treatments per group   -1.047 
Costs required to achieve debridement   -.661 
Number of work days lost   -1.763 












Appendix 16 Search Strategy 
Ovid MEDLINE  
1. health technology assessment.mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, floating sub-heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, unique 
identifier, synonyms] 
2. HTA.mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, floating sub-heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier, synonyms] 
3. cullum n.au. 
4. 1 or 2 
5. 3 and 4 
 
Scopus 
( SRCTITLE ( health  AND technology  AND assessment )  OR  SRCTITLE ( hta )  AND  




1. health technology assessment.mp. [mp=title, abstract, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword, 
floating subheading word, candidate term word] 
2. HTA.mp. [mp=title, abstract, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword, floating subheading 
word, candidate term word] 
3. cullum n.au. 
4. 1 or 2 
5. 3 and 4 
 
CINAHL 
SO health technology assessment OR SO hta AND AU Cullum 
Limiters - English Language; Exclude MEDLINE records  
Narrow by Journal: - health technology assessment  
Search modes - Find all my search terms 
